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Abstract	  From	  DNA	  replication	  and	  repair	  to	  transcription	  and	  translation,	  all	  aspects	  of	  molecular	  biology	   are	   governed	   by	   interactions	   between	   proteins	   and	   nucleic	   acids.	   Some	   of	   the	  nucleic	  acid-­‐binding	  proteins	  have	  evolved	  repetitive	   structures	  and	  a	  modular	   sequence	  recognition	  mode.	  In	  particular,	  DNA-­‐binding	  transcription	  activator-­‐like	  effectors	  (TALE)	  and	  RNA-­‐binding	  Pumilio/fem-­‐3	  binding	   factor	   homology	   (PUF)	   proteins	  were	   shown	   to	  bind	   their	   target	   sequences	   in	   a	   single	   repeat/base	   fashion.	   This	   modular	   recognition	  nature	   allowed	   researchers	   to	   rationally	  design	   these	  proteins	   for	  novel	   specificities	   and	  utilize	   them	   in	   diverse	   biotechnological	   applications	   such	   as	   genome	   engineering,	   gene	  expression	  regulation,	  and	  imaging	  of	  specific	  nucleic	  acids.	  The	  first	  part	  of	  my	  dissertation	  was	  dedicated	  to	  the	  study	  and	  engineering	  of	  TALE.	  Using	   the	   published	   specificity	   code,	   a	   pair	   of	   TALE	   nucleases	   was	   engineered	   to	   site-­‐specifically	   cut	   the	   Cystic	   Fibrosis	   Transmembrane	   Regulator	   gene	   (CFTR)	   carrying	   the	  Δ508F	  mutation	   responsible	   for	   the	  most	   cases	   of	   cystic	   fibrosis.	   Coexpression	   of	   these	  proteins	   in	   human	   cell	   lines	   allowed	   homologous	   recombination-­‐mediated	   repair	   of	   the	  episomal	   and	   chromosomal	   reporter	   gene	   interrupted	  with	   the	   sequence	   fragment	   from	  
CFTR.	   	   In	   the	   next	   project,	   the	   binding	   dynamics	   of	   TALE	   on	   DNA	   substrates	   was	  investigated	  using	  single	  molecule	  fluorescence	  microscopy.	  For	  the	  first	  time,	  the	  binding	  dynamics	  and	  1-­‐D	  diffusion	  of	  TALE	  proteins	  along	  DNA	  were	  directly	  visualized.	  The	  data	  strongly	   suggest	   that	   TALE	   searches	   its	   target	   using	   the	   facilitated	   diffusion	  mechanism,	  with	   a	   combination	   of	   1-­‐D	   and	   3-­‐D	   diffusion	   before	   it	   reaches	   its	   target	   sequence.	   This	  study	   can	   contribute	   to	   improved	   rational	   design	   of	   these	   proteins	   for	   biomedical	  applications.	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The	   aim	   of	   the	   second	   part	   of	   my	   dissertation	   was	   to	   engineer	   new	   PUF-­‐based	  biosynthetic	  tools.	  First,	  the	  Golden	  Gate	  cloning	  method	  was	  implemented	  for	  an	  efficient	  one-­‐step	  assembly	  of	  designer	  PUF	  proteins.	  To	   this	   end,	   a	   repeat	  module	   library	   that	   is	  potentially	   capable	  of	  generating	  a	  PUF	  domain	  with	  any	  desired	  specificity	  was	  created.	  The	   assembled	   novel	   PUF	   variants	   exhibited	   high	   in	  vitro	   binding	   efficiencies	   to	   cognate	  RNA	  sequences,	  corroborating	  the	  applicability	  of	  the	  modular	  assembly	  approach	  for	  PUF	  engineering.	   Next,	   the	   PUF	   domain	   was	   fused	   to	   a	   post-­‐transcriptional	   regulator,	   which	  allowed	   for	   a	   sequence-­‐specific	   reporter	   and	   endogenous	   gene	   repression	   in	   human	   cell	  lines.	   This	   work	   was	   a	   demonstration	   of	   the	   efficacy	   of	   a	   synthetic	   PUF-­‐based	   gene	  expression	  regulator.	  	  In	   the	   last	   project,	   a	   PUF-­‐based	   system	   for	   intracellular	   directional	   transport	   of	  mRNA	  was	  developed	   in	  mammalian	   cells.	  The	  biosynthetic	  device	   consists	  of	   a	   “motor”,	  which	   provides	   a	   directional	   movement,	   and	   the	   PUF	   protein	   that	   dimerizes	   with	   the	  “motor”	   in	   a	   ligand-­‐dependent	   manner.	   The	   system	   allowed	   RNA-­‐sequence	   and	   motor-­‐specific	   transport	  and	  colocalization	  of	  PUF	  and	   its	  RNA	  cargo.	  Currently,	   this	  PUF-­‐motor	  system	  is	  being	  implemented	  for	  the	  transport	  as	  well	  as	  axonal	  and	  dendritic	  local	  protein	  translation	  of	   reporter	  and	  endogenous	  genes	   in	   rat	  neurons.	  This	  prototypical	   synthetic	  device	   should	   allow	   easy	   and	   controlled	   intracellular	   mRNA	   transport	   regulation	   in	  eukaryotes	  for	  applications	  in	  basic	  science	  and	  therapeutics.	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Chapter	  1.	  Introduction1	  
1.1 	  Synthetic	  Biology	  and	  Repeat	  Proteins	  The	   field	   of	   synthetic	   biology	   aims	   to	   contribute	   to	   a	   variety	   of	   health	   and	  environmental	   challenges	   including	   the	   production	   of	   biofuels	   and	   biomaterials,	  drug	   discovery,	   drug	   production,	   development	   of	   new	   vaccines,	   as	   well	   as	  combatting	  infectious	  diseases	  and	  cancer.	  The	  main	  principle	  of	  synthetic	  biology	  is	  to	  use	  well-­‐characterized	  functional	  modules	  to	  build	  biological	  systems	  with	  novel	  functions.	  The	  functional	  modules	  that	   it	  develops	  and	  utilizes	  are	  usually	  protein-­‐coding	   or	   regulatory	   DNA	   parts,	   which	   are	   cloned	   from	   various	   organisms	   or	  synthesized,	  and	  assembled	  together	  into	  genetic	  circuits.	  	  Engineering	   devices	   for	   synthetic	   biology	   commonly	   requires	   the	   use	   of	  modules	  for	  regulation	  of	  gene	  expression	  on	  DNA	  or	  RNA	  levels.	  Emulating	  nature,	  these	   modules	   are	   often	   developed	   from	   nucleic	   acid-­‐binding	   proteins	   linked	   to	  various	   functional	   domains	   following	   the	   modular	   design	   principle,	   where	   each	  domain	  in	  a	  polypeptide	  chain	  functions	  independently	  from	  the	  rest	  of	  the	  protein.	  Highly	   sophisticated	   synthetic	   biology	   endeavors	   would	   require	   equally	   complex	  gene	   circuits,	   which	   in	   turn	   would	   require	   multiple	   orthogonal	   gene	   expression	  regulators.	  There	  are	  a	  limited	  number	  of	  orthogonal	  nucleic	  acid-­‐binding	  proteins	  in	   nature,	   however,	   and	   thus	   scaffold	   DNA-­‐	   and	   RNA-­‐binding	   proteins	   (DBPs	   and	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  Portions	  of	  this	  chapter	  were	  reprinted	  (adapted)	  with	  permission	  from	  (Abil	  et	  al.	  Mol	  Pharm	  2015,	  12(2),	  pp322-­‐331)	  Copyright	  (2015)	  American	  Chemical	  Society and	  (Sun	  et	  al.	  Biotechnol	  J	  2012	  7(9),	  pp1074-­‐1087)	  Copyright	  (2012)	  John	  Wiley	  and	  Sons.	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RBPs,	   respectfully)	  with	  easily	   reprogrammable	   specificity	  are	   required.	  Using	   the	  same	  modular	   design	   fashion,	   precision-­‐targeted	   DNA-­‐binding	   endonucleases	   can	  also	  be	  constructed	  for	  genome	  modification	  purposes,	  as	  will	  be	  discussed	  later.	  A	  single	   precise	   genome	   modification	   in	   an	   organism	   would	   also	   require	   a	   highly	  specific	   DNA-­‐binding	   domain	   (DBD),	   easily	   reprogrammable	   for	   a	   sequence	   of	  interest	   for	   each	   new	   genetic	   locus.	   Engineering	   artificial	   proteins	   with	   desired	  nucleic	   acid	   sequence	   specificity	   is	   therefore	   one	   of	   the	   important	   challenges	   of	  synthetic	  biology.	  	  It	  was	  shown	  that	  transcription	  factors	  with	  new	  DNA-­‐binding	  specificities	  can	  be	   selected1	   from	   a	   library	   of	   zinc	   fingers2.	   Subsequently,	   numerous	   new	  transcription	  factors	  and	  endonucleases	  were	  successfully	  created	  using	  zinc	  fingers	  (reviewed	  in	  3	  and	  4).	  However,	  the	  DNA-­‐binding	  specificity	  in	  zinc	  finger	  proteins	  is	  not	  fully	  reprogrammable	  and	  certain	  selection	  strategies	  have	  to	  be	  implemented	  for	  isolation	  of	  a	  zinc	  finger	  domain	  with	  desired	  specificity5-­‐6.	  Thus,	  engineering	  of	  proteins	  for	  nucleic	  acid	  specificity	  has	  not	  been	  straightforward	  until	  recently,	  with	  the	  implementation	  of	  proteins	  with	  repetitive	  structure.	  	  Proteins	   with	   repetitive	   structure,	   or	   repeat	   proteins,	   are	   widespread	   in	  nature,	   and	   include	   ankyrin,	   armadillo,	   WD,	   HEAT,	   leucine-­‐rich	   repeat	   proteins,	  tetratricopeptide	   repeat	   TPR	   proteins,	   pentatricopeptide	   repeat	   (PPR)	   proteins,	  Pumilio	  and	  fem3	  mRNA-­‐binding	  factor	  (PUF)	  homology	  proteins,	  and	  transcription	  activator-­‐like	   effector	   (TALE)	   proteins7-­‐13.	   It	   is	   generally	   believed	   that	   repeat	  proteins	  evolve	  through	  coding	  sequence	  duplication	  within	  genes,	  and	  consecutive	  divergence	  of	  each	  repeat	  sequence	  from	  the	  neighboring	  repeats.	  The	  structure	  of	  
	   3	  
such	   proteins	   is	   dominated	   by	   short-­‐range	   interactions	   that	   usually	   stack	   the	  tandem	   arrays	   of	   repeats	   in	   an	   elongated	   non-­‐globular	   structure	   with	   a	   joined	  hydrophobic	  core8,	  14.	  The	  repeat	  domain	  is	  usually	  flanked	  and	  stabilized	  by	  special	  repeats,	   or	   ‘pseudorepeats’,	   that	   shield	   the	  hydrophobic	   core	   from	   the	   solvent8,	  14.	  This	  architecture,	  in	  principle,	  allows	  for	  addition,	  exchange,	  and	  removal	  of	  repeats	  in	   an	   out	   of	   the	   repeat	   domain	   without	   compromising	   the	   overall	   structure,	   but	  varying	   the	   surface	   for	   ligand	   interaction.	   The	   extended	   architecture	   of	   repeat	  proteins	   can	   thus	   allow	   for	   modular	   engineering	   of	   these	   proteins	   for	   specific	  binding	   to	   other	   macromolecules,	   such	   as	   proteins,	   as	   was	   shown	   with	   ankyrin	  repeats15-­‐16	  and	  TPR	  proteins17.	  A	   striking	   revelation	  was	   that	   some	   of	   the	   repeat	   proteins,	   such	   as	   PUF	   and	  TALE	  proteins,	  bind	  nucleic	  acids	  in	  a	  modular	  fashion,	  where	  one	  repeat	  interacts	  with	   one	   base,	   with	   certain	   amino	   acid	   positions	   in	   each	   repeat	   dictating	   the	  specificity18-­‐21.	   This	  modular	  mode	   of	   binding	   to	   DNA	   prompted	   to	   develop	   TALE	  proteins	   as	   a	   valuable	   tool	   for	   engineering	   DNA-­‐binding	   proteins	   with	   custom	  specificity22-­‐23.	   Similarly,	   PUF	   domains	   have	   been	   successfully	   reprogrammed	   for	  altered	   RNA	   specificity18-­‐19,	   an	   accomplishment	   that	   has	   not	   been	   previously	  achieved	   with	   any	   other	   RNA-­‐binding	   protein.	   Although	   other	   repetitive	   nucleic	  acid-­‐binding	   proteins,	   such	   as	   PPR	   proteins	   also	   hold	   promise	   for	   engineering	   of	  custom	  RNA-­‐binding	   proteins24,	   in	   this	   dissertation,	   I	   focused	   on	   the	   PUF	   protein	  because	  PUF	  proteins	  have	  been	  studied	  more	  extensively.	  Cas9	  proteins	  that	  site-­‐specifically	  recognize	  DNA	  via	  RNA-­‐hybridization	  also	  hold	  promise	  in	  engineering	  custom	  DNA-­‐binding	  proteins25;	  however,	  it	  was	  beyond	  the	  scope	  of	  this	  work.	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1.2 	  TALEs	  as	  Designer	  DNA-­‐Binding	  Proteins	  TALE	   proteins	   were	   first	   discovered	   in	   a	   plant	   bacterial	   pathogen	   of	   the	   genus	  
Xanthomonas,	  which	  uses	  them	  as	  transcription	  activators	  of	  host	  plant	  genes26.	  The	  pathogen	   injects	   the	   proteins	   into	   the	   plant	   cells	   via	   a	   type	   III	   secretion	   system.	  These	   proteins	   are	   translocated	   into	   the	   plant	   cell	   nucleus	   and	   used	   to	   recognize	  target	   promoters	   and	   activate	   the	   expression	   of	   genes	   that	   are	   important	   for	  pathogen	  virulence.	  	  
1.2.1	  TALE	  DNA-­‐Recognition	  Code,	  Structure,	  and	  Preparation	  The	  number	   of	   repeats	   in	   natural	   TALEs	   varies	   between	  1.5	   and	   33.5,	  with	   15.5–19.5	  being	   the	  most	  common26-­‐27.	  However,	   it	  was	  shown	   that	  at	   least	  6.5	   repeats	  are	   required	   for	   gene	   induction	   in	   promoter	   activation	   studies21.	  While	   the	   usual	  repeat	   length	   is	   34	   amino	   acids,	   the	   last	   repeat	   is	   typically	   shorter,	   with	   only	   20	  amino	  acids,	   and	   is	   therefore	   referred	   to	   as	   a	   ‘half-­‐repeat’26.	  The	  DNA	   recognition	  code	   of	   TALE	  was	   deciphered	   in	   two	   independent	   studies20-­‐21.	  While	  most	   of	   the	  amino	  acids	  are	  highly	  conserved	  across	  repeats,	  two	  hypervariable	  amino	  acids	  at	  positions	  12	  and	  13,	  often	  referred	  to	  as	  the	  repeat-­‐variable	  diresidue	  (RVD),	  confer	  the	   specificity	   of	   each	   repeat	   to	   the	   corresponding	   nucleotide	   in	   the	   target	   DNA	  sequence	   (Figure	  1.1).	  Thus,	  RVDs	  NI	  and	  HD	  show	  strong	  preference	   for	  adenine	  and	   cytosine,	   respectively,	   while	   both	   NG	   and	   HG	   favor	   recognition	   of	   thymine.	  Some	  other	  RVDs	  are	  less	  specific:	  NS	  has	  the	  least	  definitive	  nucleotide	  preference,	  while	  NN	  recognizes	  both	  guanine	  and	  adenine.	  Thus,	  there	  is	  no	  RVD	  with	  specific	  recognition	  of	  guanine,	  which	  must	  be	  taken	  into	  account	  when	  designing	  artificial	  TALEs.	   The	   N-­‐terminal	   repeat	   of	   TALEs	   binds	   to	   the	   5ʹ′	   end	   of	   the	   target	   DNA	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sequence,	   while	   each	   consecutive	   repeat	   binds	   a	   single	   base	   downstream	   of	   the	  same	  DNA	  strand.	  	  
	  
Figure	  1.1	  Schematic	  of	  TALE	  binding	  to	  dsDNA.	  Recognition	  code	  is	  shown	  in	  a	  box.	  R	  represents	  A	  or	  G.	  N	  represents	  any	  of	  the	  four	  nucleobases.	  Amino	  acid	  residues	  in	  red	  represent	  RVD	  at	  positions	  12	  and	  13.	  	  




RVD: NI HD NG HG NN NK NS 
Base: A C T T R G N  
Figure 1.1 Schematic of repeat proteins binding to nucleic acids.(a) 
Schematic of TALE binding to dsDNA. Recognition code is shown in a box. 
R represents A or G. N represents any of the four nucle bases. Amino 
acid residues in red represent RVD at positions 12 and 13. (b) Schematic 
of PUF binding to ssRNA. Recognition code is shown in a box. Amino acid 
residues in red, as well as R12R16 represent key amino acids at positions 12 
and 16. 
TALE 






R12R16: SQ CQ NQ SE SR 
Base: A A U G C  
PUF 
RNA 3’ 5’  
a 
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with	   a	   corresponding	   nucleotide.	   Interestingly,	   comparison	   of	   TALE	   structures	   in	  DNA-­‐bound	  and	  DNA-­‐free	  forms	  revealed	  a	  significant	  conformational	  change	  along	  the	   axis	   of	   the	   TALE	   superhelix,	   which	   might	   be	   important	   for	   the	   function	   of	  TALE28.	  	  The	  modular	  recognition	  mode	  of	  TALE	  allows	  for	  easy	  design	  of	  custom	  DBD.	  However,	   the	   highly	   repetitive	   nature	   of	   the	   modules	   makes	   it	   difficult	   to	  mutagenize	   the	   protein	   using	   the	   traditional	   methods	   of	   recombinant	   DNA	  technology.	   The	   development	   of	   the	   Golden	   Gate	   cloning	   method30	   abolished	   the	  need	   for	   costly	   artificial	   DNA	   synthesis	   and	   allowed	   for	   an	   easy	   and	   efficient	   in-­‐house	  assembly	  of	  TALEs31-­‐39.	  Using	  this	  method,	  up	  to	  ten	  repeats	  can	  be	  efficiently	  assembled	   in	   a	   single	   digestion-­‐ligation	   reaction.	   The	   technique	   is	   based	   on	   the	  property	   of	   type	   IIS	   restriction	   endonucleases	   to	   cleave	   outside	   their	   recognition	  sequences,	   which	   results	   in	   unique	   non-­‐palindromic	   4-­‐bp	   overhangs.	   These	  overhangs	  can	  be	  re-­‐ligated	  in	  an	  ordered	  fashion,	  with	  a	  simultaneous	  removal	  of	  the	  recognition	  sites.	  	  In	  another	  approach,	  Reyon	  and	  coworkers40	  developed	  the	  fast	  ligation-­‐based	  automatable	   solid-­‐phase	   high-­‐throughput	   (FLASH)	   system	   to	   synthesize	   TALEs	   in	  large	   scale,	  which	   significantly	   decreases	   the	  TALE	   synthesis	   cost	   (less	   than	   $200	  per	  pair).	  An	  alternative	  high-­‐throughput	  TALE	  synthesis	  approach	  was	  proposed	  in	  a	  method	  called	  fairyTALE	  by	  Liang	  et	  al.,	  wherein	  a	  liquid-­‐phase	  Golden	  Gate-­‐based	  approach	   allowed	   efficient	   synthesis	   of	   TALEs	   at	   material	   cost	   of	   $10	   per	   TALE	  pair41.	  With	  the	  combined	  effort	  from	  several	   laboratories,	  TALE	  assembly	  toolkits	  are	   now	  available	   through	  Addgene	   and	  have	  been	  made	   accessible	   to	   the	   public.	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Moreover,	   commercial	   services	   for	   custom	   TALE	   assembly	   and	   activity	   validation	  are	   also	   conveniently	   available	   from	   Cellectis	   (Romainville,	   France),	   PNA	   Bio	  (Thousand	  Oaks,	  CA,	  USA)	  and	  Life	  Technologies	  (Grand	  Island,	  NY,	  USA).	  	  
1.2.2	  TALE	  Nuclease	  (TALEN)	  Applications	  Using	  the	  modular	  design	  principle	  of	  DNA-­‐binding	  proteins,	  it	  was	  shown	  that	  the	  activation	  domain	  of	  TALE	  proteins	  could	  be	  replaced	  with	  a	  non-­‐specific	  nuclease	  domain	  FokI.	  Such	  a	  chimeric	  protein	  can	  function	  as	  a	  highly	  specific	  endonuclease,	  which	  can	  be	  utilized	  for	  genome	  editing	  purposes	  in	  basic	  and	  applied	  science31,	  34,	  
42-­‐46.	  The	  principle	  of	  using	  endonucleases	  for	  gene	  editing	  lies	  in	  the	  ability	  of	  most	  organisms	   to	  activate	  native	  DNA	  repair	  machineries	   to	  repair	   the	  site-­‐specifically	  introduced	  double	  strand	  break	  (DSB).	  Major	  repair	  pathways	  are	  non-­‐homologous	  end	  joining	  (NHEJ)47	  and	  homologous	  recombination	  (HR)48.	  NHEJ	  is	  an	  error-­‐prone	  process,	  which	  often	  leads	  to	  micro-­‐deletions	  or	  micro-­‐insertions	  that	  often	  result	  in	  frame	   shift	  mutagenesis	   and	   a	   consequent	   gene	   knockout.	  HR	   is	   less	   error-­‐prone,	  and	  in	  native	  conditions,	   is	  achieved	  using	  a	  sister	  chromatid	  as	  a	  template	  for	  the	  repair	  of	  the	  damaged	  chromosome.	  	  In	  traditional	  gene	  targeting,	  DSB-­‐independent	  HR	  was	  utilized	  to	  mutagenize	  a	  gene	  of	  interest	  by	  providing	  an	  exogenous	  homology	  donor.	  The	  frequency	  of	  HR	  in	  such	  conditions	  was	  very	  low	  (10-­‐4	  –	  10-­‐7).	  However,	  it	  was	  later	  discovered	  that	  the	   introduction	  of	  DSBs	  via	  site-­‐specific	  endonucleases	   increases	   the	  efficiency	  of	  HR	   by	   several	   orders	   of	   magnitude49-­‐50.	   This	   site-­‐specific	   endonuclease-­‐mediated	  gene	  targeting	  approach	  is	  referred	  to	  as	  gene	  editing.	  Since	   FokI	   functions	   as	   a	   dimer51,	   TALENs	   are	   designed	   as	   heterodimers,	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where	  two	  TALE-­‐FokI	  fusions	  are	  designed	  to	  bind	  opposite	  strands	  of	  target	  DNA,	  in	  a	  head-­‐to-­‐head	  orientation.	  We	  and	  other	  groups	  performed	  optimization	  of	  the	  TALEN	  architecture	  to	  achieve	  the	  best	  efficiency	  in	  gene	  editing.	  It	  was	  shown	  that	  TALE	  truncations	   that	  retain	  20–60	  amino	  acid	  residues	  of	   the	  original	  C-­‐terminal	  residues	  and	  ~150	  residues	  at	   the	  N	   terminal	   region	  had	  a	  higher	  TALEN	  activity	  compared	   to	   the	   full-­‐length	   TALE	   sequences42,	  46,	  52.	   These	   reports	   also	   agree	   that	  longer	   C-­‐terminal	   configurations	   (~60	   compared	   to	   ~20	   residues)	   have	   a	   higher	  preference	  for	  longer	  spacer	  lengths	  between	  the	  two	  protein	  binding	  sites	  (12–30	  bp	  compared	  to	  10–16	  bp)46,	  52.	  	  From	   the	   natural	   TALE-­‐target	   promoter	   pairs	   listed	   by	   Moscou	   and	  Bogdanove20,	   Cermak	   and	   co-­‐workers31	   developed	   a	   program	   that	   calculated	  frequencies	  of	  natural	  TALE	  binding	   site	  preferences.	  Based	  on	   these	   calculations,	  they	   listed	  several	  guidelines	   for	  choosing	  an	  optimal	   synthetic	  TALEN	  target	   site.	  Thus,	  besides	  the	  favorable	  thymine	  at	  position	  –120-­‐21,	  they	  suggest	  that	  thymine	  at	  position	   1	   (the	   first	   position	   at	   the	   5ʹ′	   end	   of	   the	   target	   sequence)	   is	   disfavored,	  adenine	   at	   position	   2	   is	   disfavored,	   and	   guanine	   at	   the	   last	   and	   penultimate	  positions	   are	   disfavored,	   and	   a	   thymine	   at	   the	   last	   position	   (when	   the	   last	   half	  repeat	  contains	  the	  RVD	  NG)	  is	  highly	  favored31.	  	  The	   first	   proof-­‐of-­‐concept	   for	   using	   custom-­‐designed	   TALENs	   for	   genome	  modification	   in	   a	   trans-­‐kingdom	   host	   was	   shown	   using	   a	   LacZ	   reporter	   in	  
Saccharomyces	   cerevisiae53-­‐54.	   Soon	   after,	   in	   cultured	   mammalian	   cells,	   successful	  targeted	  gene	  disruption	  (up	  to	  21%	  efficiency)	  as	  well	  as	  editing	  (up	  to	  16%	  effi-­‐	  ciency)	   of	   endogenous	   human	   neurotrophin	   3	   (NTF3)	   and	   chemokine	   (C-­‐C	  motif)	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receptor	   5	   (CCR5)	   genes	   were	   reported46.	   In	   another	   study,	   the	   hypoxanthine	  phosphoribosyltransferase	   1	   gene	   (HPRT1)	  was	   knocked	   out	   in	   a	  mammalian	   cell	  line31.	  	  Compared	  to	  immortalized	  tumor	  cell	   lines,	  human	  pluripotent	  stem	  cells	  are	  relatively	  resistant	  to	  gene	  targeting.	  This	  limitation	  can	  be	  addressed	  by	  using	  the	  TALEN	   technology,	   as	   was	   shown	   with	   TALENs	   engineered	   for	   recognition	   of	  
PPP1R12C,	  OCT4	  and	  PITX3	  genes	   in	  human	  pluripotent	   cells43.	  With	   the	  help	  of	   a	  gene	   trap	   or	   an	   autonomous	   selection,	   they	   reported	   targeting	   in	   >50%	   of	   the	  selected	  colonies	  for	  OCT4,	  ~50%	  for	  PPP1R12C,	  and	  1–10%	  for	  PITX3.	  	  The	   first	   genome	  editing	   in	   an	   animal	  was	   shown	  by	  Tesson	   and	   coworkers,	  who	   knocked	   out	   the	   immunoglobulin	   M	   (IgM)	   gene	   by	   injecting	   TALEN-­‐coding	  nucleic	   acids	   into	  one-­‐cell	   rat	   embryos55.	  When	   the	  nucleases	  were	   introduced	  by	  transfection	  with	  coding	  DNA,	  the	  frequency	  of	  mutated	  animals	  was	  9%,	  whereas	  when	   nucleases	   were	   introduced	   to	   cells	   via	   transfection	   of	   coding	   mRNA,	   the	  frequency	  of	  modified	  animals	  was	  increased	  to	  59%.	  The	  wide	  range	  of	  variations	   in	   the	  modification	  efficiencies	  reported	  to	  date	  might	  be	  due	  to	  the	  varying	  affinities	  of	  different	  TALEs	  to	  target	  DNA,	  differences	  in	  amenability	  of	   the	  cells	  and	   tissues	   for	   the	  uptake	  of	   foreign	  genetic	  material,	   and	  the	  cell	   cycle	  status	  of	   the	  cells.	  Additionally,	   chromosomal	  context	  and	  epigenetic	  modifications	  determine	  the	  chromatin	  accessibility	  of	  tailored	  DNA	  endonucleases,	  which	  may	  play	  a	  major	  role	   in	  the	  genomic	  modification	  efficiency.	   It	   is	   therefore	  important	   to	   investigate	   the	   influence	   of	   each	   of	   these	   factors	   on	   genome	  modification	  rates	  and	  develop	  strategies	  to	  efficiently	  manipulate	  them.	  Despite	  big	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variations,	   the	   efficiency	   of	   targeted	   genome	   engineering	   in	   most	   studies	   is	   low	  (<1%);	  therefore,	  a	  powerful	  and	  seamless	  selection	  strategy	  would	  be	  valuable	  to	  enrich	  the	  targeted	  events.	  	  
1.3 	  Designer	  RNA-­‐Binding	  Proteins	  PUF	  family	  proteins	  are	  named	  after	  the	  founding	  members	  Pumilio	  from	  Drosophila	  
melanogaster	  56	  and	  fem3-­‐binding	  factor	  (FBF)	  from	  Caenorhabditis	  elegans57.	  Since	  then,	  PUF	  homology	  proteins	  have	  been	  found	  in	  all	  eukaryotic	  organisms58-­‐59.	  PUF	  domains	   usually	   bind	   to	   the	   3ʹ′	   UTR	   of	   target	   genes,	   and	   regulate	  mRNA	   stability,	  translation,	   and	   localization	   (reviewed	   in	   references	   59-­‐60),	   pre-­‐rRNA	  processing61,	  and	  even	  recognition	  of	  viral	  infections62-­‐63.	  
1.3.1 PUF	  Domain:	  Reprogrammable	  RNA-­‐Binding	  Protein	  PUF	  family	  proteins	  are	  identified	  by	  the	  presence	  of	  8	  imperfectly	  repeated	  36	  amino	   acid	   motifs	   (PUF	   repeats),	   which,	   together	   with	   flanking	   conserved	  sequences,	  form	  a	  sequence-­‐specific	  RNA-­‐binding	  domain	  (RBD),	  the	  PUF	  domain64-­‐
65.	  The	   first	  crystal	  structures	  of	  PUF	  domains	  revealed	   that	   the	  eight	  PUF	  repeats	  are	   very	   similar	   structurally,	   and	   each	   of	   them	   comprises	   a	   triangle-­‐shaped	  structural	  unit	  that	  contains	  three	  helical	  segments66-­‐67.	  These	  repeated	  units	  pack	  together	   to	   form	   a	   crescent-­‐shaped	   right-­‐handed	   superhelix	   with	   a	   continuous	  hydrophobic	  core66-­‐67.	  	  The	   crystal	   structure	   of	   a	   PUF	   domain	   from	   human	   Pumilio	   1	   (HsPUM1)	  protein	  in	  complex	  with	  RNA	  revealed	  that	  RNA	  is	  bound	  to	  the	  concave	  surface	  of	  the	  protein;	  moreover,	  each	  repeat	  interacts	  with	  a	  single	  RNA	  base,	  suggesting	  that	  RNA	  recognition	  of	   the	  PUF	  domain	   is	  highly	  modular18.	  The	  N-­‐terminal	   repeat	  of	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the	   PUF	   domain	   interacts	   with	   the	   3ʹ′	   end	   of	   the	   8-­‐base	   target	   mRNA,	   with	   each	  subsequent	   repeat	   interacting	  with	   the	  adjacent	  RNA	  base	   immediately	  upstream;	  thus	   the	   PUF	   domain	   binds	   RNA	   in	   what	   can	   be	   described	   as	   ‘antiparallel’	  configuration18.	   The	   structure	   revealed	   that	   each	   repeat	   establishes	   a	   sequence-­‐specific	   interaction	  with	  a	  Watson-­‐Crick	  edge	  of	   the	  RNA	  base	  via	  amino	  acid	  side	  chains	  at	  positions	  12	  and	  16	  in	  each	  repeat	  (Figure	  1.2).	  The	  amino	  acid	  side	  chains	  at	  position	  13	  in	  each	  repeat	  form	  stacking	  interactions	  with	  adjacent	  RNA	  bases18.	  RNA-­‐recognition	   code	   was	   proposed	   based	   on	   this	   co-­‐crystal	   structure,	   where	  NYxxQ	  (residue	  positions	  12-­‐16,	  x-­‐any	  residue)	  recognizes	  uracil,	  CRxxQ	  recognizes	  adenine,	   and	   SNxxE	   recognizes	   guanine.	   No	   code	   for	   cytosine	  was	   apparent	   from	  this	  structure,	  although	  repeat	  4	  could	  accept	  any	  base.	  
	  
Figure	   1.2	   Schematic	   of	   PUF	   binding	   to	   ssRNA.	   Recognition	   code	   is	   shown	   in	   a	   box.	   Amino	   acid	  residues	  in	  red,	  as	  well	  as	  R12R16	  represent	  key	  amino	  acids	  at	  positions	  12	  and	  16.	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Figure 1.1 ematic of repeat proteins bindi g to nucleic acids.( ) 
Schematic of TALE binding to dsDNA. Recognition code is shown in a box. 
R represents A or G. N represents any of the four nucleobases. Amino 
acid residues in red represent RVD at positions 12 and 13. (b) Schematic 
of PUF binding to ss . Recognition code is hown in a box. Amin  acid 
residues in red, as well as R12R16 represent key amino acids at positions 12 
and 16. 
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domain	   specificity	   in	   HsPUM1,	   as	   confirmed	   by	   in	   vitro	   binding	   assays18-­‐19,	   68.	  Recently,	   this	  PUF	  specificity	   code	  was	  expanded	  using	  data	  gathered	   from	  a	  high	  throughput	   sequencing	   approach.	   These	   data	   allowed	   determination	   of	   the	  specificity	   conferred	   by	   various	   combinations	   of	   the	   three	   amino	   acid	   residues	  introduced	   into	   the	   seventh	   repeat	   of	   FBF-­‐269.	   This	   elegant	   approach,	   termed	  SEQRS,	   combined	   in	   vitro	   selection,	   high-­‐throughput	   sequencing	   of	   RNA	   and	  sequence	   specificity	   landscapes.	   Multiple	   highly	   specific	   combinations	   were	  discovered	  for	  the	  recognition	  of	  uracil,	  adenine,	  and	  guanine,	  some	  of	  which	  were	  
de	  novo	  designed	  amino	  acid	  combinations.	  Thus,	   the	  de	  novo	  designed	  CFxxQ	  and	  CYxxE	   amino	   acid	   combinations	   were	   more	   specific	   for	   adenine	   than	   any	   other	  natural	  combination69.	  Identification	  of	  cytosine-­‐recognition	  code	  of	  PUF	  repeats	  expanded	  the	  RNA-­‐binding	   specificity	   of	   PUF	   domains	   to	   recognize	   any	   RNA	   target	   sequence70-­‐71.	   In	  order	   to	   select	   for	   a	   PUF	   repeat	   with	   specificity	   for	   cytosine,	   yeast	   three-­‐hybrid	  system	  was	  used,	  where	   the	   interaction	  between	   the	  PUF	  domain	  and	   target	  RNA	  was	   linked	   to	   a	   life-­‐death	   selection	   in	   S.	   cerevisiae.	   From	   a	   pool	   of	   PUF	   domain	  variants	  with	  randomized	  amino	  acid	  positions	  12	  and	  16	  in	  repeat	  6,	  PUF	  repeats	  with	  the	  SYxxR	  amino	  acid	  combination	  were	  selected70.	  In	  a	  similar	  study,	  arginine	  at	   position	   16	   was	   likewise	   selected;	   while	   in	   the	   position	   12,	   other	   small	   or	  nucleophilic	   side	   chains	   were	   also	   selected	   besides	   serine71.	   This	   code	   was	  functional	   in	   other	   PUF	   repeats70-­‐71,	   and	   PUF	   domains	   with	   multiple	   cytosine-­‐recognizing	  repeats	  were	  shown	  to	  be	  active70.	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1.3.2 PUF	  Domain	  in	  Applications	  Most	  RBPs	  have	  modular	  configuration:	  RBDs	  are	  physically	  separate	  and	  function	  independently	   from	   effector	   domains72.	   Emulating	   nature,	   artificial	   RBPs	   can	   be	  created	  in	  a	  similar	  fashion,	  by	  combining	  effector	  domains	  of	  choice	  to	  RBD’s	  with	  desired	  specificity73-­‐77.	  These	  designer	  RBPs	  can	  be	   implemented	   in	   the	  regulation	  of	  a	  broad	  range	  of	  biological	  processes	  that	  involve	  RNA	  metabolism.	  The	   first	   application	   of	   a	   PUF	   domain-­‐based	   engineered	   RBP	   was	   live-­‐cell	  tracking	  of	  mRNA.	  Visualization	  of	  RNA	   in	   live	  cells	  have	  previously	  been	  possible	  by	  tagging	  the	  RNA	  of	  interest	  with	  multiple	  copies	  of	  recognition	  elements	  and	  the	  use	   of	   RNA-­‐binding	   proteins	   fused	   to	   fluorescent	   proteins	   like	   GFP78.	   Although	  successful	   in	   detecting	   and	   tracking	   RNA	   in	   live	   ells,	   this	   system	   requires	   prior	  tagging	   of	   RNA	   of	   interest,	   which	   may	   alter	   RNA	   abundance	   and	   localization.	  Application	  of	  reprogrammable	  RNA-­‐binding	  proteins	  such	  as	  PUF	  domains	  for	  this	  purpose	  abolishes	  the	  need	  of	  tagging	  the	  RNA	  of	  interest.	  To	  this	  end,	  split-­‐protein	  systems	   were	   implemented,	   where	   two	   PUF	   domains	   were	   used	   to	   reconstitute	  enhanced	  green	  fluorescent	  protein	  (EGFP)	  or	  Venus	  from	  two	  nonfunctional	  parts	  that	  were	  brought	  to	  proximity	  on	  target	  RNA79.	  Such	  split	  protein	  system	  reduces	  background	  fluorescence	  and	  improves	  the	  signal-­‐to-­‐noise	  ratio	  compared	  with	  full-­‐length	  GFP	  fusions,	  where	  it	  is	  difficult	  to	  distinguish	  RNA-­‐bound	  protein	  GFP	  from	  RNA-­‐free	   protein.	   This	   approach	   allowed	   to	   track	   mitochondrial	   RNA79	   or	   single	  molecules	  of	  β-­‐actin	  mRNA80	  in	  cultured	  mammalian	  cells.	  In	  a	  similar	  strategy,	  split	  mCitrine-­‐PUF	  system	  was	  used	  to	  track	  tobacco	  mosaic	  virus	  RNA	  in	  plant	  cells81.	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The	   ability	   to	   control	   gene	   expression	   is	   necessary	   for	   both	   fundamental	  research	   as	   well	   as	   in	   applications	   such	   as	   cell	   fate	   manipulation	   and	   metabolic	  engineering.	   Gene	   expression	   is	   regulated	   at	   multiple	   RNA	   processing	   steps,	  including	  capping,	  polyadenylation,	  splicing,	  degradation,	  editing,	  and	  translocation.	  By	  fusing	  corresponding	  functional	  domains	  to	  RBDs	  such	  as	  PUF,	  one	  can	  envision	  development	   of	   tools	   capable	   of	   sequence-­‐specific	  manipulation	   of	   RNA	   almost	   at	  any	   processing	   step.	   One	   such	   tool	   has	   been	   developed	   to	   inhibit	   translation	   via	  regulation	   of	   the	   poly(A)	   tail	   of	   mRNA.	   To	   inhibit	   translation	   of	   microinjected	  reporter	  mRNA	   in	  Xenopus	  oocytes,	   FBF-­‐2,	   a	  PUF	  domain	   found	   in	  C.	  elegans,	  was	  fused	   to	   Xenopus	   CAF1	   protein,	   which	   has	   deadenylation	   activity	   that	   shortens	  poly(A)	   tails	   as	  well	   as	   an	   intrinsic	   translational	   repression	   activity82.	   The	   system	  induced	   deadenylation	   and	   decreased	   translation	   of	   reporter	   luciferase	  mRNA.	   In	  another	  study,	  a	  PUF	  domain	  alone,	  targeted	  to	  the	  5ʹ′	  untranslated	  region	  (UTR)	  of	  an	   open	   reading	   frame,	   was	   used	   as	   a	   steric	   block	   in	   the	   translation	   initiation	  pathway	  to	  inhibit	  the	  translation	  of	  the	  downstream	  reporter	  luciferase	  gene83.	  	  The	   use	   of	   a	   PUF	   scaffold	   for	   sequence-­‐specific	   enhancement	   of	   gene	  expression	  in	  living	  systems	  was	  first	  demonstrated	  in	  Xenopus	  oocytes.	  	  FBF-­‐2	  was	  fused	  with	  GLD2,	  a	  cytoplasmic	  poly(A)	  polymerase,	  and	  the	  chimeric	  protein	  was	  shown	   to	   direct	   polyadenylation	   of	   reporter	   RNA,	   enhance	   translation	   of	  microinjected	   luciferase	   mRNA,	   and	   direct	   polyadenylation	   of	   endogenous	  	  ribosomal	  protein	  L1	  mRNA82.	  In	  another	  elegant	  study,	  the	  PUF	  domain,	  which	  was	  targeted	   to	   the	   5ʹ′	   UTR	   of	   an	   open	   reading	   frame,	   was	   fused	   to	   the	   eukaryotic	  translation	  initiation	  factor	  4E	  (eIF4E)	  to	  enhance	  translation	  of	  reporter	  luciferase	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mRNA83.	  Furthermore,	  light-­‐inducible	  heterodimerization	  of	  PUF	  and	  eIF4E	  through	  light-­‐sensitive	   protein	   partners	   was	   demonstrated,	   thus	   allowing	   light-­‐inducible	  translation	   activation83.	   Alternatively,	   the	   PUF	   domain	   of	   FBF-­‐2	   protein	   that	   was	  mutagenized	  for	  specific	  binding	  to	  a	  new	  target	  sequence	  was	  fused	  with	  a	  segment	  of	   S.	   cerevisiae	   poly(A)-­‐binding	   protein,	   which	   is	   known	   to	   stimulate	   translation.	  This	  chimera	  protein,	  referred	  to	  as	  ‘neo-­‐activator’,	  increased	  endogenous	  cyclin	  B1	  abundance	   in	   a	   cancer	   cell	   line,	   and	   rendered	   the	   cell	   line	   hypersensitive	   to	  chemotherapeutic	  drugs69.	  Another	  strategy	  by	  which	  gene	  expression	  is	  regulated	  in	  nature	  is	  regulation	  of	  mRNA	  abundance.	  In	  many	  organisms,	  this	  strategy	  is	  achieved	  through	  the	  RNA	  interference	  (RNAi)	  pathway,	  where	  a	  multi-­‐component	  complex	  cuts	  and	  degrades	  target	   RNA84.	   An	   alternative	   synthetic	   system	   for	   RNA	   cleavage	   termed	   artificial	  site-­‐specific	   RNA	   endonuclease	   (ASRE)	   was	   designed	   using	   a	   PUF	   domain	   as	   an	  RNA-­‐recognition	   scaffold	   fused	   to	   a	   non-­‐specific	   endonuclease	   domain	   PilT	   N-­‐terminus85.	  ASRE	  targeting	  the	  endogenous	  LacZ	  transcript	  in	  Escherichia	  coli	  and	  a	  mitochondrial	   gene	   in	  human	  cultured	   cells	  were	  designed	  and	  used	   to	   sequence-­‐specifically	  degrade	  target	  mRNA	  and	  reduce	  corresponding	  protein	  levels.	  Alternative	  splicing	   is	  an	   important	  step	   in	  eukaryotic	  mRNA	  processing	   that	  allows	   for	  expression	  of	  multiple	   isoforms	  of	  proteins	  with	  distinct	   functions.	  The	  first	  attempt	  at	  engineering	  splicing	  factors	  with	  designed	  sequence	  specificities	  and	  activities	   was	   reported	   using	   a	   PUF	   domain	   as	   an	   RNA-­‐binding	   scaffold86.	   These	  engineered	   splicing	   factors	   (ESFs)	  were	   constructed	   from	  a	  wild	   type	  or	  modified	  PUF	  domain	  of	  HsPUM1	   fused	   to	  a	  glycine-­‐rich	  domain	  of	  hnRNP	  A1	  (Gly-­‐PUF)	  or	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the	  arginine-­‐serine-­‐rich	  domain	  of	  ASF/SF2	  (RS-­‐PUF).	  Consistent	  with	  the	  reported	  activities	   of	   the	   tethered	   domains,	   Gly-­‐PUF	   type	   ESF	   repressed	   inclusion	   of	   the	  cassette	  exon	  containing	  the	  cognate	  target	  sequence	  of	  PUF,	  while	  RS-­‐PUF	  type	  ESF	  promoted	   inclusion	   of	   the	   same	   cassette	   exon	   in	   reporter	   constructs70,	   86.	  Additionally,	   these	   ESFs	   could	   also	   regulate	   alternative	   use	   of	   splice	   sites.	   For	  example,	  RS-­‐PUF	   increased	   the	  use	  of	  an	  upstream	  3ʹ′	   splice	  site,	  whereas	  Gly-­‐PUF	  promoted	  the	  use	  of	  a	  downstream	  5ʹ′	  splice	  site.	  The	  designer	  ESF	  was	  shown	  to	  be	  able	   to	   shift	   splicing	  of	  endogenous	  pre-­‐mRNA	  of	  anti-­‐cancer	   target	  Bcl-­‐x	   towards	  the	  short	  Bcl-­‐xS	  isoform,	  thereby	  promoting	  apoptosis86;	  as	  well	  as	  promote	  splicing	  towards	   the	   anti-­‐angiogenic	   isoform	   b	   of	   endogenous	   VEGFA	   gene70	   in	   cultured	  cancer	  cells.	  	  
1.3.3 Potential	  use	  of	  PPR	  Proteins	  in	  RBP	  Engineering	  PPR	  are	  a	  huge	  class	  of	  proteins	  found	  primarily	  in	  mitochondria	  and	  chloroplasts	  of	  land	  plants,	  where	   they	  participate	   in	  RNA	   cleavage,	   splicing,	   degradation,	   editing	  and	   translation87-­‐88.	   The	   RNA-­‐binding	   motif	   of	   PPR	   consists	   of	   2-­‐30	   degenerate	  repeats	   that	  are	  approximately	  35-­‐amino	  acid-­‐long89	  and	  are	  organized	   in	  a	  helix-­‐turn-­‐helix	   structure90-­‐91.	   Like	   PUF	   proteins,	   PPR	   proteins	   bind	   RNA	   in	   a	   1:1	  correspondence	  between	  repeats	  and	  bases,	  and	  recognize	  single	  stranded	  RNA	  in	  a	  modular	  fashion92-­‐95.	  	  Computational,	   biochemical,	   and	   structural	   analyses	   agree	   that	   residue	   5	  (residue	   delimitation	   according	   to	   reference	   92)	   in	   each	   repeat	   contributes	   in	  distinguishing	  between	  purines	   and	  pyrimidines93-­‐95.	   Residue	  35,	  which	   is	   located	  close	  to	  the	  residue	  5	  in	  3-­‐dimensional	  space,	  allows	  the	  discrimination	  of	  adenine	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from	   guanine,	   and	   cytosine	   from	   uracil.	   In	   vitro	   binding	   assays	   confirmed	   that	  altering	  these	  two	  amino	  acids	  could	  change	  the	  RNA	  sequence	  specificity	  according	  to	   the	   code93.	   Another	   amino	   acid,	   which	   is	   located	   at	   position	   2,	   is	   sandwiched	  between	  two	  adjacent	  bases	  in	  a	  stacking	  interaction92,	  96,	  and	  thus	  is	  analogous	  to	  the	  residue	  at	  position	  13	  in	  PUF	  proteins.	  Unlike	  the	  PUF	  domain,	  the	  PPR	  protein	  binds	  RNA	  in	  a	  parallel	  configuration,	  i.e.	  the	  N-­‐terminal	  repeat	  of	  PPR	  binds	  to	  the	  5ʹ′-­‐end	   of	   the	   target	   RNA	   sequence,	   and	   the	   following	   repeats	   bind	   a	   stretch	   of	  consecutive	  bases	  downstream.	  	  Due	  to	  only	  a	  recent	  confirmation	  of	  the	  RNA-­‐recognition	  code	  of	  PPR	  via	  a	  co-­‐crystal	  structure92,	  PPR	  proteins	  have	  not	  yet	  been	  used	  as	  widely	  as	  PUF	  proteins	  in	   reprogramming	   specificity	   to	   RNA	   or	   engineering	   of	   designer	   RBP.	   However,	  unlike	  PUF	  proteins,	  PPR	  proteins	  differ	  widely	  in	  their	  recognized	  RNA	  sequences,	  which	  may	  be	   an	   indication	  of	   a	   greater	  plasticity	   and	   amenability	   in	   engineering	  specificity.	  
1.4 	  Scope	  and	  Goals	  of	  This	  Dissertation	  The	  first	  part	  of	  this	  dissertation	  is	  dedicated	  to	  the	  study	  and	  engineering	  of	  TALE	  proteins.	  In	  Chapter	  2,	  the	  engineering	  of	  TALEN	  for	  targeting	  Cystic	  Fibrosis	  Transmembrane	  Regulator	  gene	   (CFTR)	   is	  discussed.	  The	  Δ508F	  mutation	   in	  exon	  10	  of	  CFTR	   is	  responsible	  for	  the	  most	  cases	  of	  cystic	  fibrosis97,	  and	  was	  chosen	  as	  the	   target	   site	   for	   the	   engineered	  TALEN.	   Expression	   of	   the	   engineered	  TALEN	   in	  human	  cell	  lines	  allowed	  HR-­‐mediated	  repair	  of	  the	  episomally	  and	  chromosomally	  located	   reporter	   green	   fluorescent	   protein	   gene	   interrupted	   with	   the	   sequence	  fragment	  from	  CFTR.	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In	  Chapter	  3,	  we	  described	  the	  binding	  dynamics	  of	  TALE	  on	  DNA	  substrates	  measured	   by	   single	   molecule	   fluorescence	   microscopy.	   For	   the	   first	   time,	   the	  binding	  dynamics	  and	  one-­‐dimensional	  diffusion	  of	  TALE	  proteins	  along	  DNA	  were	  directly	   visualized.	   The	   data	   strongly	   suggest	   that	   the	   TALE	   protein	   searches	   its	  target	   using	   the	   facilitated	   diffusion	  mechanism,	   as	   was	   reported	   for	  many	   other	  transcription	   factors.	   This	   study	   can	   contribute	   to	   improved	   rational	   design	   of	  TALEs	  for	  biomedical	  applications.	  The	  aim	  of	  the	  second	  part	  of	  my	  dissertation	  was	  to	  engineer	  new	  PUF-­‐based	  biosynthetic	   tools.	  Chapter	  4	  discusses	   implementation	  of	   the	  Golden	  Gate	  cloning	  method	  for	  an	  efficient	  one-­‐step	  assembly	  of	  designer	  PUF	  proteins.	  To	  this	  end,	  a	  repeat	  module	   library	   that	   is	  potentially	  capable	  of	  generating	  a	  PUF	  domain	  with	  any	   desired	   specificity	   was	   created.	   The	   assembled	   novel	   PUF	   variants	   exhibited	  high	   in	   vitro	   binding	   efficiencies	   to	   cognate	   RNA	   sequences,	   corroborating	   the	  applicability	  of	   the	  modular	  assembly	  approach	  for	  PUF	  engineering.	   In	  Chapter	  5,	  we	  described	  the	  development	  of	  a	  designer	  translation	  inhibitor.	  The	  PUF	  domain	  was	   fused	   to	   human	   TTP,	   which	   allowed	   for	   a	   sequence-­‐specific	   reporter	   and	  endogenous	  gene	  repression	  in	  human	  cell	  lines.	  This	  work	  was	  a	  demonstration	  of	  the	  efficacy	  of	  a	  synthetic	  PUF-­‐based	  gene	  expression	  regulator.	  	  In	   Chapter	   6,	   a	   PUF-­‐based	   system	   for	   intracellular	   directional	   transport	   of	  mRNA	   was	   described.	   The	   synthetic	   biology	   device	   consists	   of	   a	   “motor”,	   which	  provides	   a	   directional	   movement,	   and	   the	   PUF	   protein	   that	   dimerizes	   with	   the	  “motor”	   in	   a	   ligand-­‐dependent	   manner.	   The	   system	   allowed	   RNA-­‐sequence	   and	  motor-­‐specific	   transport	   and	   colocalization	   of	   PUF	   and	   its	   RNA	   cargo.	   The	   PUF-­‐
	   19	  
motor	   system	   was	   implemented	   for	   the	   reporter	   and	   endogenous	   mRNA	   in	  transport	   in	   rat	   hippocampal	   neurons.	   This	   prototypical	   synthetic	   device	   should	  allow	  easy	  and	  controlled	  intracellular	  mRNA	  transport	  regulation	  in	  eukaryotes	  for	  applications	  in	  basic	  science	  and	  therapeutics.	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Chapter	  2.	  Engineering	  of	  TALEN	  for	  Editing	  of	  the	  Cystic	  Fibrosis-­‐
Associated	  Mutation	  
2.1	  Introduction	  Cystic	  fibrosis	  (CF)	  is	  a	  chronic	  autosomal	  recessive	  disorder	  with	  an	  incidence	  of	   about	   one	   in	   2,500	   and	   symptoms	   including	   elevated	   sweat	   chloride	  concentrations,	   exocrine	   pancreatic	   insufficiency,	   progressive	   obstructive	   lung	  disease,	   and	   male	   infertility1-­‐2.	   The	   disease	   is	   caused	   by	   mutations	   in	   the	   cystic	  fibrosis	   transmembrane	   conductance	   regulator	   (CFTR)	   gene3-­‐4.	   Thousands	   of	  mutations	  in	  the	  CFTR	  gene	  have	  been	  reported,	  and	  the	  most	  common	  one	  is	  a	  3	  bp	  deletion	   in	   exon	   10	   found	   in	   almost	   70%	   of	   patients5.	   This	   genotype	   causes	   the	  deletion	  of	  phenylalanine	  at	  the	  508	  position	  (F508del),	  resulting	  in	  misfolding	  and	  biosynthetic	  arrest	  of	  CFTR6-­‐7.	  Due	  to	  its	  monogenic	  nature,	  CF	  is	  a	  potentially	  ideal	  target	  for	  genome-­‐based	  therapies.	  While	  the	  initial	  demonstration	  that	  transduction	  of	  CFTR	  cDNA	  could	  correct	  the	  CF	  phenotype	  in	  cultured	  cells	  was	  promicing8,	  in	  patients	  with	  CF,	  adenovirus-­‐mediated	  gene	  transfer	  of	  CFTR	  cDNA	  demonstrated	  only	  transient	  correction	  of	  the	  chloride	  transport	  defect9.	  One	  reason	  of	  a	  transient	  effect	  of	  the	  aforesaid	  approach	  could	  be	  the	  absence	  of	  the	  endogenous	  gene	  expression	  regulation	  of	  heterogenous	  
CFTR.	  	  Due	  to	  its	  ability	  to	  permanently	  correct	  a	  genetic	  deficiency,	  targeted	  genetic	  manipulation	   using	   custom-­‐designed	   nucleases	   has	   become	   a	   powerful	   approach	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recently10-­‐13.	  This	  approach	  is	  based	  on	  the	  observation	  that	  induction	  of	  a	  double-­‐strand	   break	   (DSB)	   in	   the	   target	   DNA	   sequence	   increases	   the	   homologous	  recombination	   efficacy	   by	   several	   orders	   of	   magnitude14-­‐15.	   Thus,	   it	   was	  demonstrated	   that	   co-­‐delivery	   of	   a	   site-­‐specific	   nuclease	   with	   a	   donor	   plasmid	  bearing	  locus-­‐specific	  homology	  arms	  can	  efficiently	  correct	  a	  genetic	  abnormality16.	  Transcription	   activator-­‐like	   effector	   (TALE)	   protein	   fusions	   with	   nonspecific	  endonuclease	  FokI	  (TALEN)	  are	  one	  of	  the	  recently	  developed	  potent	  tools	  used	  for	  targeted	  genome	  modification.	  	  TALE	  proteins	  are	  transcription	  activators	  that	  were	  found	   to	   be	   secreted	   into	   host	   plant	   cells	   by	   plant-­‐pathogenic	   Xanthomonas	  bacteria17-­‐19.	   	  The	  central	  part	  of	  the	  TALE	  gene	  is	  a	  highly	  repetitive	  DNA	  binding	  motif,	  consisting	  of	  nearly	  identical	  repeats	  of	  33-­‐35	  amino	  acids20-­‐21,	  while	  the	  last	  repeat	   is	  only	  a	  half	  repeat	  consisting	  of	  19-­‐20	  amino	  acids20.	  The	  target	  sequence	  recognition	   by	   TALE	   proteins	   is	   governed	   by	   two	   hypervariable	   amino	   acids	   at	  positions	   12	   and	   13	   referred	   to	   as	   “repeat	   variable	   di-­‐residue”	   (RVD)22-­‐23.	   The	  preference	   of	   certain	   nucleobases	   in	   the	   target	   sequence	   by	   a	   succession	   of	   RVD	  follows	  a	  simple	  code	  and	  a	  modular	  1	  repeat	  :	  1	  base	  recognition	  pattern.	  Thus,	  the	  RVD	   NI	   prefers	   adenine,	   NG	   thymine,	   HD	   a	   cytosine,	   while	   NN	   recognizes	   either	  adenine	   or	   a	   guanine22-­‐23.	   A	   TALE	   with	   a	   desired	   specificity	   can	   be	   designed	   by	  assembling	   the	   individual	   repeats	  by	   following	   this	  code22.	  The	  aim	  of	   this	  project	  was	   to	   design	   a	  TALEN	   specific	   for	   the	  CFTR	   gene	   to	   permit	   a	   highly	   specific	   and	  efficient	   homologous	   recombination	   event	   and	   correction	   of	   the	   CFTR	   gene	   in	  airway	  epithelial	  cells	  with	  the	  F508del	  genotype	  of	  CFTR.	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2.2	  Results	  
2.2.1	  Design	  and	  Optimization	  of	  TALENs	  Using	  the	  Episomal	  GFP	  Reporter	  Because	   the	   FokI	   endonuclease	   functions	   as	   a	   dimer24,	   a	   TALEN	   heterodimer	  (TALEN-­‐CFTR-­‐L	   and	   TALEN-­‐CFTR-­‐R)	   was	   designed,	   where	   each	   TALE	   was	  constructed	  to	  target	  a	  20	  bp	  sequence	  separated	  by	  a	  16	  bp	  spacer.	  Each	  RVD	  was	  chosen	  in	  accordance	  with	  the	  TALE	  DNA	  recognition	  code22-­‐23	  (Figure	  2.1	  a,	  b	  and	  c).	   The	   trinucleotide	   deletion	   responsible	   for	   the	   F508del	  was	   excluded	   from	   the	  TALEN-­‐CFTR-­‐L	  target	  site,	  so	  that	  it	  binds	  to	  the	  mutant	  F508del	  locus	  of	  CFTR,	  and	  not	  the	  wild	  type	  CFTR	  locus.	  Each	  TALE	  was	  fused	  with	  a	  nonspecific	  DNA	  cleavage	  domain	  of	  FokI	  endonuclease	  via	  a	   flexible	  G4S	   linker.	  The	  TALE	  were	  constructed	  using	  the	  AvrXa10	  TALE	  25	  as	  a	  template.	  The	  N-­‐terminal	  region	  (NTR)	  of	  the	  TALEs	  were	   designed	   to	   exclude	   the	   first	   152	   amino	   acids	   in	   the	   native	   TALE,	   as	   it	  was	  shown	  that	  this	  region	  specifies	  the	  transport	  of	   the	  protein	   into	  plant	  cells	  and	   is	  not	   essential	   for	   other	   functions26.	   To	   study	   the	   effect	   of	   the	   C-­‐terminal	   length	   of	  TALE	   on	   the	   efficacy	   of	   TALEN	   heterodimerization	   and	   function,	   the	   C-­‐terminal	  region	  (CTR)	  was	  truncated	  to	  various	  lengths.	  Our	  TALEN	  constructs	  contained	  the	  first	   20,	   31,	   62	   amino	   acids	   of	   the	   AvrXa10	   TALE,	   or	   the	   first	   31	   amino	   acids	  followed	  by	   a	   long	   (G4S)x6	   linker	   (CTRs	  C20,	  C31,	  C62,	   and	  C31-­‐GS,	   respectively).	  	  The	  TALE-­‐FokI	  fusions	  L	  and	  R	  were	  cloned	  separately	  under	  the	  cytomegalovirus	  (CMV)	  promoter.	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Figure	  2.1	  Design	  of	  TALEN-­‐CFTR.	   (a)	  Schematic	  of	  CFTR	  exon	  10	  sequence	  fragment	  and	  TALEN-­‐CFTR.	  Red	  sequence,	  F508del	  mutation.	  Underlined	  sequence,	  TALEN-­‐binding	  sites.	  (b)	  Schematic	  of	  TALEN.	  NLS,	  SV40	  nuclear	  localization	  signal.	  FLAG,	  FLAG	  protein	  tag.	  NTR,	  N-­‐terminal	  region.	  CRD,	  Central	  repeat	  domain.	  CTR,	  C-­‐terminal	  region.	  (c)	  The	  5’-­‐3’	  sequences	  of	  TALEN-­‐CFTR	  binding	  sites	  as	  well	  as	  RVD	  array	  of	  the	  TALEN,	  listed	  from	  the	  N-­‐terminus	  to	  the	  C-­‐terminus	  of	  the	  proteins.	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37	   bp	   at	   the	   5ʹ′	   of	   its	   sequence.	   Upon	   introduction	   of	   a	   double	   stranded	   break	  adjacent	   to	   the	   F508del,	   the	   cell’s	   homologous	   recombination	   machinery	   should	  facilitate	  the	  repair	  of	  the	  reporter	  EGFP	  using	  the	  donor	  EGFP	  sequence	  (Figure	  2.2	  b).	   The	   donor-­‐reporter	   EGFP	   plasmid,	   as	   well	   as	   the	   TALEN-­‐CFTR-­‐L	   and	   TALEN-­‐CFTR-­‐R	  plasmids	  were	  used	  to	  co-­‐transfect	  the	  HeLa	  cell	  line,	  and	  72	  hours	  later,	  the	  percentage	   of	   EGFP-­‐positive	   cells	   was	  measured	   using	   flow	   cytometry.	   The	  EGFP	  correction	  efficacy	  was	  estimated	  as	  the	  percentage	  of	  EGFP-­‐positive	  cells.	  	  a	  
	  b	  
	  
Figure	   2.2	   Schematic	   of	   EGFP	   gene	   targeting	   reporter	   system.	   (a)	   The	   structure	   of	   the	   EGFP-­‐interrupting	  insert,	  with	  TALEN-­‐binding	  sites	  (red),	  and	  a	  16-­‐nt	  spacer	  (white).	  Stop	  codon	  position	  is	   indicated	   with	   a	   “Stop”	   sign.	   (b)	   Schematic	   of	   EGFP	   correction	   through	   a	   homologous	  recombination	  event.	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In	   the	  presence	  of	  TALENs,	  4.2%	   to	  8.5	  %	  EGFP-­‐positive	   cells	  were	  detected	  (Figure	  2.3),	  while	  in	  the	  absence	  of	  TALENs,	  the	  percentage	  of	  eGFP-­‐positive	  cells	  was	   undetectably	   small	   (data	   not	   shown),	   indicating	   that	   successful	   gene	   editing	  events	   took	   place	   due	   to	   the	   endonuclease	   activity	   of	   designer	   TALENs.	   We	   also	  observed	   that	   TALENs	   with	   longer	   CTRs	   generally	   exhibited	   slightly	   increased	  correction	  efficacies	  compared	  to	  shorter	  CTRs	  (Figure	  2.3),	  whereas	  TALENs	  with	  the	  C31-­‐GS	  truncations	  demonstrated	  correction	  efficacies	  considerably	  lower	  than	  C62	   truncations,	  despite	   the	  same	   total	  number	  of	  amino	  acids	  after	   the	  CRD.	  The	  worse	  performance	  of	  C31-­‐GS	  constructs	  could	  be	  due	  to	  the	  shorter	  effective	  length	  of	   C31-­‐GS,	   due	   to	   a	   more	   compact	   structure	   of	   the	   random	   coil	   the	   GS	   linker	  assumes.	   It	   is	   possible	   that	   the	   C62	   tail	   forms	   a	   more	   rigid	   structure,	   allowing	  enough	   length	   for	   the	   two	  FokI	   domains	   to	   reach	   each	   other,	   bridging	   the	   16	  bp-­‐spacer	  between	  the	  two	  TALE	  recognition	  sites.	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Figure	   2.4	   Analysis	   of	   TALEN	   performance	   with	   various	   NTR	   and	   CTR	   lengths,	   measured	   by	  episomal	  reporter	  correction.	  Reporter	  correction	  in	  HeLa	  cells	  was	  estimated	  by	  quantifying	  EGFP-­‐positive	  cells	  via	  flow	  cytometry.	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2.2.2	  Optimization	  of	  TALENs	  Using	  the	  Chromosomal	  GFP	  Reporter	  
	  
Figure	   2.5	   Analysis	   of	   TALEN	   performance	  with	   various	   CTR	   lengths,	  measured	   by	   chromosomal	  reporter	   correction.	  Reporter	   correction	   in	  HeLa	   cells	  was	   estimated	  by	  quantifying	  EGFP-­‐positive	  cells	  via	  flow	  cytometry.	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lowest	  when	  TALENs	  with	  longest	  CTR	  were	  used,	  and	  highest	  when	  TALENs	  with	  the	  C31-­‐GS	  tales	  were	  used	  (Figure	  2.5).	  We	  suggest	   that	   these	  contrasting	  results	  are	   due	   to	   different	   states	   of	   chromosomal	   structure	   in	   episomal	   versus	  chromosomally	  located	  target	  sequences.	  It	  is	  conceivable	  that	  due	  to	  higher	  order	  chromatin	  structure,	  the	  effective	  length	  of	  the	  16	  bp-­‐spacer	  between	  the	  two	  TALE	  -­‐binding	  sites	  was	  shorter	  in	  a	  chromosomally	  located	  EGFP	  reporter,	  and	  that	  the	  CTR	  length	  of	  62	  amino	  acids	  was	  too	  long	  for	  favorable	  dimerization	  of	  FokI.	  
	  
Figure	   2.6	   Analysis	   of	   TALEN	   performance	   with	   various	   NTR	   lengths,	   measured	   by	   episomal	  reporter	  correction.	  CTR	  configuration	  L-­‐C31/R-­‐C31-­‐GS	  was	  used.	  Reporter	  correction	  in	  HeLa	  cells	  was	  estimated	  by	  quantifying	  EGFP-­‐positive	  cells	  via	  flow	  cytometry.	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2.2.3	  Correction	  of	  Endogenous	  CFTR	  Gene	  in	  Airway	  Epithelial	  Cells	  To	  test	  the	  gene	  correction	  efficacy	  of	  the	  designer	  TALEN	  in	  targeting	  endogenous	  
CFTR,	  we	  utilized	   the	  human	  airway	  epithelial	   cell	   lines	  KKLEB27,	  UNCCF3T27,	   and	  CFT128.	   All	   three	   cell	   lines	   were	   developed	   by	   immortalization	   from	   airway	  epithelial	  tissues	  of	  patients	  homozygous	  for	  the	  F508del	  mutation	  of	  CFTR27-­‐28.	  By	  transfection	  of	  plasmids	  encoding	  GFP	  under	  CMV	  promoter	  using	  the	  Nucleofector	  Technology,	   we	   measured	   transfection	   efficiencies	   ranging	   between	   20-­‐40%	   for	  KKLEB,	  8-­‐13%	  for	  UNCCF3T,	  and	  60-­‐70	  %	  for	  the	  CFT1	  cell	  line	  (Table	  2.1).	  Due	  to	  its	   highest	   efficiency	   of	   being	   transfected,	   CFT1	   cells	   were	   used	   further	   for	  CFTR	  correction	  experiments.	  
	  
Table	  2.1	  Characteristics	  of	  the	  human	  airway	  epithelia	  cell	  lines	  used	  in	  this	  study.	  
For	   the	   correction	   of	   endogenous	   CFTR	   with	   the	   F508del	   genotype,	   we	  constructed	  homology	  donors	  with	  various	  homology	   lengths	   and	   structure.	   Since	  efficient	  intrachromosomal	  recombination	  requires	  uninterrupted	  homology	  of	  134-­‐232	   bp29,	   and	   because	   of	   the	   positive	   correlation	   between	   the	   frequency	   of	  homologous	   recombination	   and	   homology	   length30,	   we	   constructed	   plasmids	  containing	   300	   bp,	   500	   bp,	   and	   1000	   bp	   homology	   arms	   on	   each	   side	   of	   the	  mutation-­‐containing	  mismatch.	  With	  recent	  reports	  of	  genome	  editing	  using	  single	  stranded	   oligodeoxynucleotides	   (ssODN)	   in	   combination	   with	   zinc-­‐finger	  
Name( Cell(type( ImmortalizaGon( NucleofecGon(
eﬃciency(
KKLEB27( Bronchial(( hTERT/SV40LT( 20B40%(
UNCCF3T27( Bronchial(( BmiB1/hTERT( 8B13%(
CFT128( Tracheobronchial( E6/E7( 60B70%(
9(
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nucleases31-­‐32,	  we	  also	  constructed	  ssODNs	  containing	  CFTR	  homology	  sequences	  50	  and	  100	  nt	  in	  length	  to	  use	  with	  our	  designer	  TALENs.	  All	  of	  the	  homology	  donors	  we	   constructed	   contained	   not	   only	   the	   F508del	   correcting	   insertion,	   but	   also	  TALEN-­‐blocking	  mutations	  –	  8	  silent	  mutations	   to	  minimize	  re-­‐binding	  of	  TALENs	  after	  the	  homologous	  recombination	  event	  (Figure	  2.7a	  and	  b).	  Two	  of	  these	  silent	  mutations	  also	  created	  a	  unique	  new	  EcoRV	  restriction	  site,	  which	  we	  subsequently	  used	  for	  estimation	  of	  correction	  efficacy	  using	  restriction-­‐digestion.	  
	  
Figure	   2.7	   Illustration	   of	   endogenous	  CFTR	   exon	   10	   and	   homology	   donor.	   (a)	   Schematic	   of	   CFTR	  exon	   10,	   including	   TALEN-­‐binding	   sites	   and	   a	   16-­‐bp	   spacer	   between	   them	   (top)	   and	   schematic	   of	  homology	  donor,	  including	  TALEN-­‐blocking	  mutations	  (red	  wedges)	  and	  the	  F508	  insertion	  (purple	  wedge).	  Locations	  of	  primer	  pairs	  1,	  2,	  and	  3	  for	  quantitative	  PCR	  are	  indicated	  with	  arrows.	  (b)	  DNA	  sequence	   showing	   TALEN-­‐binding	   sites,	   TALEN-­‐blocking	   mutations,	   and	   the	   CTT	   trinucleotide	  (coding	  for	  F508).	  
Flanking(intron(Flanking(intron(




Screen clipping taken: 9/7/2011, 12:37 AM
Screen clipping taken: 9/7/2011, 1:44 AM
We have found that gene conversion can take place efficiently
between sequences that share a short stretch of homology
(250 bp n each broken arm, OI30). The coupling to crossing
over, in contrast, requires a minimal homology length of
about 1.7 kb (MK201).
The Relationhsip between homology length and crossing over  during the repair of the broken 
chromosome. Inbar. The Journal of Biological Chemistry. 275.:40 30833-38.
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   We	   co-­‐nucleofected	   different	   donor	   constructs	   separately	   with	   the	   plasmids	  encoding	   TALEN-­‐CFTR	   with	   the	   CTR	   configuration	   L-­‐C31/R-­‐C31-­‐GS	   and	   NTR	  configuration	   d152N,	   and	   allowed	   the	   cells	   to	   grow	   for	   72	   hours	   before	   analysis.	  Since	   correction	   efficacy	   estimation	   through	   PCR	   amplification	   and	   consecutive	  restriction	  digestion	  did	  not	  yield	  correction	  efficacy	  above	  the	  detection	  limit	  (~2	  %,	  data	  not	  shown),	  we	  designed	  an	  alternative	  quantitative-­‐PCR	  based	  method	  for	  detection	   of	   low	   correction	   efficacies.	   The	  method	   consists	   of	   amplifying	   the	  DNA	  sequence	  with	  the	  primers	  located	  outside	  the	  sequences	  covered	  by	  the	  homology	  donor	  (primer	  pair	  1,	  Figure	  2.7a)	  from	  genomic	  DNA	  isolated	  from	  TALEN/CFTR-­‐donor	  treated	  cells.	  This	   is	   followed	  by	  gel-­‐purification	  of	  the	  amplified	  product	  to	  remove	  any	  trace	  homology	  donor	  still	  present	  in	  cells.	  Control	  reactions	  are	  carried	  out	  without	  the	  DNA-­‐polymerase,	  to	  confirm	  that	  the	  template	  for	  the	  next	  round	  of	  PCR	   is	   the	   PCR	   product	   amplified	   from	   genomic	   DNA,	   and	   not	   non-­‐specific	  background	   amplification.	   Quantitative	   PCR	   is	   performed	   using	   the	   previous	  amplification	  product	  as	  a	  template,	  using	  primer	  pairs	  2	  or	  3	  (Figure	  2.7a).	  Primer	  pair	  2	  binds	  to	  the	  sequence	  containing	  the	  TALEN-­‐blocking	  mutations,	  and	  the	  3′-­‐end	   of	   one	   of	   the	   primers	   also	   ends	   with	   the	   sequence	   corresponding	   to	   the	  correcting	   mutation,	   absent	   in	   the	   uncorrected	   genomic	   CFTR	   sequence	   of	   CFT1	  (F508	  insertion,	  Figure	  2.7a).	  Hence,	  primer	  pair	  2	  only	  amplifies	  from	  the	  corrected	  
CFTR	   sequence.	  Primer	  pair	  3	  binds	   to	   sequences	   immediately	  outside	   the	  primer	  pair	  2,	  and	  is	  used	  as	  a	  control	  for	  template	  loading.	  The	  same	  amount	  of	  template	  was	  used	  in	  all	  quantitative	  PCR	  reactions,	  which	  was	  confirmed	  by	  almost	  identical	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Ct	  values	  in	  all	  amplifications	  using	  the	  primer	  pair	  3.	  For	  construction	  of	  a	  standard	  curve	   for	   estimation	   of	   correction	   efficacy,	   we	  mixed	   PCR	   amplification	   products	  from	   F508del	   (amplified	   from	   genomic	   DNA	   of	   CFT1	   cells)	   or	   donor	   sequence	  (amplified	  from	  the	  p2x1000	  donor	  plasmid)	  in	  ratios	  ranging	  from	  0.01	  %	  to	  100	  %	  of	  donor	  sequence.	  
	  
Figure	  2.8	  Correction	  efficiency	  of	  endogenous	  CFTR	  measured	  by	  quantitative	  PCR.	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2.3	  Discussion	  Designer	   nucleases,	   such	   as	   zinc-­‐finger	   nucleases	   (ZFN),	   TALEN,	   and	   the	  CRISPR/Cas9	   system	   (Cas9	   nuclease	   in	   combination	   with	   the	   clustered	   regularly	  interspaced	  short	  palindromic	  repeats,	  CRISPR)	  have	  been	  developed	  as	  invaluable	  tools	   for	   genome	   editing	   applications.	   Especially	   promising	   is	   the	   application	   of	  these	  tools	  for	  treating	  genetic	  diseases,	  for	  they	  allow	  high-­‐efficacy	  correction	  of	  an	  endogenous	  gene	  without	  the	  need	  of	  introducing	  an	  additional	  copy	  of	  a	  gene	  with	  unnatural	   expression	   regulation.	   In	   this	   work,	   we	   designed	   and	   optimized	   the	  TALEN	  system	  for	  the	  editing	  of	  the	  F508del	  mutation	  of	  CFTR,	  as	  an	  application	  of	  TALENs	  for	  tackling	  CF.	  By	  comparison	  of	  various	  truncations,	  we	  investigated	  the	  optimal	  architecture	  of	  TALEN	   for	   the	   cleavage	  of	   a	   sequence	   from	  exon	  10	  of	  CFTR.	   The	  optimal	  NTR	  length	  was	  reported	  to	  be	  147	  residues	  N-­‐terminally	  of	  TAL	  repeats	  in	  the	  context	  of	  TALE	   transcription	   factor33,	   155	   residues34	   or	   136	   residues35	   in	   the	   context	   of	  TALENs,	  which	  is	  in	  agreement	  with	  our	  TALEN	  architecture	  with	  140	  residues.	  This	  region	   was	   reported	   to	   contain	   at	   least	   126	   residues	   that	   form	   a	   superhelical	  structure	  with	  four	  continuous	  pseudo-­‐repeats	  resembling	  CRD	  repeats,	  which	  are	  important	  for	  the	  nonspecific	  binding	  of	  TALE	  to	  DNA36.	  Studies	  on	  ZFN	  demonstrated	  that	  the	  protein	  linker	  length	  that	  connects	  the	  DNA-­‐binding	   domain	   to	   FokI	   affects	   the	   optimal	   spacer	   length	   between	   the	   two	  protein-­‐binding	   sites37-­‐38.	   Similarly,	   studies	   on	   TALEN	   showed	   that	   longer	   C-­‐terminal	  configurations	  (~60	  compared	  to	  ~20	  residues)	  have	  a	  higher	  preference	  for	   longer	   spacer	   lengths	   between	   the	   two	   protein	   binding	   sites	   (12–30	   bp	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compared	  to	  10–16	  bp)34-­‐35,	  39.	  In	  accordance	  with	  these	  observations,	  we	  observed	  TALEN	   activity	   with	   both	   CTR	   linkers	   of	   31	   or	   63	   residues	   in	   the	   context	   of	   our	  target	  site	  with	  a	  16	  bp	  spacer.	  Surprisingly,	  the	  optimal	  CTR	  linker	  length	  of	  TALEN	  varied	   dramatically	   depending	   on	   whether	   the	   reporter	   gene	   was	   episomal	   or	  chromosomal.	  These	  results	   indicate	   that	   the	   local	  DNA	  conformation	  at	   the	  TALE	  target	  site	  plays	  as	  an	  important	  role	  in	  the	  effective	  distance	  between	  the	  two	  DNA-­‐binding	  domains,	   as	   the	   length	  of	   the	  DNA	  backbone	  between	   them.	  We	   therefore	  conclude	   that	   for	   optimal	   results,	   the	   best	   TALE	   configuration	   with	   CTR	   ranging	  between	  20	  and	  60	  residues	  must	  be	  determined	  for	  each	  genomic	  target	  site.	  Recently,	   correction	   of	   endogenous	   CFTR	  with	   the	   F508del	   using	   ZFN40	   and	  CRISPR/Cas941	   was	   reported,	   however	   it	   is	   difficult	   to	   compare	   editing	   efficacies	  obtained	  by	  us	  with	  those	  reported	  previously.	  Using	  a	  4.3	  kb	  wild	  type	  CFTR	  donor	  sequence	   and	   an	   engineered	   ZFN	   cleaving	   203	   bp	   upstream	   of	   the	   F508del,	  correction	  of	  the	  mutation	  was	  observed	  in	  CF	  tracheal	  epithelial	  cells	  using	  a	  PCR	  assay40.	  However,	   the	   correction	   efficacy	   could	   not	   be	   determined	   due	   to	   it	   being	  below	   the	   detection	   limit	   of	   the	   assay	   based	   on	   PCR	   amplification/restriction	  digestion.	  The	   authors	   suggested	   that	   low	  editing	   efficacy	   (estimated	   to	  be	  <	  1%)	  could	  be	  due	  to	  the	  long	  distance	  between	  the	  double	  strand	  break	  and	  the	  F508del	  mutation40.	   In	   another	   study,	   CRISPR/Cas9	   genome-­‐editing	   system	   was	   used	   to	  correct	  the	  F508del	  mutation	  in	  CF	  patient-­‐derived	  cultured	  intestinal	  stem	  cells41.	  Since	   the	   gene	   correction	   procedure	   involved	   selection	   for	   puromycin-­‐resistant	  cells41,	   it	   is	   once	   again	   difficult	   to	   compare	   the	   correction	   efficacies	   between	   our	  investigations.	  However,	   their	  results	   imply	   that	  efficient	  nuclease-­‐assisted	  editing	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of	  CFTR	   is	   possible,	   provided	   that	   it	   is	   done	   in	   combination	  with	   site-­‐specific	   co-­‐integration	  of	  selection	  markers	  and	  subsequent	  selection	  for	  marker-­‐resistant	  cells.	  Given	   these	   results,	   we	   conclude	   that	   the	   TALEN	   developed	   in	   this	   study	   for	   the	  correction	  of	  the	  F508del	  mutation	  of	  CFTR	  could	  potentially	  be	  used	  for	  editing	  of	  endogenous	   CFTR	   from	   CF	   patient-­‐derived	   stem	   cells	   in	   combination	   with	   a	  homology	  donor	  sequence	  containing	  the	  exon	  10	  of	  CFTR	  and	  a	  selection	  marker.	  
2.4	  Materials	  and	  Methods	  
2.4.1	  Cloning	  of	  DNA	  Constructs	  For	   chromosomal	   reporter	   correction,	   the	   enhanced	   green	   fluorescence	   protein	  (EGFP)	  gene	  was	  disrupted	  in	  the	  middle	  by	  the	  insertion	  of	  a	  sequence	  containing	  an	  in-­‐frame	  stop	  codon	  and	  a	  56	  bp	  CFTR	  gene	  locus	  that	  is	  the	  target	  sequence	  for	  the	  engineered	  TALEN.	  This	  non-­‐functional	  EGFP	  reporter	  sequence	  was	  cloned	  into	  the	  pLNCX2	  retroviral	  vector	  (Clontech)	  downstream	  of	  the	  cytomegalovirus	  (CMV)	  promoter	   using	   the	   SalI	   and	  HindIII	   restriction	   sites	   (plasmid	   pLNCX2-­‐het-­‐CFTR-­‐EGFP*)	   and	   stably	   integrated	   into	   the	   HeLa	   cell	   line	   genome	   via	   retroviral	  transduction	  according	  to	  the	  manufacturer’s	  protocol.	  Transfected	  Hela	  cells	  were	  selected	   in	  500	  mg/ml	  G418	   for	   two	  weeks.	  A	  donor	  plasmid	  pCMV5-­‐eGFP-­‐donor	  containing	  the	  EGFP	  gene	  lacking	  a	  promoter	  and	  the	  first	  37	  bp	  of	  its	  sequence	  into	  the	  pNEB193	  vector	  (New	  England	  Biolabs)	  was	  described	  elsewhere39.	  	  For	   episomal	   reporter	   construction,	   the	   plasmid	   pCMV5-­‐Het-­‐CFTR-­‐EGFP1	  containing	   both	   the	   donor	   and	   reporter	   EGFP	   sequences	   was	   constructed	   in	   the	  pCMV5	   vector.	   For	   this	   purpose,	   the	   non-­‐functional	   EGFP	   sequence	   with	   a	   stop	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codon	  and	  the	  56	  bp	  CFTR	  gene	  locus	  insert	  (reporter	  EGFP)	  was	  sub-­‐cloned	  using	  
HindIII	  and	  SalI	  restriction	  sites	  into	  the	  pCMV5-­‐eGFP-­‐donor	  plasmid.	  TALEN-­‐CFTR	   L	   and	   TALEN-­‐CFTR	   R	   central	   repeat	   domain	   sequences	   were	  codon-­‐optimized	   for	  expression	   in	  human	  cells	  and	  synthesized	  at	  DNA2.0	   (Menlo	  Park,	   CA)	   in	   the	   pJ247	   vector.	   The	   two	   constructs	  were	   each	   sub-­‐cloned	   into	   the	  pCMV5	  vector	  (a	  kind	  gift	  of	  Dr.	  David	  Russel,	  University	  of	  Texas	  Soutwestern),	  so	  that	  each	  contain	  a	  Kozac	  sequence,	  nuclear	  localization	  signal	  from	  Simian	  virus	  40	  (SV40),	   a	   FLAG	   tag	   at	   the	   N-­‐terminus	   of	   the	   construct,	   NTR	   and	   CTR,	   or	   linker	  sequences	  of	  specified	  lengths,	  and	  FokI	  sequence	  at	  the	  C-­‐terminus.	  The	  constructs	  were	   spliced	   using	   overlap	   extension	   PCR	  with	   primers	   bearing	   100	   bp	   overlaps,	  and	  inserted	  into	  the	  vector	  using	  NotI	  and	  HindIII	  restriction	  sites.	  The	  sense	  sequence	  of	  the	  50	  bp	  olygodeoxynucleotide	  (ODN)	  donor	  sequence	  was	  5′-­‐CAGTTTTCCTGGATTATGCCTGGCACGATCAAAGAGAATATTATCTTTGGTGTTTCCTATGATGA 
ATACAGATATCGAAGCGTTATCAAAGCATGCCAACTAGAAGAGGT-­‐3′,	   and	   the	   sense	   sequence	   of	  the	   100	   bp	   ODN	   donor	   sequence	   was	   5′-­‐
CAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGCACGATCAAAGAGAATATTATCT
TTGGTGTTTCCTATGATGAATACAGATATCGAAGCGTTATCAAAGCATGCCAACTAGAAGAGGTAAGAAAC
TATGTGAAAACTTTTTG-­‐3′.	  To	  construct	  donor	  plasmids	  containing	  CFTR	  gene	  exon	  10	  homology	   arms	   of	   300	   bp,	   500	   bp,	   and	   1000	   bp,	   genomic	   DNA	   from	   the	   airway	  epithelial	   cells	   CFT1	   was	   purified	   using	   Wizard	   genomic	   DNA	   purification	   kit	  (Promega)	   according	   to	  manufacturer’s	   instructions.	   The	   3′	   half-­‐fragments	   of	   the	  donor	  constructs	  were	  amplified	  from	  the	  genomic	  DNA	  using	  the	  50	  bp	  sense	  ODN	  as	   a	   forward	   primer	   and	   the	   following	   reverse	   primers:	   5′-­‐
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GCATGCCTGCAGAATGAGTGAACAAAATTCTCACCATTTCATAAAATGCATTTA-­‐3′	   for	   p2x300,	   5′-­‐
GCATGCCTGCAGACAATTTTACCCCTCTAATTCTCTGCTGGC-­‐3′	   for	   p2x500,	   5′-­‐
GCATGCCTGCAGCTGTTGAATGACTGAGTATATACATGGAAAGCCATTCAT-­‐3′	   for	   p2x1000.	   These	  amplicons	  were	  subsequently	  used	  as	  mega-­‐primers	  for	  amplification	  of	  the	  entire	  fragments,	   with	   the	   following	   forward	   primers:	   5′-­‐
TCTAGAGTCGACACTTTCCCTTGTATCTTTTGTGCATAGCAGAG-­‐3′	   for	   p2x300,	   5′-­‐
TCTAGAGTCGACTGTGAAGATTAAATAAATTAATATAGTTAAAGCACATAGAACAGCA-­‐3′	   for	   p2x500,	  and	   	   5′-­‐TCTAGAGTCGACCAGATTTATCTTTGTATTGTTAAATCTGCTTATGCTTCTATTACTT-­‐3′	   for	  p2x1000.	   These	   three	   fragments	   were	   subsequently	   inserted	   into	   the	   pNEB-­‐193	  vector	  (New	  England	  Biolabs)	  using	  SalI	  and	  PstI	  restriction	  sites.	  All	  plasmid	  DNA	  used	  for	  airway	  epithelial	  cell	  nucleofection	  was	  purified	  using	  the	  Plasmid	  Mini	  Kit	  (Qiagen).	  	  
2.4.2	  Transfection	  Reporter	   HeLa	   cells	   were	   maintained	   in	   modified	   Eagle’s	   Medium	   (MEM)	  supplemented	  with	  10	  %	  Fetal	  Bovine	  Serum	  (FBS).	  HeLa	   cells	  were	  plated	  a	  day	  before	  transfection	  at	  a	  density	  of	  1x105	  cells/well	  in	  a	  12-­‐well	  plate	  in	  1	  ml	  of	  MEM	  with	  10%	  FBS.	  The	  next	  day,	  transfection	  mixtures	  were	  prepared	  by	  mixing	  50	  μl	  OptiMEM	   (Life	   Technologies),	   1	   μg	   DNA,	   and	   3	   μl	   Fugene	  HD	   reagent	   (Promega).	  The	  DNA	  mixture	  contained	  400	  ng	  TALEN-­‐CFTR	  L,	  400	  ng	  TALEN-­‐CFTR	  R,	  and	  200	  ng	   donor	   plasmid	   (or	   the	   pCMV-­‐donor-­‐reporter	   plasmid,	   in	   the	   case	   of	   episomal	  correction).	   The	   transfection	   mixtures	   were	   incubated	   for	   15	   minutes	   at	   room	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temperature	   and	   added	   to	   the	  wells	  with	   cells.	   The	   cells	  were	   allowed	   to	   recover	  and	  grow	  for	  72	  hours	  before	  flow	  cytometry.	  
2.4.3	  Flow	  Cytometry	  Cells	   were	   trypsinized	   from	   their	   culturing	   plates	   and	   resuspended	   in	   200	   μl	  phosphate	  buffered	  saline	  (PBS)	  supplemented	  with	  10	  mM	  EDTA.	  To	  determine	  the	  percentage	   of	   GFP-­‐positive	   cells,	   20	   000	   cells	   were	   analyzed	   by	   a	   BD	   LSRII	   flow	  cytometer	  (BD	  Biosciences).	  Transfection	  efficiency	  was	  determined	  by	  determining	  the	  percentage	  of	  GFP-­‐positive	  cells	  that	  were	  transfected	  with	  functional	  GFP	  only.	  The	   transfection	   efficiency	  was	   determined	   to	   be	   around	   80	  %.	   The	   rate	   of	   gene	  targeting	   was	   determined	   by	   normalizing	   the	   percentage	   of	   GFP-­‐positive	   cells	   in	  TALEN	   and	   donor	   co-­‐transfected	   reporter	   cells	   to	   the	   transfection	   efficiency.	   The	  flow	   cytometry	   data	   were	   analyzed	   using	   the	   FCS	   Express	   4	   (BD	   Biosciences)	  software.	  	  
	  
2.4.4	  Airway	  Epithelial	  Cell	  Line	  Maintenance	  and	  Transfection	  The	  CFT1	  airway	  epithelial	  cell	   line	  (kind	  gift	  of	   James	  R.	  Yankaskas,	  University	  of	  North	  Carolina	  at	  Chapel	  Hill)	  was	  maintained	  on	  BD	  Biocoat	  Collagen	  I-­‐coated	  100	  mm	   plates	   (BD	   Biosciiences)	   in	   the	   F12-­‐7X	   medium	   containing	   200	   μg/ml	  gentamicin	   (Sigma),	   10	   μg/ml	   insulin	   (Sigma),	   5	   μg/ml	   transferrin	   (Sigma),	   1	   μM	  hydrocortisone	  (Sigma),	  3.75	  μg/ml	  endothelial	  cell	  growth	  supplement	  (Sigma),	  30	  nM	   triiodothyronine	   (Sigma),	   25	   ng/ml	   epidermal	   growth	   factor	   (Sigma),	   and	   10	  ng/ml	  Cholera	  toxin	  (Sigma).	  The	  cells	  were	  passaged	  at	  maximum	  expansion	  ratio	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of	   1:3	   using	   0.1	   %	   trypsin/1	   mM	   EDTA,	   and	   the	   trypsin	   was	   neutralized	   using	  twofold	  v/v	  excess	  soybean	  trypsin	  inhibitor	  (STI,	  Sigma).	  The	  UNCCF3T	  as	  well	  as	  the	   KKLEB	   airway	   epithelial	   cell	   lines	   (kind	   gift	   of	   Scott	   H.	   Randell,	   University	   of	  North	  Carolina	  at	  Chapel	  Hill)	  were	  maintained	  on	  BD	  Biocoat	  Collagen	  I-­‐coated	  100	  mm	  plates	  (BD	  Biosciences)	  in	  the	  CnT-­‐17	  PCT	  Airway	  epithelium	  medium	  (Zenbio)	  and	  passaged	  at	  maximum	  expansion	  ratio	  of	  1:8	  using	  0.1	  %	  trypsin/1	  mM	  EDTA,	  and	  the	  trypsin	  was	  neutralized	  using	  twofold	  v/v	  excess	  STI.	  The	  Airway	  epithelial	  cells	  were	  transfected	  using	  Amaxa	  Epithelial,	  Bronchial	  (NHBE)	   Nucleofector	   Kit	   (Lonza)	   according	   to	   the	   manufacturer’s	   instructions.	  Briefly,	  5x105	  cells	  were	  nucleofected	  with	  1	  μg	  of	  each	  TALEN	  construct	  and	  1	  μg	  donor	   DNA.	   UNCN3T/UNCCF3T	   cells	   were	   nucleofected	   using	   the	   W-­‐001	  Nucleofector	   program,	   whereas	   HBE1/CFT1	   and	   AALEB/KKLEB	   cells	   were	  nuclefected	   using	   T-­‐020	   Nucleofector	   program	   on	   the	   Nucleofector	   I	   Device.	   The	  cells	  were	  grown	  for	  72	  hours	  before	  assaying.	  
2.4.5	  Quantitative	  PCR	  Genomic	   DNA	   of	   CFT1	   cells	   nucleofected	   with	   TALEN	   and	   donor	   constructs	   was	  purified	  using	  the	  Wizard	  Genomic	  DNA	  purification	  kit	  (Promega)	  according	  to	  the	  manufacturer’s	   instructions.	   The	   CFTR	   exon	   10	   was	   amplified	   using	   primers	   5′-­‐
CCTTCTACTCAGTTTTAGTCAGTAG-­‐3′	   and	   5′-­‐GTGTATAAAAAATAAGGATGGGGCTC-3′.	   In	  controls	   for	   nonspecific	   amplification,	   the	   Phusion	   High	   fidelity	   DNA	   polymerase	  (New	   England	   Biolabs)	   was	   omitted.	   Amplified	   CFTR	   exon	   10	  was	   gel-­‐purified	   to	  remove	  any	  trace	  co-­‐purified	  donor	  plasmid,	  and	  used	  as	  a	  template	  for	  quantitative	  PCR	   using	   (a)	   CFTR-­‐TBM	   primers	   binding	   to	   the	   regions	   with	   TALEN	   blocking	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mutations	   5′-­‐GCCTGGCACGATCAAAGAGAATATTATCT-­‐3ʹ′	   and	   5′-­‐
GGCATGCTTTGATAACGCTTCGATATCTG-­‐3ʹ′,	  and	   (b)	   CFTR-­‐con	  primers	   binding	   to	   regions	  immediately	   outside	   of	   the	   regions	   with	   TALEN	   blocking	   mutations	   5′-­‐
GTTTTCCTGGATTATGCCTGGCAC-­‐3ʹ′	   and	   5ʹ′-­‐ACCTCTTCTAGTTGGCATGCTTTG-­‐3ʹ′.	   For	  construction	  of	  the	  standard	  curve,	  a	  ‘modified	  reference’	  2	  kb	  fragment	  consisting	  entirely	  of	  the	  donor	  CFTR	  sequence	  was	  amplified	  from	  the	  pNEB-­‐2x1000	  plasmid	  and	   gel-­‐purified.	   Likewise,	   an	   ‘unmodified	   reference’	   2	   kb	   fragment	   consisting	  entirely	   of	   unmodified	   F508del	  CFTR	   sequence	  was	   amplified	   from	   genomic	   DNA	  purified	   from	   untransfected	   CFT1	   cells,	   and	   gel-­‐purified.	   Mixtures	   of	   these	   two	  references	   were	   prepared	   with	   the	   fraction	   of	   ‘modified	   reference’	   ranging	   from	  0.01	   %	   to	   100%,	   and	   the	   Ct	   values	   obtained	   using	   amplification	   with	   the	   TBM	  primers	  were	  used	  to	  generate	  the	  standard	  curve	  for	  the	  F508del	  CFTR	   sequence	  correction.	  Quantitative	  PCRs	  were	  run	  with	  10	  ng	  template,	  500	  nM	  primers,	  0.02	  U/μl	  Phusion	  High	  Fidelity	  DNA	  Polymerase	  in	  1x	  Failsafe	  PCR	  Premix	  G	  (Epicentre).	  The	   correction	   efficacies	  were	   calculated	   by	   plotting	   the	   Ct	   values	   from	  unknown	  samples	  on	  the	  standard	  curve.	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Chapter	  3.	  Investigation	  of	  TALE	  DNA-­‐Binding	  and	  Target	  
Search	  Mechanism2	  
3.1	  Introduction	  The	  ability	  to	  engineer	  site-­‐specific	  genome	  editing	  and	  modification	  tools	  is	  a	  powerful	  capability	  that	  paves	  the	  way	  for	  both	  important	  research	  and	  therapeutic	  applications.	  Transcription	   activator-­‐like	   effectors	   (TALEs)	  have	   recently	   emerged	  as	  a	  scaffold	  of	  choice	   for	  engineering	  designer	  DNA-­‐binding	   fusion	  proteins	   to	  be	  used	  as	  gene	  editing	  tools1,2.	  Naturally	  found	  in	  the	  bacterial	  pathogen	  Xanthomonas,	  TALE	   proteins	   are	   injected	   into	   host	   plant	   cells,	   where	   they	   transcriptionally	  activate	  genes	  required	   for	  bacterial	  colonization	  and	  spread3,4.	  TALE	  proteins	  are	  characterized	  by	   three	  conserved	  regions	  (Figure	  1a):	  an	  N-­‐terminal	  region	  (NTR)	  containing	   the	   type	   III	   translocation	   system	   required	   for	   secretion,	   the	   central	  repeat	  domain	  (CRD),	  and	  a	  C-­‐terminal	  region	  (CTR)	  containing	  nuclear	  localization	  signals	  and	  an	  acidic	  activation	  domain3,4.	  The	  promoter	  specificity	  of	  the	  TALEs	  is	  conferred	   by	   the	   CRD,	  which	   harbors	   a	   series	   of	   tandem	  protein	   repeats	   that	   are	  typically	   34	   amino	   acids	   in	   length3,5.	   Sequence	   specific	   recognition	   is	   achieved	   by	  the	   repeat	   variable	   diresidues	   (RVD),	   amino	   acids	   at	   positions	   12	   and	   13	   of	   each	  repeat,	   that	   recognize	   one	   of	   the	   four	   nucleobases	   at	   each	   position	   of	   the	   target	  binding	   site6,7.	   Thus,	   this	   family	   of	   proteins	   is	   unique	   among	   other	   DNA-­‐binding	  proteins	   in	   their	   ‘single	   repeat	   to	   single	   base	   recognition	   mode’.	   It	   is	   therefore	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  2	  This	  work	  was	  done	  in	  collaboration	  with	  Dr.	  Charles	  M.	  Schroeder	  and	  Luke	  Cuculis.	  LC	  and	  ZA	  contributed	  equally	  to	  this	  work.	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possible	   to	   design	   a	   TALE	   protein	   to	   recognize	   virtually	   any	   DNA	   sequence	   by	  simply	   reprogramming	   the	  RVD	  regions	   to	  bind	   the	   sequence	  of	   choice.	   	  Once	   the	  binding	   code	   of	   TALEs	   was	   revealed,	   fusion	   proteins	   constructed	   with	   TALEs	   as	  specific	  binding	  domains	  linked	  to	  nuclease	  domains	  (typically	  the	  dimeric	  nuclease	  FokI)	  were	   shown	   to	   function	  as	  highly	   specific	  designer	  nucleases.	   Following	   the	  first	  demonstration	  of	  TALEs	  as	  artificial	  nucleases8,9,	  TALE	  proteins	  have	  also	  been	  used	   as	   artificial	   transcriptional	   activators10,11,12,	   transcriptional	   repressors11,13,14,	  demethylases15,	   and	   fluorescent	   probes	   to	   study	   chromatin	   dynamics	   in	   live	  cells16,17.	  Understanding	   DNA	   recognition	   by	   TALEs	   will	   greatly	   improve	   the	   rational	  design	   of	   these	   proteins	   for	   biotechnological	   applications.	   A	   step	   towards	  rationalization	  of	  sequence-­‐specific	  DNA	  recognition	  by	  TALEs	  has	  been	  achieved	  by	  solving	   the	   crystal	   structures	   of	   TALEs	   in	   both	   DNA-­‐free	   and	   DNA-­‐bound	   forms	  (Figure	  1b)18,19,20.	  The	  repeats	  of	  the	  TALE	  CRD	  were	  shown	  to	  form	  a	  right-­‐handed	  superhelical	   structure	   that	   wraps	   along	   the	   major	   groove	   of	   the	   B-­‐form	   of	   DNA	  duplex.	  Each	  repeat	  comprises	  two	  α-­‐helices	  that	  span	  residues	  3-­‐11	  and	  14(15)-­‐33	  and	   flank	   the	   loop	   region	   containing	   the	   RVDs.	   The	   residue	   at	   position	   13	  specifically	  interacts	  with	  a	  single	  base,	  while	  the	  residue	  at	  position	  12	  contributes	  to	  the	  stability	  of	  the	  RVD	  loop.	  The	  NTR	  also	  displays	  a	  right-­‐handed	  superhelical	  structure	   with	   four	   continuous	   repeats	   that	   are	   strikingly	   similar	   in	   structure	   to	  those	  of	  the	  CRD20.	  In	  addition,	  comparison	  of	  free	  and	  DNA-­‐bound	  forms	  of	  TALEs	  revealed	   that	   the	   protein	   undergoes	   a	   conformational	   change	   to	   a	  more	   compact	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form,	  with	  the	  superhelical	  pitch	  being	  reduced	  from	  60	  Å	  in	  DNA-­‐free	  form	  to	  35	  Å	  upon	  binding	  to	  target	  DNA18,21.	  	  While	   crystal	   structures	   of	   TALEs	   provide	   valuable	   insight	   as	   to	   the	   basis	   of	  TALE-­‐DNA	   recognition,	   a	   central	   understanding	   of	   the	   molecular	   mechanism	  governing	  TALE	  sequence	  search	  is	  currently	  lacking.	  A	  critical	  need	  in	  the	  rational	  design	   of	   new,	   more	   efficient	   TALEN	   systems	   lies	   in	   the	   understanding	   of	   TALE	  binding	  dynamics	  and	  functions	  of	  TALE	  subdomains	  as	  they	  relate	  to	  target	  search.	  In	  this	  work,	  we	  utilize	  bulk	  binding	  assays	  as	  well	  as	  single	  molecule	  fluorescence	  microscopy	  in	  order	  to	  study	  the	  binding	  dynamics	  and	  sequence	  search	  mechanism	  of	  TALE	  proteins	  and	  TALE	  subdomains.	  
3.2	  Results	  
3.2.1	  Measurements	  of	  TALE-­‐SCA2/DNA	  Binding	  Affinity	  in	  a	  Bulk	  Assay	  To	   investigate	   the	  mechanism	   of	   TALE	   binding	   to	   DNA,	   we	   set	   to	   assay	   the	  difference	  in	  TALE	  binding	  to	  cognate	  and	  random	  DNA	  sequences.	  To	  ensure	  that	  the	  recombinant	  TALE	  we	  use	  in	  this	  study	  is	  functionally	  active,	  we	  utilized	  a	  TALE	  protein	  architecture	  previously	  reported	   for	   the	  correction	  of	   the	  human	  β–globin	  gene	   harboring	   a	   mutation	   associated	   with	   sickle	   cell	   disease22.	   	   The	   CRD	   of	   the	  protein,	  which	  contains	  21.5	  repeats,	  was	  engineered	  using	  the	  Golden	  Gate	  cloning	  method,	  and	  the	  flanking	  regions	  were	  truncated	  to	  208	  amino	  acids	  of	  NTR	  and	  63	  amino	  acids	  of	  CTR	  (Figure	  3.1a	  and	  b).	  The	  TAL	  effector	  variable	  di-­‐residues	  as	  well	  as	   the	   predicted	   binding	   site	   are	   provided	   in	   the	   Appendix	   A.	   The	   His-­‐tagged	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recombinant	  TALE	  protein	  was	  purified	  by	  affinity	  chromatography	  to	  homogeneity	  for	  subsequent	  in	  vitro	  binding	  assays.	  
 
Figure	   3.1	   TALE	   protein	   structure	   and	   subdomain	   schematic.	   (a)	   General	   schematic	   of	   the	   TALE	  polypeptide	  chain.	  The	  N-­‐terminal	  region	  (NTR)	  contains	  the	  type	  III	  translocation	  system	  necessary	  for	   secretion,	   the	   central	   repeat	   domain	   (CRD)	   contains	   the	   conserved	   34	   amino	   acid	   repeats	   for	  sequence-­‐specific	  DNA	  binding,	  and	   the	  C-­‐terminal	   region	  contains	  nuclear	   localization	  signals	  and	  an	  acidic	  activation	  domain.	  (b)	  Co-­‐crystal	  structure	  of	   the	  PthXo1	  TALE	  bound	  to	   its	  specific	  DNA	  target22,	  with	  only	  the	  CRD	  region	  shown	  for	  display.	  	  
In	   vitro	   binding	   of	   the	   TALE	   to	   cognate	   and	   random	   DNA	   was	   investigated	  using	   fluorescence	   anisotropy.	   In	   our	   initial	   experiments,	   50	   bp-­‐long	   fluorescein-­‐labeled	  double-­‐stranded	  DNA	  oligos	  were	  used	  as	  the	  ligand,	  and	  were	  designed	  to	  contain	  22	  nt	  sequence	  of	  interest	  flanked	  by	  unrelated	  14	  bp	  sequences.	  The	  22	  nt	  sequence	   of	   interest	  was	   either	   the	   cognate	   22	   nt	   sequence	   to	   the	   TALE	   (“50	   bp	  
Cuculis	  et	  al.	  Nat	  Commun	  	  2015,	  accepted	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cognate	   sequence”),	   or	   an	   unrelated	   22	   nt	   sequence	   with	   the	   same	   sequence	  composition	   but	   with	   the	   order	   completely	   scrambled	   compared	   to	   the	   cognate	  sequence,	   (“50	   bp	   random	   sequence”).	   These	   ds	   oligos	   were	   prepared	   by	   primer	  extension	  from	  two	  ss	  oligos	  that	  have	  an	  overlap	  region	  among	  them.	  One	  of	  these	  ss	  oligos	  was	  5’-­‐fluorescein-­‐labeled	  for	  the	  fluorescence	  polarization	  measurements.	  In	   order	   to	   investigate	   TALE	   binding	   to	   DNA,	   we	   sought	   to	   determine	   the	  conditions	   in	   which	   the	   greatest	   difference	   in	   binding	   affinities	   to	   cognate	   and	  random	  DNA	  would	  be	  observed.	  The	  initial	  buffer	  composition	  was	  25	  mM	  Tris-­‐HCl	  pH7.5	  buffer	  with	  0.5	  mM	  EDTA.	  We	  compared	  the	  effect	  of	  the	  additives	  including	  0.1	   mg/ml	   BSA,	   1	   mg/ml	   BSA,	   6	   mg/ml	   salmon	   sperm	   DNA	   (Figure	   3.2),	   β-­‐mercaptoethanol,	   and	   DTT	   (data	   not	   shown).	   In	   all	   cases,	   we	   did	   not	   observe	  significant	   difference	   between	   TALE	   binding	   to	   cognate	   and	   random	  DNA	   (Figure	  3.2).	   We	   reasoned	   that	   high	   concentrations	   of	   salmon	   sperm	   DNA	   would	   screen	  nonspecific	  binding	  of	  TALE	  to	  DNA,	  thus	  allowing	  to	  observe	  a	  greater	  difference	  in	  binding	   affinities	   between	   cognate	   and	   random	   oligos	   in	   the	   presence	   of	   this	  additive.	   Salmon	   sperm	   DNA	   indeed	   significantly	   reduced	   the	   apparent	   binding	  affinity	   of	   TALE	   to	   ds	   oligos;	   however,	   it	   did	   not	   result	   in	   resolved	   specificity	   of	  TALE	  (Figure	  3.2).	  	  We	   reasoned	   that	   increasing	   ionic	   strength	   could	   also	   screen	   unspecific	  interactions	   of	   TALE	  with	   DNA,	   since	   the	   positively	   charged	   patches	   of	   the	   TALE	  CRD	   inner	   surface18,	   20	   of	   the	   TALE	   solenoid	   would	   be	   screened	   from	   interacting	  with	   the	   negatively	   charged	   phosphate	   backbone	   of	   DNA.	   We	   therefore	   assayed	  TALE	  binding	   in	  various	   ionic	  strengths	   in	  the	  presence	  of	  50-­‐200	  mM	  NaCl.	  Little	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difference	  in	  binding	  affinity	  was	  observed	  for	  salt	  concentrations	  ranging	  between	  0	   and	   100	   mM,	   while	   a	   significant	   decrease	   in	   apparent	   binding	   affinity	   was	  observed	   in	  a	  buffer	  with	  150	  mM	  NaCl	   (Figure	  3.3).	   In	  200	  mM	  NaCl,	  no	  binding	  was	  observed	  at	  1	  μ	  M	  protein	  concentration	  (data	  not	  shown).	  In	  neither	  of	  these	  conditions,	  however,	  did	  we	  observe	  the	  resolution	  of	  specific	  binding	  of	  the	  TALE.	  
 
Figure	   3.2	   Fluorescence	   polarization	   assay	   of	   TALE21.5	   binding	   to	   50	   bp-­‐long	   ds	  oligodeoxynucleotide	  in	  25	  mM	  Tris-­‐HCl	  pH7.5	  buffer	  with	  different	  additives.	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 Cognate DNA, ssDNA
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see	  Appendix	  A).	  As	  previously,	  we	  titrated	  the	  TALE	  with	  either	  cognate	  or	  random	  DNA	   in	   different	   NaCl	   concentrations.	   Interestingly,	   at	   50	  mM	   and	   100	  mM	  NaCl	  concentrations,	  we	  observed	  even	  tighter	  binding	  of	  TALE	  to	  29	  bp	  oligos	  compared	  with	  50	  bp	  oligos	  (Figure	  3.4).	  We	  also	  observed	  a	  small,	  yet	  significant	  difference	  (~2-­‐fold	  difference	  in	  dissociation	  constant	  KD)	  in	  TALE	  binding	  affinities	  to	  cognate	  versus	  random	  DNA	  at	  100	  mM	  and	  150	  mM	  NaCl	  concentrations.	  
 
Figure	   3.3	   Fluorescence	   polarization	   assay	   of	   TALE21.5	   binding	   to	   50	   bp-­‐long	   ds	  oligodeoxynucleotide	  in	  25	  mM	  Tris-­‐HCl	  pH7.5	  at	  different	  NaCl	  concentrations.	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 Cognate DNA, 150 mM NaCl









	   57	  
perplexing	  given	  the	  enormity	  of	  the	  nonspecific	  sequence	  volume	  which	  the	  TALEs	  naturally	  have	  to	  screen	  in	  search	  of	  the	  few	  binding	  sites	  in	  plant	  genomes.	  These	  observations	   might	   indicate	   that	   the	   mechanism	   by	   which	   TALEs	   recognize	   the	  target	  DNA	  is	  governed	  by	  other	  factors	  than	  just	  DNA	  association	  and	  dissociation	  rates.	  As	  proposed	  previously,	  TALEs	  could	  bind	  DNA	  nonspecifically	  and	  search	  the	  target	  sites	  by	  1D	  diffusion20.	  Hence,	   it	   is	  plausible	   that	   the	  residence	   times	  of	   the	  protein	  on	  the	  target	  site,	  as	  compared	  with	  other	  sites,	  is	  imperative	  for	  the	  TALE	  activity.	  	  
 
Figure	   3.4	   Fluorescence	   polarization	   assay	   of	   TALE21.5	   binding	   to	   29	   bp-­‐long	   ds	  oligodeoxynucleotide	  in	  Tris-­‐HCl	  pH7.5	  buffer	  at	  different	  salt	  concentrations.	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3.2.2	   Optimization	   of	   Protein	   and	   DNA	   Manipulation	   for	   Single	   Molecule	  
Imaging	  	  Although	   predicted20,	   the	   1D	   target	   search	  mechanism	   of	   TALEs	   has	   not	   yet	  been	  demonstrated.	  In	  order	  to	  directly	  observe	  the	  binding	  dynamics	  and	  sequence	  search	   mechanism	   of	   TALE	   proteins,	   we	   utilized	   single	   molecule	   imaging	  microscopy.	   To	   fluorescently	   label	   the	   TALE	   tSCA2,	   a	   bioorthogonal	   aldehyde	  labeling	   scheme25-­‐26	   was	   employed,	   which	   allowed	   the	   site-­‐specific	   and	  nonperturbative	   attachment	   of	   a	   hydrazide	   functionalized	   Cy3	   organic	   dye.	   To	  record	   the	   binding	   dynamics	   of	   single	   TALEs,	   we	   utilized	   dual-­‐tethered	   DNA	  substrates	  illuminated	  via	  total	  internal	  reflection	  (TIRF)	  in	  milli-­‐fluidic	  flow	  cells.	  
	  
Figure	   3.5	   Aldehyde	   labeling	   scheme	   used	   to	   achieve	   non-­‐perturbative	   one-­‐to-­‐one	   dye-­‐to-­‐protein	  stoichiometry.	   	  A	  six-­‐amino	  acid	  motif	   (LCTPSR)	   is	  cloned	   into	   the	  N-­‐terminus	  of	   the	  TALE	  protein	  and	  the	  construct	  is	  co-­‐expressed	  with	  formylglycine	  generating	  enzyme	  (FGE)	  which	  then	  converts	  the	   cysteine	   to	   a	   formylglycine	   bearing	   an	   unnatural	   aldehyde.	   	   Aldehyde	   specific	   conjugation	   via	  hydrazide-­‐functionalized	  Cy3	  organic	  dyes	  then	  allows	  for	  non-­‐perturbative,	  site-­‐specific	  labeling.	  
	   To	   label	   the	   protein,	   an	   aldehyde	   tag	   (hexapeptide	   LCTPSR)	   was	   cloned	  upstream	   of	   the	   N-­‐terminal	   His6	   tag	   and	   co-­‐expressed	   with	   formylglycine-­‐generating	   enzyme	   (FGE),	   which	   recognizes	   the	   6-­‐amino-­‐acid	   motif	   and	   oxidizes	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cysteine	  to	  formylglycine	  in	  vivo25	  (Figure	  3.5).	  To	  this	  end,	  the	  BL21	  (DE3)	  strain	  of	  
E.	  coli	  was	  co-­‐transformed	  with	  arabinose-­‐inducible	  pBAD-­‐FGE	  and	  IPTG-­‐inducible	  pET28-­‐Naldt-­‐tSCA	   plasmids.	   Induction	   of	   both	   or	   either	   of	   the	   proteins	   did	   not	  result	  in	  noticeable	  TALE	  or	  FGE	  expression,	  as	  observed	  by	  SDS-­‐PAGE	  gels	  (Figure	  3.6a).	  Nevertheless,	  purification	  of	  the	  TALE	  protein	  from	  500	  ml	  of	  induced	  culture	  using	  affinity	  chromatography	  yielded	  TALE	  protein	  in	  >	  90	  %	  purity	  (Figure	  3.6b).	  	  	  
Analysis	  of	  the	  purified	  protein	  using	  LC-­‐MS/MS	  indicated	  that	  >	  82.7	  %	  of	  the	  cysteines	   in	   the	  LCTPSR	  hexapeptide	  were	  modified	   to	   formylglycine	   (Figure	  3.7).	  The	   aldehyde-­‐tagged	   protein	   was	   next	   site-­‐specifically	   modified	   with	   Cy3-­‐hydrazide.	   After	   incubation	   of	   the	   protein	   with	   Cy3-­‐hydrazide,	   the	   protein	   was	  purified	   from	   unreacted	   organic	   dye	   using	  micro	   bio-­‐spin	   size	   exclusion	   columns	  (Bio-­‐Rad).	  A	  time	  course	  of	  TALE	  labeling	  showed	  that	  the	  reaction	  starts	  to	  plateau	  at	   room	   temperature	   after	   approximately	   48	   hours	   of	   incubation,	   reaching	   the	  
Figure	   3.6	   SDS-­‐PAGE	   analysis	   of	   (a)	   aldehyde-­‐tagged	   TALE	   expressed	   in	   BL21	   (DE3)	   and	   (b)	  purified	  using	  affinity	  chromatography.	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efficiency	   60	   %	   of	   labeled	   protein	   at	   48	   hours	   of	   incubation	   (Figure	   3.8a),	   as	  measured	  by	   absorption	   at	   548	  nm	   (Figure	  3.8b)	   and	  Bradford	   assay.	   To	   check	   if	  unreacted	  Cy3	  was	  still	  present	  in	  the	  solution,	  we	  imaged	  fluorescence	  of	  TALE	  ran	  through	   a	   SDS-­‐PAGE	   gel,	   and	   observed	   that	   there	   was	   no	   significant	   amount	   of	  unreacted	  Cy3	  (Figure	  3.8c).	  	  
	  
Figure	   3.7	   LC-­‐MS/MS	  analysis	  of	   aldehyde-­‐tagged	  TALE21.5.	  The	   cysteines	  of	   the	  purified	  protein	  were	   protected	   by	   alkylation	   with	   iodoacetamide	   and	   trypsin	   digested	   prior	   to	   LC-­‐MS/MS.	   The	  percentage	   of	   the	   peak	   counts	   of	   peptides	   containing	   formylglycine	   (2.07*107)	   among	   all	   peptide	  peak	  counts	  containing	  alkylated	  cysteine	  (2.50x107)	  was	  calculated	  to	  be	  82.8	  %,	  which	  we	  assume	  to	  correspond	  to	  the	  aldehyde	  labeling	  efficiency.	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Figure	   3.8	   Labeling	  of	  TALE21.5	  with	  Cy3	   and	  CF640R.	   (a)	  Time	   course	  of	   labeling	  of	  Nald-­‐TALE	  with	   Cy3-­‐Hz	   at	   room	   temperature.	   (b)	   UV/Vis	   spectroscopy	   of	   Cy3-­‐labeled	   TALE21.5.	   (c)	  Fluorescence	  imaging	  of	  Cy3-­‐labeled	  TALE21.5	  ran	  on	  an	  SDS-­‐PAGE	  gel.	  (d)	  UV/Vis	  spectroscopy	  of	  CF640R-­‐labeled	  TALE21.5.	  (e)	  Fluorescence	  imaging	  of	  CF640R-­‐labeled	  TALE21.5.	  
	  
Figure	   3.9	   TALE21.5	   labeled	   with	   different	   fluorophores	   binding	   to	   cognate	   DNA	   oligomer.	  Fluorescence	   polarization	   was	   performed	   with	   unlabeled,	   Cy3-­‐labeled,	   and	   CF640	   R-­‐labeled	  TALE21.5.	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Figure	   3.10	   Schematic	   of	   the	   single	  molecule	   imaging	  microscopy	   set	   up	   for	   the	   tracking	  of	  TALE	  protein	   dynamics.	   (a)	   Schematic	   of	   experimental	   setup	   showing	   microfluidic	   flow	   cell	   and	  microscope	  objective	  lens	  for	  TIRF-­‐M.	  (b)	  Schematic	  of	  dual-­‐tethering	  of	  a	  DNA	  substrate.	  The	  45	  kb	  plasmid	   is	   linearized	  with	   the	   SnaBI	   restriction	   enzyme.	   The	   3ʹ′-­‐5ʹ′	   exonuclease	   activity	   of	   T4	  DNA	  polymerase	   is	  used	   to	  create	   the	  5ʹ′	  overhangs	  at	  both	  ends	  of	   the	   linearized	  DNA.	  The	  exposed	  5ʹ′-­‐overhangs	   are	   used	   to	   sequence-­‐specifically	   anneal	   3ʹ′-­‐biotinylated	   oligonucleotides.	   First,	  oligonucleotide	  A	  is	  annealed	  to	  the	  substrate	  DNA.	  The	  substrate	  DNA	  is	  attached	  to	  the	  surface	  of	  the	   slide	   of	   the	   microfluidic	   flow	   chamber	   through	   the	   biotin-­‐neutravidin	   interactions.	  Oligonucleotide	  B	   is	   flown	   through	   the	   chamber	  and	   is	   annealed	   to	   the	   second	  5ʹ′-­‐overhang,	  which	  results	  in	  the	  attachment	  of	  the	  second	  end	  of	  the	  substrate	  DNA.	  
	   In	   order	   to	   determine	   if	   the	   labeling	   affected	   the	   tSCA2	   binding	   to	   DNA,	  we	  performed	   fluorescence	   polarization	   assay	   as	   previously,	   but	   did	   not	   observe	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significant	  difference	   in	  binding	  affinity	  (Figure	  3.9).	  To	  additionally	  check	  for	  Cy3	  interference	  with	  the	  TALE	  binding	  activity,	  we	  also	  similarly	  labeled	  the	  TALE	  with	  CF640	   R-­‐hydrazide	   (Figure	   3.8d	   and	   e),	   and	   similarly	   did	   not	   observe	   significant	  difference	  in	  binding	  to	  cognate	  DNA	  by	  fluorescence	  anisotropy	  (Figure	  3.9).	  For	  the	  construction	  of	  the	  milli-­‐fluidic	  flow	  cells,	  we	  functionalized	  coverslips	  consecutively	  with	  PEG/PEG-­‐biotin	  and	  neutravidin	  for	  surface	  attachment	  of	  DNA	  and	  reduction	  of	  nonspecific	  protein	  adsorption	  (Figure	  3.10a).	  As	  a	  DNA	  substrate	  on	  which	  the	  TALE	  movement	  would	  be	  tracked,	  we	  chose	  a	  44,898	  bp	  plasmid	  in	  our	  lab	  that	  contains	  a	  neoaureothin	  synthesis	  pathway	  from	  Streptomyces	  orinoci.	  This	  plasmid	  does	  not	  contain	  binding	  sites	  for	  the	  engineered	  TALE,	  and	  contains	  a	  single	   SnaBI	   digestion	   site,	   which	   was	   used	   to	   linearize	   the	   plasmid.	   The	   ssDNA	  overhangs	   on	   both	   ends	   of	   the	   linearized	   plasmid	   were	   created	   by	   the	   3’-­‐5’	  exonuclease	   activity	   of	   T4	   polymerase	   at	   room	   temperature	   in	   the	   absence	   of	  dNTPs,	  as	  described	  in	  SLIC	  cloning27.	  The	  DNA	  was	  double-­‐tethered	  to	  the	  bottom	  of	   the	   flow	   cell	   via	   neutravidin-­‐biotin	   interactions.	   For	   this	   purpose,	   DNA	   was	  biotinylated	  with	  3’-­‐biotinylated	  oligos	  complementary	  to	  the	  ssDNA	  overhangs	  on	  both	  ends	  of	  the	  substrate	  DNA,	  consecutively	  (Figure	  3.10b).	  First,	  one	  oligo	  would	  be	   annealed	   to	   the	   substrate	  DNA,	   after	  which	   the	  DNA	  would	   be	   attached	   to	   the	  flow	   cell	   under	   flow.	   Second,	   the	   remaining	   oligo	   complementary	   to	   the	   second	  ssDNA	  overhang	  would	  be	  added	  to	  the	  flow	  cell,	   thus	  attaching	  the	  second	  end	  of	  the	  substrate	  DNA.	  The	  labeled	  TALE	  protein	  was	  passed	  through	  the	  flow	  cell	  last,	  and	  the	  single	  molecule	  TALE	  binding	  events	  on	  stretched	  DNA	  were	  imaged	  in	  the	  absence	   of	   the	   flow	   (Figure	   3.11a	   and	   b).	   Note	   that	   all	   the	   experiments	   on	   single	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molecule	   spectroscopy	   and	   corresponding	  data	   analysis	  were	   carried	  out	  by	  Luke	  Cuculis.	  	  
	  
Figure	  3.11	  Visualization	  of	  single	  molecules	  of	  TALE	  and	  DNA	  substrate.	   (a)	  Double-­‐tethered	  DNA	  substrate	  molecules	  were	  stained	  with	  SYTOX	  Green	  and	  excited	  using	  a	  488	  nm	  DPSS	  laser	  	  (b)	  Cy3-­‐labeled	  TALE21.5	  was	  excited	  using	  532	  nm	  diode-­‐pumped	  solid	  state	  (DPSS)	  laser	  	  
	  
3.2.3	  One	  dimensional	  diffusion	  of	  TALE	  along	  DNA	  templates	  The	  positions	  of	  single	  TALE	  molecules	  were	  recorded	  and	  tracked	  by	  fitting	  a	  two	  dimensional	  Gaussian	  point	  spread	  function	  to	  the	  diffraction-­‐limited	  spots.	  We	  were	   able	   to	   directly	   observe	   TALE	   molecules	   diffusing	   one	   dimensionally	   along	  stretched	   DNA	   substrates	   (Figure	   3.12a).	   The	   1D	   mean-­‐squared	   displacement	  (MSD)	  of	  the	  diffusing	  TALES	  increased	  linearly	  with	  time	  (Figure	  3.12b),	  which	  is	  indicative	   of	   a	   Brownian	   motion.	   These	   observations	   corroborate	   the	   hypothesis	  that	   TALE	   proteins	   search	   for	   their	   targets	   via	   facilitated	   diffusion,	   where	   1D	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movement	   of	   TALEs	   along	   random	   sequences	   of	   DNA	   shortens	   the	   target	   search	  time.	  	  
	   	  Figure	   3.12	   TALE	   proteins	   exhibit	   rapid	   1-­‐D	   diffusion	   along	   DNA	   templates.	   (a)	   Single	   molecule	  trajectories	  of	  TALE	  diffusion	  events	  over	  short	  time	  scales	  (~1	  sec)	  at	  90	  mM	  KCl.	  (b)	  Mean-­‐squared	  displacement	  of	  an	  ensemble	  of	  TALE	  proteins	  diffusing	  along	  non-­‐specific	  DNA	  templates	  at	  90	  mM	  KCl.	  	  





Figure 3: TALE proteins exhibit rapid 1-D diffusion along DNA templates. (a) Single molecule 
trajectories of TALE diffusion events over short time scales (~1 sec) at 90 mM KCl. (b) and (c) 
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were	  determined	  to	  be	  1.5*106	  bp2/s	  and	  5.9*106	  bp2/s	  at	  30	  mM	  and	  90	  mM	  KCl	  concentrations,	   respectively	   (Figure	   3.13a	   and	   b).	   Thus,	   increasing	   KCl	  concentration	   resulted	   in	   a	   nearly	   four-­‐fold	   increase	   in	   1D	  diffusion	   speed,	  which	  implies	   that	   the	   TALEs	   diffuse	   along	   their	   DNA	   substrates	   at	   least	   in	   part	   by	   a	  hopping	  mechanism.	  
	  
Figure	   3.13	   TALE	   proteins	   exhibit	   rapid	   1-­‐D	   diffusion	   along	   DNA	   templates.	   Histograms	   of	   TALE	  step	  sizes	  along	  non-­‐specific	  DNA	  at	  30	  (a)	  and	  90	  mM	  KCl	  (b),	  respectively.	  
	   Analysis	   of	   long	   (12-­‐15	   seconds)	   trajectories	   of	   TALE	   molecules	   along	   DNA	  substrates	   revealed	   at	   least	   two	  modes	   diffusion:	   rapid	   diffusion	   alternating	  with	  periods	   of	   relatively	   stagnant	   behavior,	   where	   diffusion	   slows	   and	   the	   protein	  remains	   constrained	   to	   a	   comparatively	   short	   distance	   (Figure	   3.14a).	   We	   next	  analyzed	   the	   binding	   times	   of	   TALE	   proteins	   at	   30	   mM	   and	   80	   mM	   KCl	  concentrations.	  The	  binding	  times	  of	  the	  protein	  at	  both	  concentrations	  fit	  a	  double-­‐exponential	   function	   (Figure	   3.14b	   and	   inset),	   which	   is	   another	   indication	   of	  multiple	  modes	  of	  binding.	  These	  data	  imply	  that	  TALE	  proteins	  assume	  at	  least	  two	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modes	   of	   DNA	   binding:	   a	   “search”	  mode,	   in	  which	   the	   protein	   diffuses	   rapidly	   in	  search	   of	   the	   target	   site,	   and	   a	   “binding”	  mode,	   in	  which	   the	  protein	   assumes	   the	  conformation	  described	   in	   the	  co-­‐crystal	   structures	  with	  cognate	  DNA	  sequence18,	  and	  is	  more	  restricted	  in	  diffusive	  ability.	  
	  
Figure	   3.14	   TALE	   proteins	   exhibit	   rapid	   1-­‐D	   diffusion	   along	   DNA	   templates.	   (a)	   Single	   molecule	  trajectory	  at	  90	  mM	  KCl	  over	  long	  time	  scales	  (>5	  sec)	  shows	  periods	  of	  rapid	  diffusion	  interspersed	  with	  periods	  of	  arrested	  motion.	  (b)	  Distribution	  of	  characteristic	  TALE	  bound	  times	  at	  30	  mM	  KCl	  and	  (inset)	  80	  mM	  KCl	  with	  corresponding	  double-­‐exponential	  fits.	  





Figure 3: TALE proteins exhibit rapid 1-D diffusion along DNA templates. (a) Single molecule 
trajectories of TALE diffusion events over short time scales (~1 sec) at 90 mM KCl. (b) and (c) 
Histograms of TALE step sizes along non-specific DNA at 30 and 90 mM KCl, respectively. (d) 
Mean-squared displacement of an ense ble of TALE proteins diffusing along non-specific DNA 
templates at 90 mM KCl. (e) Single molecule trajectory at 90 mM KCl over long time scales (>5 
sec) shows periods of rapid diffusion interspersed with periods of arrested motion. (f) 
Distribution of characteristic TALE bound times at 30 mM KCl and (inset) 80 mM KCl with 











Cuculis	  et	  al.	  Nat	  Commun	  	  2015,	  accepted	  
	   68	  
	  	  
	  
Figure	  3.15	  Bulk	  and	  single	  molecule	  analysis	  of	  NTR	  binding	  to	  random	  DNA.	  (a)	  Left	  panel:	  SDS-­‐PAGE	  analysis	  of	  NTR	  purified	  using	  affinity	  chromatography.	  Right	  panel:	  SDS-­‐PAGE	  analysis	  of	  Cy3-­‐labeled	   NTR.	   (b)	   Fluorescence	   polarization	   aldehyde-­‐tagged,	   unlabeled	   NTR	   and	   random	   DNA	  oligomer.	   (c)	   Histogram	   of	   step	   size	   distribution	   for	   NTR	   diffusion	   along	   DNA	   at	   30	   mM	   KCl	   (d)	  Histogram	  of	   step	   size	  distribution	   for	  NTR	  diffusion	  along	  DNA	  at	  10	  mM	  KCl.	   (e)	  Distribution	  of	  bound	   times	   for	   NTR	   truncation	   mutant	   on	   DNA	   templates,	   which	   is	   described	   by	   a	   single	  exponential	  decay.	  	   Cuculis	  et	  al.	  Nat	  Commun	  	  2015,	  accepted	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alone	  was	  found	  not	  to	  bind	  DNA20.	  These	  findings	  suggest	  that	  the	  NTR	  serves	  as	  a	  nucleation	  site	  for	  TALE	  binding	  to	  DNA,	  allowing	  sliding	  of	  the	  TALE	  along	  DNA	  in	  search	  of	   the	  target	  sequence20.	   In	   this	  case,	   the	  NTR	  alone	  should	  be	  able	   to	  bind	  DNA	  and	  move	  along	  the	  DNA	  substrates.	  We	  therefore	  truncated	  the	  TALE	  protein	  sequence	  to	  NTR	  alone	  and	  studied	  its	  behavior	  on	  double-­‐tethered	  DNA	  substrates.	  The	  208	  amino	  acid-­‐long	  NTR	  was	  aldehyde-­‐tagged	  and	  purified	  using	  affinity	  chromatography.	  The	  ~25	  kDa	  NTR	  was	  co-­‐purified	  with	  proteins	  with	  the	  sizes	  of	  50	   and	   75	   kDa,	   as	   shown	   by	   SDS-­‐PAGE	   analysis	   (Figure	   3.15a	   left	   panel).	   Gel	  filtration	  allowed	  resolution	  of	  the	  three	  protein	  sizes	  into	  separate	  fractions	  (data	  not	  shown).	  However,	  the	  purified	  smallest	  size	  fraction	  again	  revealed	  three	  sizes	  of	  protein	  on	  SDS-­‐PAGE	  (data	  not	  shown),	  which	  suggests	   that	   the	  observed	  three	  protein	  sizes	  are	  dimers	  and	  trimers	  of	  the	  purified	  NTR.	  Surprisingly,	  cy3-­‐labeled	  NTR	  (~90	  %	  labeled,	  as	  measured	  by	  absorbance	  at	  548	  nm	  in	  the	  Bradford	  assay),	  showed	   a	   much	   weaker	   tendency	   to	   aggregate	   into	   higher	   molecular	   structures	  (Figure	  3.15	  a	  right	  panel).	  Using	  fluorescence	  anisotropy,	  we	  found	  that	  unlabeled	  NTR	   binds	   to	   random	   DNA,	   although	   with	   reduced	   affinity	   compared	   with	   “full-­‐length”	   TALE	   (Figure	   3.15b,	   Table	   3.1),	   which	   is	   consistent	   with	   available	  literature20.	   This	   reduced	   apparent	   affinity	   of	  NTR	   towards	   random	  DNA	   could	   at	  least	   partially	   be	   explained	   by	   the	   instability	   of	   NTR	   in	   solution	   due	   to	   high	  propensity	  of	  NTR	  towards	  aggregation.	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Table	  3.1	  Binding	  affinities	  of	  TALE	  truncations	  with	  cognate	  and	  random	  DNA	  oligomers,	  measured	  via	   fluorescence	   polarization	   assay.	   Dissociation	   constants,	   Kd,	   are	   represented	   as	   average	   ±	   STD	  (n=3-­‐5).	  ND,	  not	  determined.	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We	   also	   generated	   a	   fluorescently	   labeled	   TALE	   truncation	   that	   lacked	   the	  NTR,	  containing	  only	  the	  CRD	  and	  CTR	  regions.	  Consistent	  with	  previous	  reports20,	  the	  CRD-­‐CTR	  truncation	  of	  TALE	  did	  not	  bind	  DNA	  in	  neither	  bulk	  or	  single	  molecule	  assays,	   further	  corroborating	   the	   importance	  of	  NTR	  as	  a	  nucleation	  site	   in	  TALE-­‐DNA	  binding.	  
	  
Figure	   3.16	   Bulk	   analyses	   of	   truncated	   TALEs.	   (a)	   and	   (c)	   SDS-­‐PAGE	   analysis	   of	   affinity-­‐purified	  TALE15.5	  and	  TALE10.5,	   respectively.	  (b)	   and	  (d)	  Fluorescence	  anisotropy	  assay	  of	  TALE15.5	  and	  TALE	  11.5	  binding	  to	  cognate	  and	  random	  DNA	  oligomers.	  Fluorescence	  polarization	  was	  performed	  with	   aldehyde	   tagged,	   fluorophore-­‐free	   TALEs.	   Fluorescein	   labeled	   29-­‐mer	   DNA	   oligomers	   were	  individually	  assayed	  with	  the	  proteins.	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Figure	  3.17	  Effect	  of	  CRD	  size	  on	  1-­‐D	  diffusion	  coefficient	  of	  TALE	  proteins.	  TALEs	  with	  11.5,	  15.5,	  and	   21.5	   central	   repeats	   were	   generated	   and	   their	   apparent	   1-­‐D	   diffusion	   coefficients	   were	  determined	   at	   30	   mM	   KCl	   (square	   symbols).	   Experimental	   data	   is	   compared	   to	   two	   different	  hydrodynamic	   models	   of	   diffusion	   that	   consider	   protein	   conformation	   as	   a	   diffusing	   helix	   and	   a	  spherical	  protein	  tracking	  the	  DNA	  helix,	  shown	  by	  the	  dashed	  and	  solid	  lines,	  respectively.	  	  






Figure 5: Effect of CRD size on 1-D diffusion coefficient of TALE proteins. TALEs with 11.5, 
15.5, and 21.5 central repeats were generated and their apparent 1-D diffusion coefficients were 
determined at 30 mM KCl (square symbols). Experimental data is compared to two different 
hydrodynamic models of diffusion that consider protein conformation as a diffusing helix and a 
spherical protein tracking the DNA helix, shown by the dashed and solid lines, respectively. 
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drag	  given	  by	  the	  additional	  repeats	  as	  modeled	  for	  a	  rigid	  helical	  body	  diffusing	  one	  dimensionally32	   (Figure	   3.17,	   dashed	   line).	   Hence,	   the	   extent	   of	   the	   diffusion	  coefficient	   decrease	   from	   TALES	  with	   10.5	   repeats	   to	   TALEs	  with	   21.5	   repeats	   is	  governed	  by	  more	  factors	  than	  simply	  the	  length	  of	  the	  TALE	  protein	  superhelix.	  We	  suggest	  that	  at	  least	  partially	  this	  change	  in	  the	  diffusion	  speeds	  is	  due	  to	  an	  altered	  equilibrium	   of	   the	   two	   modes	   of	   DNA	   binding	   among	   the	   TALEs	   with	   different	  lengths	  of	  the	  CRD.	  
3.3	  Discussion	  The	   ability	   of	   DNA-­‐binding	   proteins	   (DBP)	   such	   as	   lac	   repressor	   to	   locate	   target	  sites	  orders	  of	  magnitude	  faster	  than	  that	  predicted	  by	  3D	  diffusion	  has	   long	  been	  noted33.	   Resolution	   to	   this	   conundrum	   was	   offered	   by	   a	   now	   widely	   accepted	  concept	   of	   facilitated	   diffusion,	  where	   non-­‐specific	   association	   of	   proteins	   to	  DNA	  can	   reduce	   the	   amount	   of	   search	   time	   of	   the	   target	   sequence33-­‐37.	   It	   was	   later	  proposed	   that	   a	  most	   efficient	   search	  mechanism	  would	  be	  a	   combination	  of	  one-­‐dimensional	  diffusion	  along	  DNA	  and	  three-­‐dimensional	  diffusion,	  assuming	  that	  the	  search	   is	   conducted	   by	   just	   one	   protein	   molecule38-­‐39.	   Nevertheless,	   whether	   in	  physiological	  conditions	  DBPs	   localize	  their	  targets	  primarily	  by	  1-­‐D	  diffusion,	  3-­‐D	  diffusion,	  or	  a	  combination	  thereof	  remains	  an	  open	  question.	  Escherichia	  coli	  RNA	  polymerase,	   for	  example,	  was	  reported	   to	  search	   for	   its	   target	  promoter	  primarily	  by	   a	   3-­‐D	   diffusion	   at	   physiological	   concentrations	   of	   the	   protein40.	   Similarly,	   the	  CRISPR	  RNA-­‐guided	  endonuclease	  Cas9	  was	  also	  reported	  to	  find	  targets	  primarily	  by	   3-­‐D	   diffusion	   until	   it	   finds	   the	   short	   trinucleotide	   sequence	   PAM	   required	   for	  Cas9	   activity41.	   It	   is	   possible	   that	   different	   DBPs	   utilize	   different	   target	   search	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mechanisms,	  which	  suggests	  that	  different	  classes	  of	  DBPs	  should	  be	  investigated	  on	  a	  case-­‐by-­‐case	  basis.	  	  Given	   that	   TALE	   proteins	   stand	   out	   among	   other	   DBPs	   in	   their	   unique	  structure	   and	   DNA	   recognition	   mechanism,	   their	   mechanism	   of	   target	   search	   is	  particularly	  obscure.	   	  In	  this	  work,	  we	  investigated	  the	  DNA-­‐binding	  dynamics	  and	  the	   target	   search	   mechanism	   of	   a	   TALE	   protein	   and	   the	   contribution	   of	   its	  subdomains	   in	   these	  processes.	   For	   the	   first	   time,	  we	  were	  able	   to	  observe	   single	  molecules	  of	  TALE	  moving	  by	  a	  1-­‐D	  diffusion	  on	  a	  double-­‐tethered	  DNA	  substrate,	  which	  implies	  that	  TALEs	  can	  in	  principle	  utilize	  facilitated	  diffusion	  mechanism	  of	  target	  search.	  Whether	  TALE	  proteins	  search	  for	  their	  target	  sites	  primarily	  by	  1-­‐D	  diffusion	  or	  also	  rely	  heavily	  on	  3-­‐D	  diffusion	  in	  physiological	  conditions	  remains	  to	  be	   investigated.	   However,	   the	   conclusions	   from	   the	   in	  vitro	   experiments	   reported	  here	  encompass	  an	  important	  step	  in	  the	  elucidation	  of	  the	  complete	  mechanism.	  The	   finding	   that	   the	  NTR	  demonstrates	   only	   a	   sliding	   behavior,	  whereas	   the	  “full-­‐length”	   TALE	   exhibits	   a	   combination	   of	   hopping	   and	   sliding	   indicates	   that	  different	  domains	  of	  the	  TALE	  are	  responsible	  for	  distinct	  modes	  of	  motion.	  Thus,	  it	  could	  be	  speculated	  that	  the	  positively	  charged	  patches	  on	  the	  surface	  of	  NTR20	  are	  responsible	  for	  the	  initial	  interaction	  of	  the	  protein	  with	  the	  phosphate	  backbone	  of	  DNA,	   and	   subsequently	   are	   responsible	   for	   the	   continuous	   interaction	   with	   the	  phosphate	   backbone,	   allowing	   the	  movement	   of	   the	   full-­‐length	   TALE	   by	   a	   sliding	  mechanism.	  The	  CRD,	  on	  the	  other	  hand,	  could	  be	  interacting	  with	  DNA	  with	  a	  much	  rougher	  energy	  landscape,	  thus	  destabilizing	  the	  complex	  and	  forcing	  the	  protein	  to	  dissociate	  more	  often	  compared	  with	  the	  NTR	  alone.	  The	  hopping	  behavior	  arising	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as	   a	   result	   can	   be	   an	   advantageous	   translocation	   mechanism	   that	   would	   allow	  bypassing	  of	  a	  bound	  protein	  or	  sampling	  both	  strands	  of	  the	  DNA	  substrate42.	  Most	   DBPs,	   including	   TALEs,	   bind	   their	   target	   DNA	   sequences	   with	   large	  binding	   energies.	   For	   a	   rigid	   protein,	   this	  would	   cause	   the	   energy	   landscape	   of	   a	  sliding	  protein	  on	  nonspecific	  DNA	  so	  rough,	   that	   the	   target	  search	   time	  would	  be	  unreasonably	  slow,	  a	  phenomenon	  known	  as	  the	  search-­‐speed	  stability	  paradox43-­‐44.	  A	   solution	   to	   the	   paradox	   proposes	   a	   DBP	   capable	   of	   switching	   between	   two	  conformations	   separated	   by	   a	   free	   energy	   barrier43-­‐44.	   In	   a	   “searching	  mode”,	   the	  protein	  is	  loosely	  bound	  to	  DNA,	  and	  can	  rapidly	  slide	  along	  DNA	  due	  to	  a	  relatively	  smooth	  binding	  energy	  landscape.	  In	  a	  “recognition	  mode”,	  the	  protein	  is	  bound	  to	  DNA	  more	  tightly	  and	  can	  be	  trapped	  in	  a	  deep	  energy	  well,	  which	  would	  reduce	  its	  diffusion	   speed	   dramatically.	   In	   this	   work,	   we	   have	   demonstrated	   that	   the	   TALE	  protein	  indeed	  exhibits	  a	  two-­‐mode	  binding	  behavior.	  	  Although	   no	   direct	   evidence	   of	   two	   conformations	   of	   TALEs	   bound	   to	   DNA	  substrates	  exists,	  conformational	  plasticity	  of	  TALEs	  in	  the	  DNA-­‐free	  form	  as	  well	  as	  an	  almost	  two-­‐fold	  decrease	  in	  the	  superhelical	  pitch	  of	  TALEs	  upon	  specific	  binding	  are	  widely	   reported	   both	   experimentally	   and	   computationally18,	  21,	  45-­‐47.	   Thus,	  we	  suggest	  that	  the	  TALE	  conformation	  corresponding	  to	  the	  recognition	  mode	  closely	  resembles	   that	   of	   the	   observed	   in	   the	   co-­‐crystal	   structure18-­‐19,	   while	   the	   TALE	  conformation	  corresponding	  to	  the	  searching	  mode	  has	  a	  larger	  superhelical	  pitch,	  either	  resembling	  that	  of	  the	  DNA-­‐free	  structure	  of	  TALE18,	  or	  anywhere	  in	  between	  (Figure	  3.18).	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Figure	   3.18	   Schematic	   of	   two-­‐state	   model	   for	   TALE	   protein	   diffusion	   along	   DNA.	   A	   TALE	   is	   in	  equilibrium	   between	   the	   ‘searching	  mode’	   and	   ‘recognition	  modes’.	   In	   the	   ‘recognition	  mode’,	   the	  TALE	  protein	   is	   tightly	  bound	   to	   the	  major	   groove	  of	   a	  DNA	  via	   electrostatic	   interactions	  with	   the	  phosphate	   backbone.	   In	   the	   ‘searching	   mode’,	   the	   protein	   assumes	   a	   conformation	   with	   a	   larger	  superhelical	  pitch,	  analogous	  to	  the	  DNA-­‐free	  structures	  of	  TALEs.	  
















Figure 6: chematic of t o-state model for TALE protein diffusion along DNA. TALE proteins 
undergo a conformational change from the ‘search’ to ‘bind’ mode upon encountering target 
DNA. In the ‘bind’ mode, the TALE protein is tightly bound to th  major groove of a DNA 
template with non-covalent interactions forming along the phosphate backbone. In the ‘search’ 
mode, the protein assumes a looser conformation with a larger h lical pitch, analogous to the 
structure DNA-free TALEs. In either mode, the NTR remains in a nearly identical conformation 
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TALE	   proteins	   sample	   the	   DNA	   sequence	   by	   one-­‐dimensional	   diffusion,	   which	   is	  achieved	  by	  a	  combination	  of	  hopping	  and	  sliding	  movements.	  While	  bound	  to	  DNA,	  the	   protein	   exhibits	   at	   least	   two	   conformations	   that	   are	   in	   an	   equilibrium:	   the	  conformation	  with	  a	  superhelical	  pitch	  matching	  that	  of	  the	  DNA	  helix	  pitch,	  the	  so	  called	   “recognition	   mode”,	   and	   at	   least	   one	   more	   conformation	   with	   a	   larger	  superhelical	   pitch,	   or	   “searching	  mode”	   (Figure	   3.18).	   In	   the	   searching	  mode,	   the	  superhelical	  pitch	   is	   larger	   than	   that	  of	   the	  DNA	  double	  helix,	   and	   the	  nonspecific	  interactions	  of	   the	  TALE	  CRD	  are	  mostly	  out	  of	   register	   to	   interact	   favorably	  with	  the	   phosphate	   backbone.	   This	   conformation	   would	   minimize	   the	   nonspecific	  electrostatic	   interactions	   of	   the	   CRD	   with	   the	   DNA,	   while	   the	   nonspecific	  interactions	  of	  NTR	  with	  DNA	  would	  allow	  a	  fast	  sliding	  movement	  along	  the	  DNA	  backbone.	  The	  stability	  of	   the	  recognition	  mode	  at	  a	  given	  DNA	  sequence	  depends	  on	   the	  matching	   of	   the	   DNA	   sequence	   to	   the	   RVD	   array.	   TALE	   in	   the	   recognition	  mode	   interacting	   with	   a	   noncognate	   DNA	   sequence	   would	   experience	   steric	   and	  electrostatic	   clashes	   that	   would	   exert	   a	   disruptive	   effect	   on	   the	   nonspecific	  interactions	  of	  G14,	  K16,	  and/or	  Q17	  with	  the	  DNA	  backbone,	  thus	  destabilizing	  the	  complex.	  In	  the	  case	  of	  a	  match,	  the	  amino	  acids	  G14,	  K16,	  and	  Q17	  favorably	  align	  and	   nonspecifically	   interact	   with	   the	   phosphate	   backbone	   of	   the	   DNA,	   thus	  stabilizing	   the	   complex.	   A	   co-­‐crystal	   structure	   of	   a	   TALE	   with	   noncognate	   DNA	  would	  be	  helpful	   in	   testing	   the	  validity	  of	   this	  model,	  and	  would	  shed	   light	  on	   the	  nature	  of	  the	  searching	  mode	  of	  TALEs.	  The	   fundamental	   understanding	   of	   TALE	   target	   search	   mechanism	   could	  enable	  the	  development	  of	  more	  specific	  and	  efficient	  TALE	  proteins	  for	  use	  in	  basic	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science	  or	  genome	  engineering	  applications.	  This	  work	  provides	  a	  molecular-­‐level	  view	  of	  the	  dynamic	  search	  process	  of	  TALEs,	  which	  is	  a	  step	  forward	  in	  gaining	  a	  fundamental	  understanding	  of	  the	  target	  search	  process.	  
	  
3.4	  Materials	  and	  Methods	  
3.4.1	  Preparation	  of	  DNA	  constructs	  Preparation	  of	  substrate	  DNA	  The	  plasmid	  was	  purified	  using	   the	  Plasmid	  Midi	  Kit	   (Qiagen)	  and	   linearized	  with	  SnaBI	  enzyme	  (New	  England	  Biolabs	  (NEB))	   for	  3	  hours.	   It	  was	  next	  purified	  using	  phenol-­‐chloroform	  extraction	  and	  ethanol	  precipitation.	  The	  purified	  plasmid	  was	   subjected	   to	   the	   3ʹ′-­‐5ʹ′	   exonuclease	   activity	   of	   T4	   DNA	   polymerase	   (NEB)	   to	  create	  the	  5ʹ′	  overhangs	  at	  both	  ends	  of	  the	  linearized	  DNA.	  10	  μg	  DNA	  was	  treated	  with	   5	   units	   of	   T4	   DNA	   polymerase	   in	   NEB	   buffer	   2	   supplemented	   with	   bovine	  serum	  albumin	  (BSA)	  for	  1	  hour	  at	  25	  °C.	  The	  reaction	  was	  stopped	  with	  1	  μl	  20	  mM	  dCTP	  and	  the	  enzyme	  was	  heat	  deactivated	  at	  75	  °C	  for	  20	  minutes.	  The	  exposed	  5ʹ′	  overhangs	   were	   used	   to	   sequence-­‐specifically	   anneal	   3ʹ′-­‐biotinylated	  oligonucleotides.	   First,	   the	   oligonucleotide	   with	   the	   sequence	  cagcagttcaacctgttgatagtac/3BioTEG/	  (IDT)	  was	  annealed	  in	  50x	  molar	  excess	  to	  the	  substrate	  DNA	  by	  heating	  the	  mixture	  at	  90	  °C	  for	  5	  minutes	  and	  gradually	  cooling	  to	   4	   °C.	   The	   second	   oligonucleotide	  with	   the	   sequence	   tacgtgaaacatgagagcttagtac-­‐/3BioTEG/	   was	   annealed	   subsequently	   in	   the	   microfluidic	   flow	   chamber,	   as	  described	  later.	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Cloning	  of	  TALE21.5	  and	  Naldt-­‐TALE21.5	  	  The	  gene	  coding	  for	  the	  untagged	  TAL	  effector	  protein	  (TALE21.5)	  was	  assembled	  using	   the	   Golden	   Gate	   cloning	   method	   (Addgene	   TALEN	   Kit	   #1000000024,	   as	  described	   in49),	   into	   a	   specifically	   engineered	   destination	   vector,	   pET28-­‐GG-­‐TALE.	  The	  destination	  vector	  contained	  an	  N-­‐terminal	  His-­‐tag	  and	  flanking	  N-­‐	  (208	  aa)	  and	  C-­‐	   (63	   aa)	   terminal	   regions	   of	   the	   TAL	   effector	   as	   well	   as	   the	   BsmBI	   sites	  corresponding	  to	  the	  kit	  BsmBI	  sites.	  For	  fluorescent	  tagging	  of	  the	  TAL	  effector,	  we	  modified	  the	  original	  plasmid	  pET-­‐tSCA2	  with	  an	  oligonucleotide	  insert	  encoding	  N-­‐terminal	   LCPTSR	   hexapeptide	   (aldehyde	   tag25,26)	   upstream	   of	   the	   His-­‐tag.	   To	   this	  end,	   the	  plasmid	  was	  amplified	   in	   fragments	   containing	   the	   insert,	   and	  assembled	  using	   the	   Gibson	   Assembly	   Kit	   (NEB).	   The	   protein	   sequence	   of	   the	   tagged	   Naldt-­‐TALE21.5	  is	  provided	  in	  the	  Appendix	  A.	  Cloning	  Naldt-­‐TALE15.5	  and	  Naldt-­‐TALE11.5	  	  In	  order	  to	  construct	  TAL	  effectors	  shortened	  to	  the	  first	  15.5	  and	  11.5	  repeats,	  we	  first	   engineered	   a	   destination	   vector	   pET28-­‐Naldt-­‐GG-­‐TALE,	   which	   contains	   the	  aldehyde	  tag	  upstream	  of	  the	  His-­‐tag,	  using	  the	  Gibson	  Assembly	  Master	  Mix	  (NEB).	  Naldt-­‐TALE15.5	  and	  Nald-­‐TALE11.5	  were	  assembled	  using	  the	  Golden	  Gate	  cloning	  method49	  into	  the	  destination	  vector	  pET-­‐NaldT-­‐GG-­‐TALE.	  	  Cloning	  of	  Naldt-­‐NTR	  	  To	   create	   the	   NTR	   truncation,	   we	   digested	   pET-­‐Naldt-­‐TALE21.5	   with	   SacII	   and	  
HindIII,	   and	   inserted	   the	  CAAAGCGTGGTGGCGTGACCGCGGTGGAAGCGGTCCATGCCTGGCGTAATGCGTTGACGGGCGCCCCCCTGAACTAAGTCAGATAACCGGATACAGACAAGCTTGCGGCCGCACTCGAGC
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ACCAC	   sequence	   synthesized	   as	   a	   gBlock	   Gene	   Fragment	   (Integrated	   DNA	  Technologies	  (IDT)),	  using	  the	  Gibson	  Assembly	  Master	  Mix	  (NEB).	  The	  sequence	  of	  the	  NTR	  is	  provided	  in	  the	  Appendix	  A.	  Cloning	  of	  Naldt-­‐CRD-­‐CTR	  	  Primers	   (IDT)	   containing	  BsmBI	   sites	   corresponding	   to	  BsmBI	   sites	   from	  previous	  destination	   vectors	  were	   used	   to	   PCR-­‐amplify	   the	   backbone	   of	   the	   pET-­‐Naldt-­‐GG-­‐TALE,	   excluding	   the	  NTR-­‐region.	  The	  CRD	   containing	  21.5	   repeats	  was	   assembled	  into	  this	  PCR-­‐amplified	  product	  using	  the	  Golden	  Gate	  method	  as	  described	  above.	  The	  protein	  sequence	  of	  Naldt-­‐CRD-­‐CTR	   is	  provided	   in	   the	  Appendix	  A.	  All	  primer	  and	  plasmid	  sequences	  are	  available	  upon	  request.	  
3.4.2	  Protein	  Expression	  BL21	  (DE3)	  electrocompetent	  E.	  coli	  cells	  were	  co-­‐transformed	  with	  plasmids	  encoding	  TAL	  effector	   constructs	   and	   the	  pBAD-­‐FGE	  plasmid	   (generous	  gift	   of	  Dr.	  Taekjip	  Ha,	  University	  of	  Illinois	  at	  Urbana-­‐Champaign).	  A	  single	  colony	  was	  grown	  in	  5	  ml	  LB	  supplemented	  with	  100	  μg/ml	  ampicillin	  and	  25	  μg/ml	  kanamycin	  as	  a	  seeding	  culture	  until	  saturation,	  and	  subsequently	  in	  500	  ml	  of	  Terrific	  Broth	  at	  37	  °C	  and	  250	  revolutions	  per	  minute	  (RPM)	  with	   the	  corresponding	  antibiotics	  until	  OD600	  of	  0.3-­‐0.4.	   	  FGE	  expression	  was	  induced	  with	  0.2	  %	  L-­‐arabinose	  (Sigma)	  and	  the	  culture	  was	  grown	  further	  at	  37	  °C	  250	  RPM	  until	  it	  reached	  OD600	  0.7-­‐0.8.	  TAL	  effector	   expression	   was	   induced	   with	   0.4	   mM	   isopropyl	   β-­‐D-­‐1-­‐thiogalactopyranoside	  (IPTG)	  (Sigma).	  	  The	  proteins	  were	  expressed	  overnight	  at	  16	  °C	  and	  250	  RPM.	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3.4.3	  Protein	  Purification	  The	   cultures	  were	   centrifuged	   at	   4,000	   RPM	   at	   4	   °C	   for	   15	  minutes	   and	   the	  pellets	   re-­‐suspended	   in	  10-­‐20	  ml	   of	   lysis	   buffer	   (25	  mM	  Tris-­‐HCl	   (Fisher)	  pH	  7.5,	  300	  mM	  NaCl	  (Fisher),	  0.5	  %	  triton	  (Sigma),	  5	  %	  glycerol	  (Sigma),	  4	  U/ml	  DNase	  I	  (NEB),	   0.3	   mM	   phenylmethanesulfonylfluoride	   (Sigma),	   1	   mg/ml	   lysozyme	  (Sigma)).	  The	  cells	  were	  lysed	  by	  sonication	  for	  20	  minutes	  total	  with	  alternating	  5	  seconds	  of	  pulse	  and	  5	  seconds	  of	  rest,	  and	  cell	  debris	  were	  centrifuged	  at	  13,000	  RPM	  for	  20	  min	  at	  4	  °C.	  The	  His-­‐tagged	  TAL	  effectors	  were	  purified	  using	  AKTA	  pure	  chromatography	   system	   (GE	   Healthcare)	   with	   a	   5	   ml	   HisTrap	   column	   (GE	  Healthcare).	  The	  cleared	  lysate	  was	  loaded	  on	  the	  column,	  washed	  with	  20	  mM	  Tris-­‐HCl	  pH	  7.5,	  500	  mM	  NaCl,	   and	  20	  mM	   imidazole	   (Sigma),	   and	  eluted	  with	  20	  mM	  Tris-­‐HCl	   pH	   7.5,	   500	  mM	  NaCl,	   and	   250	  mM	   imidazole.	   The	   purified	   protein	  was	  dialyzed	   in	   2	   L	   50	   mM	   phosphate	   buffer	   pH	   7-­‐8.4	   (depending	   on	   the	   predicted	  protein	   isoelectric	   point),	   500	   mM	   NaCl	   at	   4	   °C	   overnight.	   When	   necessary,	   the	  protein	   was	   further	   purified	   using	   16/600	   200	   pg	   gel	   filtration	   column	   (GE	  Healthcare)	   using	  50	  mM	  phosphate	  buffer	   pH	  7-­‐8.4	   (depending	  on	   the	  predicted	  protein	  isoelectric	  point),	  500	  mM	  NaCl.	  	  The	   in	   vivo	   aldehyde	   labeling	   efficiency	   was	   quantified	   using	   data	   from	   LC-­‐MS/MS.	  Briefly,	   unmodified	  TALE	   cysteines	  were	  alkylated	  using	   iodoacetamide50,	  the	  protein	  was	  ran	  on	  SDS-­‐PAGE	  gel	  (BioRad),	  and	  the	  band	  corresponding	  to	  the	  TALE	  was	  in-­‐gel	  trypsin	  digested	  and	  analyzed	  by	  LC-­‐MS/MS	  using	  the	  VG	  Quattro	  Electrospray	  Mass	  Spectrometer	  at	  the	  	  Roy	  J.	  Carver	  Biotechnology	  Center	  at	  UIUC.	  The	  masses	  of	  the	  peptides	  containing	  the	  untagged	  and	  tagged	  hexapeptide	  motifs	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were	   filtered	   from	   the	   raw	   chromatograms	   and	   their	   relative	   quantities	   were	  derived	   from	   their	   peak	   counts.	   Fluorescence	   gel	   images	   were	   taken	   using	   the	  Molecular	   Dynamics	   Typhoon	   9400	   Multilaser	   Scanner	   at	   the	   Roy	   J.	   Carver	  Biotechnology	   Center.	   UV/Vis	   spectroscopic	   measurements	   were	   taken	   on	  Nanodrop	  200	  UV-­‐Vis	  Spectrophotometer	  (Thermo	  Scientific).	  
3.4.4	  Protein	  Labeling	  The	  purified	   (>90	  %	  purity	   by	   SDS-­‐PAGE)	  TAL	   effector	   proteins	  were	   buffer	  exchanged	   using	   Amicon	   Ultra-­‐0.5	   ml	   centrifugal	   units	   (EMD	   Millipore)	   and	  concentrated	   to	   100-­‐300	   μM	   in	   30	   μl	   of	   labeling	   buffer	   (250	   mM	   potassium	  phosphate	   pH	   6,	   500	   mM	   KCl	   (Fisher),	   5	   mM	   dithiothreitol	   (Roche)).	   The	  concentrated	   protein	   solutions	  were	   used	   to	   re-­‐suspend	   1	  mg	   Cy3-­‐hydrazide	   (GE	  Healthcare)	  or	  CF640R	  (Sigma)	  and	  labeled	  for	  24	  hours	  at	  room	  temperature	  in	  the	  dark.	  The	  labeled	  proteins	  were	  diluted	  with	  400	  μl	  fluorescence	  anisotropy	  buffer	  (20	   μM	   Tris-­‐HCl	   pH	   7.5	   100	   mM	   Nacl	   0.5	   mM	   ethylenediaminetetraacetic	   acid	  (EDTA)	   (Fisher))	   and	  purified	   from	  unreacted	  Cy3	  or	  CF640R	  by	   two	   consecutive	  passages	   through	   Micro	   Bio-­‐spin	   6	   columns	   (Bio-­‐Rad)	   following	   manufacturer’s	  instructions.	   In	   the	  case	  of	  NTR	   labeling,	   the	  purification	  of	   labeled	  NTR	  from	  free	  dye	   was	   performed	   using	   a	   TALON	   Spin	   Column	   (Clontech	   Laboratories)	   as	   per	  manufacturer’s	   instructions,	  except	   that	   the	  column	  was	  washed	  10	  times	  until	  no	  more	  dye	  was	  observed	  in	  the	  flow-­‐through.	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3.4.5	  Fluorescence	  Anisotropy	  Twenty-­‐nine	   bp-­‐long	   oligonucleotide	   containing	   the	   23	   nt-­‐long	   TAL	   effector	  binding	  site	  was	  labeled	  at	  the	  5ʹ′	  end	  with	  6-­‐FAM	  (fluorescein)	  (IDT)	  and	  annealed	  with	   its	   reverse-­‐complementing	   oligonucleotide	   in	   the	   annealing	   buffer	   (10	   mM	  Tris-­‐HCl	  1	  mM	  EDTA	  pH	  8,	  50	  mM	  NaCl)	  by	  heating	  up	  the	  mixture	  at	  90	  °C	   for	  2	  minutes	   and	  gradually	   cooling	   to	  4	   °C.	   	  A	   control	  double	   stranded	  oligonucleotide	  was	  prepared	  similarly,	  except	  the	  sequence	  was	  randomized	  to	  contain	  no	  binding	  site	  (sequences	  provided	  in	  the	  Appendix	  A).	  Mixtures	   of	   1	   nM	   ds	   oligonucleotide	   and	   various	   concentrations	   of	   proteins	  were	   prepared	   in	   the	   fluorescence	   anisotropy	   buffer,	   and	   200	   μl	   samples	   were	  assayed	   in	  black	  96-­‐well	  plates	   (Corning),	   in	  duplicates.	  Fluorescence	  polarization	  measurements	   were	   taken	   on	   Infinite	   200	   Pro	   microplate	   reader	   (Tecan)	   using	  excitation	   and	   emission	   wavelengths	   of	   485	   nm	   and	   535	   nm,	   respectively.	   The	  fluorescence	  polarization	  values	  were	  converted	  to	   fluorescence	  anisotropy	  values	  using	   Equation	   1,	   where	   A	   is	   anisotropy	   and	   P	   is	   polarization.	   The	   KD	   value	  was	  calculated	  by	   curve	   fitting	   on	  Origin	  8.5	   (OriginLab)	  using	  Equation	  2,	  where	  A	   is	  observed	  anisotropy	  value,	  Af	   is	  anisotropy	  of	   free	  DNA,	  Ab	   is	  anisotropy	  of	  bound	  DNA,	   LT	   is	   total	   ligand	   (DNA)	   concentration,	   and	   RT	   is	   total	   receptor	   (protein)	  concentration.	  
	  	  	  	  	  	  	  	  	  (1)	   	  
	  	  	  	  	  	  (2)	  
A = 2P3−P
A = Af + (Ab − Af )*
(LT +KD + RT )− (LT +KD + RT )2 − 4LTRT
2LT
	   84	  
	  
3.4.6	  Flow	  Cell	  Preparation	  and	  DNA	  Substrate	  Attachment	  (performed	  by	  Luke	  Cuculis,	  Dr.	  Charles	  M.	  Schroeder	  Lab)	  Mili-­‐fluidic	   flow	  cells	  were	  constructed	  by	  sandwiching	  two	  pieces	  of	  double-­‐sided	  tape	  between	  a	  pre-­‐drilled	  quartz	  microscope	  slide	  and	  glass	  coverslip	  to	  form	  a	   flow	   channel.	   	   Prior	   to	   assembly	   of	   the	   flow	   cell,	   coverslips	  were	   functionalized	  with	  PEG/PEG-­‐biotin	  and	  Neutravidin	  for	  surface	  attachment	  of	  DNA	  and	  reduction	  of	   nonspecific	   protein	   adsorption.	   	   Polyethylene	   tubing	   was	   affixed	   to	   the	   ports	  drilled	   in	   each	   end	   of	   the	   flow	   cell	   in	   order	   to	   facilitate	   rapid	   exchange	   of	   buffer	  solutions	  and	  allow	  for	  stretching	  of	  tethered	  DNA.	  	  	  Assembled	   flow	   cells	   were	   first	   incubated	   with	   a	   blocking	   solution	   (50	   mM	  MOPS,	  10-­‐110	  mM	  KCl,	  0.1	  mM	  EDTA	  ,	  5%	  glycerol,	  0.3	  mg/mL	  BSA,	  pH	  =	  8.1)	  for	  10	  minutes	   and	   then	   5	   pM	   biotin-­‐functionalized	   DNA	   for	   45	  minutes.	   Unbound	   DNA	  was	   washed	   with	   blocking	   solution	   and	   double	   tethered	   DNA	   was	   subsequently	  formed	   by	   flowing	   100	   nM	   biotinylated	   primer,	   complementary	   to	   the	   single	  stranded	  overhangs	  previously	  generated	  on	  the	  long,	  single	  tethered	  DNA,	  at	  a	  rate	  of	   100	   μL/min	   in	   the	   presence	   of	   100	   μM	   chloroquine	   (Sigma	   Aldrich).	   	   The	  presence	  of	  chloroquine	  in	  the	  primer	  solution	  allows	  for	  the	  DNA	  to	  be	  extended	  to	  ~85%	  of	   its	   contour	   length	   immediately	   prior	   to	   formation	   of	   the	   second	   surface	  tether,	   reducing	   substrate	   fluctuations	   during	   single	   molecule	   imaging51.	  	  Chloroquine	   is	   subsequently	   removed	   by	   washing	   the	   flow	   cell	   with	   blocking	  solution	  containing	  40	  mM	  MgCl2	  and	  200	  mM	  NaCl	  for	  5	  minutes.	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3.4.7	   Single	   Molecule	   Imaging	   (performed	   by	   Luke	   Cuculis,	   Dr.	   Charles	   M.	  Schroeder	  Lab)	  Single	   molecule	   imaging	   experiments	   were	   carried	   out	   on	   an	   inverted	   total	  internal	  fluorescence	  (TIRF)	  microscope	  (Nikon	  IX70)	  coupled	  to	  an	  EMCCD	  camera	  (Andor	   iXon	  Ultra	  897).	   	  Cy3	   labeled	  proteins	  were	  excited	  using	  a	  532	  nm	  diode-­‐pumped	  solid	  state	  (DPSS)	   laser	  (CrystaLaser)	  and	  SYTOX	  Green	   labeled	  DNA	  was	  excited	   using	   a	   488	   nm	   DPSS	   laser	   (SpectraPhysics	   Excelsior).	   	   Image	   sequences	  were	   acquired	   at	   a	   rate	   of	   30-­‐50Hz.	   	   Labeled	   TALE	   proteins	   were	   added	   at	  concentrations	  typically	  ranging	  from	  25	  to	  100	  pM,	  and	  in	  the	  case	  of	  the	  NTD,	  in	  the	  presence	  of	  1	  to	  2	  nM	  unlabeled	  constructs.	   	  A	  triplet	  state	  quencher	  (7	  mM	  β-­‐mercaptoethanol,	   Sigma	   Aldrich)	   and	   oxygen	   scavenging	   system	   (glucose	   oxidase	  and	  bovine	  liver	  catalse)	  along	  with	  1%	  v/v	  glucose	  were	  added	  to	  blocking	  buffer,	  along	  with	  the	  protein.	  
3.4.8	  Data	  Analysis	  (performed	  by	  Luke	  Cuculis,	  Dr.	  Charles	  M.	  Schroeder	  Lab)	  Image	  sequences	  were	  recorded	  as	  TIF	  stacks	  using	  the	  Andor	  Solis	  software.	  	  Regions	   of	   interest	   containing	   single	   diffusing	   TALE	   proteins	   were	   isolated	   using	  ImageJ	   and	   the	   centroid	   locations	   of	   single	   proteins	   were	   determined	   using	  RapidStorm	   super	   resolution	   fitting	   software52.	   	   Single	  molecule	   trajectories	  were	  then	  further	  analyzed	  using	  custom	  MATLAB	  scripts.	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Chapter	  4.	  PUF	  Module	  Library	  Creation	  and	  PUF	  Assembly	  
4.1	  Introduction	  The	   presence	   of	   RNA-­‐binding	   proteins	   (RBPs)	   in	   RNA	   biology	   is	   ubiquitous.	  Hundreds	   to	   thousands	   of	   eukaryotic	   proteins	   are	   estimated	   to	   function	   as	  RBPs1	  and	  govern	  many	  aspects	  of	  RNA	  biology	  including	  translation,	  turnover,	  processing,	  and	  cellular	  localization2-­‐4.	  Despite	  their	  great	  diversity	  in	  function,	  only	  a	  few	  types	  of	   RNA-­‐binding	   domains	   are	   known,	   which	   are	   combined	   in	   different	   structural	  arrangements	   with	   a	   variety	   of	   functional	   domains5.	   This	   modular	   architecture	  makes	   RBPs	   an	   attractive	   tool	   for	   studying	   the	   vast	   complexity	   of	   eukaryotic	  transcriptomes	  as	  well	  as	  manipulating	  RNA	  for	  therapeutic	  purposes6-­‐7.	  The	  function	  of	  many	  RBPs	  can	  be	  studied8-­‐11	  by	  tethering	  them	  to	  a	  reporter	  RNA	   through	   a	   well-­‐characterized	   RNA-­‐binding	   peptide	   with	   a	   fixed	   specificity12.	  However,	   this	   approach	   can	   only	   be	   applied	   to	   manipulate	   heterologous	   RNA	  because	  prior	   tagging	   of	   the	  RNA	   is	   required.	   In	   order	   to	  manipulate	   endogenous	  RNA	  in	  its	  native	  expression	  conditions,	  one	  could	  envision	  a	  designer	  RBP	  with	  an	  RNA-­‐binding	   scaffold	   that	   could	   be	   easily	   engineered	   for	   sequence	   specificity.	   To	  date,	   only	   pentatricopeptide	   repeat13-­‐14	   and	   Pumilio/fem-­‐3	   mRNA	   binding	   factor	  (PUF)15-­‐18	   proteins	   have	  been	  demonstrated	   to	   have	   the	  potential	   to	   be	   rationally	  modified	  for	  predictable	  and	  specific	  RNA	  recognition.	  PUF	   proteins	   are	   eukaryotic	   RBPs	   that	   are	   involved	   in	   post-­‐transcriptional	  gene	  regulation19.	  The	  crystal	  structure	  of	  Pumilio	  homology	  domain	  (PUM-­‐HD),	  the	  RNA-­‐binding	  region	  of	  the	  human	  Pumilio	  1	  (PUM1)	  protein	  (Figure	  4.1a),	  reveals	  8	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structural	   repeats,	   each	   containing	   ~36	   amino	   acids	   (aa),	   and	   flanking	   N-­‐and	   C-­‐terminal	  regions20-­‐21.	  The	  structure	  also	  suggests	  that	  recognition	  of	  the	  target	  RNA	  sequence	  is	  highly	  modular	  since	  each	  repeat	  binds	  to	  a	  single	  RNA	  base15.	  The	  N-­‐terminal	  repeat	  (R1)	  binds	  to	  the	  3ʹ′-­‐nucleotide	  residue	  (N8)	  of	  the	  target	  sequence	  (Figure	   4.1a	   and	   b),	   while	   the	   C-­‐terminal	   repeat	   (R8)	   binds	   to	   the	   5ʹ′-­‐nucleotide	  residue	  (N1).	  Residues	  at	  positions	  12	  and	  16	  in	  each	  repeat	  directly	  interact	  with	  a	  Watson-­‐Crick	   edge	   of	   a	   base,	   whereas	   the	   residue	   at	   position	   13	   is	   involved	   in	   a	  stacking	   interaction	   between	   two	   adjacent	   bases15.	   The	   structure	   suggests	   a	  recognition	  “code”,	  where	  residues	  at	  positions	  12	  and	  16	  in	  each	  repeat	  contribute	  to	  specific	  recognition	  of	  a	  base,	  with	  N12Q16	  recognizing	  uracil,	  C12Q16	  adenine,	  and	  S12E16	   guanine15.	   The	   residue	   combination	   S12R16	   was	   engineered	   to	   recognize	  cytosine17-­‐18.	   By	   swapping	   the	   key	   residues	   at	   these	   positions,	   it	   was	   shown	   that	  designed	  PUF	  proteins	  with	  altered	  specificity	  could	  be	  engineered16,	  22.	  In	  the	  past	  several	  years,	  engineered	  PUF	  domains	  were	  successfully	  fused	  to	  different	  effector	  domains	   for	   polyadenylation	   of	   an	   endogenous	   gene	   or	   repression	   of	   a	   reporter	  gene	   in	   Xenopus23,	   cleavage	   of	   a	   mitochondrial-­‐encoded	   gene	   in	   human	   cells24,	  splicing	   regulation	   of	   endogenous	  Bcl-­‐X	   pre-­‐mRNA	   in	   human	   cells25,	   and	   imaging	  endogenous	  RNA26-­‐28.	   These	   advancements	  demonstrate	   the	   growing	  potential	   for	  the	  RBPs	  with	  various	  functional	  domains	  and	  engineered	  specificity.	  However,	  PUF-­‐based	  RBPs	  are	  still	   far	   from	  widespread	  implementation.	  One	  of	  the	  limitations	  in	  engineering	  PUF	  domains	  with	  novel	  specificities	  is	  the	  lack	  of	  a	  cloning	  platform	  capable	  of	  rapid	  and	  efficient	  introduction	  of	  multiple	  mutations	  in	  separate	  repeats	  simultaneously.	  In	  this	  study,	  we	  report	  the	  implementation	  of	  the	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Golden	  Gate	   (GG)	   cloning,	   Type	   IIS	   restriction	   endonuclease-­‐based	   approach29	   for	  engineering	  of	  PUF-­‐based	  RBPs.	  To	  demonstrate	  the	  efficiency	  of	  this	  approach,	  we	  first	  used	  this	  cloning	  method	  for	  construction	  of	  several	  mutant	  PUF	  domains	  with	  novel	  specificities	  and	  assayed	  their	  binding	  affinities	  in	  vitro.	  Second,	  we	  tested	  the	  binding	  activity	  of	  multiple	  PUF	  mutants	  in	  yeast	  and	  compared	  the	  effect	  of	  various	  mutations	  at	  different	  positions	  on	  PUF	  functionality	  in	  vivo.	  
4.2	  Results	  and	  Discussion	  
4.2.1	  Assembly	  of	  the	  PUF	  Gene	  from	  Modules	  Using	  the	  Golden	  Gate	  Method	  The	  GG	  cloning	  method,	  which	  is	  implemented	  here	  for	  the	  assembly	  of	  custom	  PUF	  domains,	  is	  based	  on	  the	  ability	  of	  Type	  IIS	  restriction	  enzymes	  to	  cleave	  outside	  of	  their	  non-­‐palindromic	  recognition	  sequence29,	  thus	  creating	  overhangs	  unrelated	  to	  the	   recognition	   sequence.	   This	   polarity	   and	   flexibility	   in	   the	   overhang	   sequence	  allows	  for	  a	  seamless	  removal	  of	  the	  original	  restriction	  site	  as	  well	  as	  a	  ligation	  of	  multiple	  fragments	  in	  one	  step.	  As	  a	  scaffold	  for	  the	  development	  of	  the	  assembly	  toolkit,	  we	  used	  the	  human	  PUM-­‐HD,	   which	   consists	   of	   the	   amino	   acids	   828-­‐1176	   of	   the	   full-­‐length	   PUM121.	  Each	  of	  the	  8	  structural	  repeats	  of	  PUM-­‐HD	  was	  cloned	  individually	  into	  a	  pNEB193-­‐based	   “intermediate	  vector”	  and	  was	  used	  as	  a	   separate	  assembly	  module	   (Figure	  4.1c).	  We	  designed	  all	  8	  modules	  as	  well	  as	  the	  lacZα	  gene	  in	  the	  “receiving	  vector”	  to	  be	  flanked	  by	  two	  BsaI	  sites	  in	  such	  a	  way	  that	  would	  allow	  creation	  of	  9	  unique	  overhangs	   (Figure	   4.1c).	   In	   a	   one-­‐pot	   reaction,	   the	   8	   modules	   and	   the	   receiving	  vector	  can	  be	  efficiently	  cut	  and	  re-­‐ligated	  in	  a	  predefined	  order	  (Figure	  4.1d).	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assembled	   in	   the	   receiving	   vector.	   (e)	   Schematic	   of	   the	   GG	   library.	   R,	   module;	   N,	   nucleotide;	  recognized	  nucleotides	  indicated	  in	  the	  top	  row.	  First	  and	  last	  letters	  in	  the	  module	  names	  represent	  aa	   residues	   12	   and	   16,	   in	   each	   module,	   respectively.	   Middle	   letter,	   if	   present,	   represents	   the	  “stacking”	  aa	  13.	  Black	   font,	  WT	  modules.	  Red	   font,	  mutant	  modules.	  Green,	  yellow,	  pink,	   and	  blue	  fillings	  for	  modules	  recognizing	  A,	  G,	  U,	  and	  C,	  respectively.	  We	   constructed	   two	   receiving	   vectors,	   pET28-­‐GG-­‐PUF	   for	   Escherichia	   coli	  expression	   and	   pCMV-­‐TTP(C147R)-­‐GG-­‐PUF	   for	  mammalian	   expression.	   They	   both	  contain	   a	   lacZα	   gene	   for	   easy	   identification	   of	   assembled	   clones	   using	   blue-­‐white	  screening,	  as	  well	  as	   the	   flanking	  N-­‐	  and	  C-­‐terminal	  regions	  of	  PUM-­‐HD,	  which	  we	  refer	  to	  as	  R1ʹ′	  and	  R8ʹ′,	  respectively.	  	  In	   order	   to	   test	   the	   efficiency	   of	   the	   method,	   we	   re-­‐assembled	   the	   original	  PUM-­‐HD	   from	   the	   WT	   modules	   into	   both	   receiving	   vectors.	   We	   analyzed	   10	  randomly	  chosen	  clones	  from	  each	  assembly	  by	  restriction	  digestion	  and	  found	  that	  all	   produced	   the	   anticipated	   digestion	   pattern	   (Figure	   4.2a	   and	   b).	   Next,	   we	  sequenced	   one	   clone	   from	   each	   assembly	   and	   found	   that	   both	   sequences	   were	  correct,	   indicating	   that	   the	   assembly	   process	   is	   highly	   efficient	   regardless	   of	   a	  receiving	  vector.	  	  Assembly	  of	  the	  consecutive	  mutant	  PUF	  domains	  was	  as	  efficient	  as	  the	  assembly	  of	  the	  WT	  PUF	  domain	  (data	  not	  shown).	  	  The	  entire	  process	  takes	  3	  days,	  with	  the	  GG	  reaction	  and	  E.	  coli	  transformation	  on	  day	  1,	  colony	  picking	  on	  day	  2,	  and	  plasmid	  purification	  and	  digestion-­‐confirmation	  of	   the	  clones	  on	  day	  3.	  The	  procedure	   is	   therefore	   ideal	   for	   the	   rapid	   introduction	   of	  multiple	  mutations	   in	   a	  PUF	  domain	  with	  high	  efficiency.	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Figure	   4.2	   Confirmation	   through	   restriction	   enzyme	   digestion	   and	   gel-­‐electrophoresis	   of	   GG	  assembled	  plasmids	   from	  randomly	  picked	  clones.	  First	  and	   last	   lanes,	  1	  kb	  DNA	  ladder	  (NEB).	  (a)	  
KpnI	  and	  HindIII	  digestion	  of	  PUF(WT)	  clones	  assembled	  into	  pET28-­‐GG-­‐PUF	  receiving	  vector.	  1	  kb	  fragment	   contains	   the	   full	   length	   of	   the	   assembled	   PUF	   domain.	   (b)	   SalI	   and	   KpnI	   digestion	   of	  PUF(WT)	   clones	   assembled	   into	   pCMV-­‐TTP-­‐GG-­‐PUF	   receiving	   vector.	   1	   kb	   fragment	   contains	   the	  assembled	  PUF	  domain	  region.	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Repeat	   Recognition	   AA	  sequence	  1ʹ′	   	   MGRSRLLEDFRNNRYPNLQLREIAG 1	   A	   HIMEFSQDQHGSRFIQLKLERATPAERQLVFNEILQ 1	   G	   HIMEFSQDQHGSRFIELKLERATPAERQLVFNEILQ 1	   U	   HIMEFSQDQHGNRFIQLKLERATPAERQLVFNEILQ 1	   C	   HIMEFSQDQHGSRFIRLKLERATPAERQLVFNEILQ 2	   A	   AAYQLMVDVFGCYVIQKFFEFGSLEQKLALAERIRG 2	   G	   AAYQLMVDVFGSYVIEKFFEFGSLEQKLALAERIRG 2	   U	   AAYQLMVDVFGNYVIQKFFEFGSLEQKLALAERIRG 2	   C	   AAYQLMVDVFGSYVIRKFFEFGSLEQKLALAERIRG 3	   A	   HVLSLALQMYGCRVIQKALEFIPSDQQNEMVRELDG 3	   G	   HVLSLALQMYGSRVIEKALEFIPSDQQNEMVRELDG 3	   U	   HVLSLALQMYGNRVIQKALEFIPSDQQNEMVRELDG 3	   C	   HVLSLALQMYGSRVIRKALEFIPSDQQNEMVRELDG 4	   A	   HVLKCVKDQNGCHVVQKCIECVQPQSLQFIIDAFKG 4	   G	   HVLKCVKDQNGSHVVEKCIECVQPQSLQFIIDAFKG 4	   U	   HVLKCVKDQNGNHVVQKCIECVQPQSLQFIIDAFKG 4	   C	   HVLKCVKDQNGSHVVRKCIECVQPQSLQFIIDAFKG 4	   A	   HVLKCVKDQNGCYVVQKCIECVQPQSLQFIIDAFKG 4	   G	   HVLKCVKDQNGSYVVEKCIECVQPQSLQFIIDAFKG 4	   U	   HVLKCVKDQNGNYVVQKCIECVQPQSLQFIIDAFKG 4	   C	   HVLKCVKDQNGSYVVRKCIECVQPQSLQFIIDAFKG 5	   A	   QVFALSTHPYGCRVIQRILEHCLPDQTLPILEELHQ 5	   G	   QVFALSTHPYGSRVIERILEHCLPDQTLPILEELHQ 5	   U	   QVFALSTHPYGNRVIQRILEHCLPDQTLPILEELHQ 5	   C	   QVFALSTHPYGSRVIRRILEHCLPDQTLPILEELHQ 6	   A	   HTEQLVQDQYGCYVIQHVLEHGRPEDKSKIVAEIRG 6	   G	   HTEQLVQDQYGSYVIEHVLEHGRPEDKSKIVAEIRG 6	   U	   HTEQLVQDQYGNYVIQHVLEHGRPEDKSKIVAEIRG 6	   C	   HTEQLVQDQYGSYVIRHVLEHGRPEDKSKIVAEIRG 7	   A	   NVLVLSQHKFACNVVQKCVTHASRTERAVLIDEVCTMNDGPHS 7	   G	   NVLVLSQHKFASNVVEKCVTHASRTERAVLIDEVCTMNDGPHS 7	   U	   NVLVLSQHKFANNVVQKCVTHASRTERAVLIDEVCTMNDGPHS 7	   C	   NVLVLSQHKFASYVVRKCVTHASRTERAVLIDEVCTMNDGPHS 8	   A	   ALYTMMKDQYACYVVQKMIDVAEPGQRKIVMHKIRP 8	   G	   ALYTMMKDQYASYVVEKMIDVAEPGQRKIVMHKIRP 8	   U	   ALYTMMKDQYANYVVQKMIDVAEPGQRKIVMHKIRP 8	   C	   ALYTMMKDQYASYVVRKMIDVAEPGQRKIVMHKIRP 8ʹ′	   	   HIATLRKYTYGKHILAKLEKYYMKNGVDLG Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	  Table	  4.1	  (Cont.	  on	  next	  page)	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Table	   4.1	  GG	   library	  sequences	  (a)	  Aa	  sequences	  of	  WT	  and	  mutant	  modules.	   	  Black,	  WT	  aa.	   	  Red,	  mutant	   aa.	   (b)	   DNA	   sequences	   of	   WT	   and	   mutant	   modules.	   	   Black,	   WT	   sequence.	   	   Red,	   mutant	  nucleotides.	  	  	  accordance	  with	  a	  previous	  report	  by	  Dong	  et	  al.	  18.	  Since	  module	  3S	  12R16	  requires	  a	  tyrosine	  as	  a	  “stacking”	  residue	  in	  the	  adjacent	  module	  4	  for	  in	  vivo	  activity18,	  there	  	  are	   four	  additional	  module	  4	  variants,	  where	   the	   “stacking”	  residue	  at	  position	  13	  was	   mutated	   from	   histidine	   to	   tyrosine.	   The	   entire	   library	   hence	   consists	   of	   36	  intermediate	   vectors	   and	   2	   receiving	   vectors.	   Thus,	   our	   library	   of	   PUF	   repeat	  modules	   is	   potentially	   capable	   of	   a	   one-­‐step	   assembly	   of	   PUF	   domains	   with	  specificity	   for	   any	   RNA	   sequence	   of	   8	   nt,	   given	   that	   they	   can	   be	   expressed	   in	   a	  soluble	  manner.	  
4.2.3	  Analysis	  of	  PUF	  RNA-­‐Binding	  in	  vitro	  With	  the	  combinatorial	  assembly	  tool	  in	  hand,	  we	  set	  to	  determine	  if	  increasing	  the	  number	   of	   mutations	   affects	   the	   activity	   or	   specificity	   of	   a	   PUF	   domain.	   We	  assembled	  four	  variant	  PUF	  domains	  with	  2,	  4,	  6,	  and	  8	  mutant	  modules	  that	  were	  named	   PUF(S2),	   PUF(S4),	   PUF(S6),	   and	   PUF(S8),	   respectively	   (Table	   4.2).	   To	   test	  their	  in	  vitro	  activity,	  we	  assayed	  the	  binding	  affinity	  of	  the	  proteins	  to	  WT	  and	  their	  cognate	  RNA	  sequences	  using	  a	  fluorescence	  polarization	  assay	  (Figure	  4.3b-­‐f).	  We	  found	  that	  the	  WT	  PUF	  as	  well	  as	  the	  PUF	  variants	  all	  bound	  to	  their	  cognate	  RNA	  sequences	   with	   high	   affinity	   (Table	   4.2).	   As	   predicted,	   all	   of	   the	   PUF	   proteins	  exhibited	   lower	   affinity	   to	   noncognate	   RNA,	   which	   contained	   between	   2	   and	   8	  nucleotide	  mismatches	  with	  the	  cognate	  RNA	  (Table	  4.2,	  Figure	  4.3b-­‐f).	  The	  binding	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Figure	   4.3	   Representative	   fluorescence	   anisotropy	   data	   for	   RNA	   binding	   to	   various	   PUF	   proteins.	  	  
(a)	  Representative	  saturation	  curve	  of	  PUF(S4).	  (b)	  Binding	  curves	  of	  PUF(WT)	  (c)	  Binding	  curves	  of	  PUF(S2)	  (d)	  Binding	  curves	  of	  PUF(S4)	  (e)	  Binding	  curves	  of	  PUF(S6)	  (f)	  Binding	  curves	  of	  PUF(S8).	  	  Black,	  binding	  to	  cognate	  RNA.	  Red,	  binding	  to	  non-­‐cognate	  RNA.	  	  Each	  data	  point	  is	  represented	  by	  the	  mean	  ±	  SD.	  	  KD	  values	  were	  calculated	  from	  nonlinear	  curve	  fitting.	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affinities	  to	  cognate	  sequences	  decreased	  from	  PUF(WT)	  to	  PUF(S8),	  indicating	  that	  there	  is	  a	  weak	  negative	  correlation	  between	  the	  number	  of	  mutations	  and	  binding	  affinity	   to	   cognate	   RNA,	   although	   the	   correlation	   is	   not	   strictly	   linear	   (Table	   4.2).	  However,	  even	  PUF(S8),	  which	  has	  8/8	  mutant	  modules,	  binds	  specifically	  and	  with	  	  	  	  
	  	  
	  
Table	  4.2	  Mutations,	  cognate	  and	  non-­‐cognate	  RNA	  oligonucleotide	  sequences,	  and	  binding	  affinities	  of	   PUF(WT),	   and	   PUFs	   S2-­‐S8.	   Black,	   WT	   modules	   and	   corresponding	   RNA	   bases.	   Red,	   mutant	  modules	  and	  corresponding	  RNA	  bases.	  Bold,	  mismatching	  RNA	  nucleotides.	  Ct,	  C-­‐terminus,	  and	  Nt,	  N-­‐terminus	  of	  the	  protein.	  KD	  values	  were	  determined	  using	  nonlinear	  curve	  fitting	  and	  represent	  the	  mean	  ±	  SD	  (n=3).	  ND,	  KD	  not	  determined	  due	  to	  little	  binding	  at	  300	  nM	  PUF(S8)	  to	  WT	  RNA.	  	  
	  high	   affinity	   to	   its	   cognate	   RNA.	   	   These	   results	   further	   corroborate	   the	   study	   by	  Cheong	  and	  Hall,	  who	  demonstrated	   the	  specificity	  and	  modularity	  of	  PUF	  protein	  target	  recognition16.	  
	  
4.2.4	  Analysis	  of	  PUF	  RNA-­‐Binding	  in	  Saccharomyces	  cerevisiae3	  	  The	   modular	   nature	   of	   RNA	   recognition	   by	   PUF	   proteins	   has	   been	   previously	  reported15-­‐18,	   and	   suggests	   that	   the	   specificity	   of	   the	   protein	   can	   be	   predictably	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  This	  section	  was	  done	  in	  collaboration	  with	  Stella	  Xinzi	  Wu,	  University	  of	  Illinois.	  
Protein" Protein"modules" Cognate"RNA"sequence" KD,"nM" Noncognate"RNA"sequence" KD,"nM"
Ct"" 8  7  6  5  4  3  2  1  Nt"    5' 12345678 3'"  5' 12345678 3'"
PUF(WT)" NQ-SE-NQ-CQ-NQ-CQ-NQ-SQ CCAGAAUUGUAUAUAUUCG 0.043"±"0.023" CCAGAAUAGUAUAUUUUCG 3.56"±"0.90"
PUF(S2)" CQ-SE-NQ-CQ-NQ-CQ-NQ-NQ CCAGAAUAGUAUAUUUUCG 0.76"±"0.11" CCAGAAUUGUAUAUAUUCG 6.29"±"2.80"
PUF(S4)" NQ-SE-CQ-NQ-CYQ-NQ-NQ-SQ CCAGAAUUGAUAUUAUUCG 0.59"±"0.10" CCAGAAUUGUAUAUAUUCG 5.77"±"1.33"
PUF(S6)" CQ-SE-CQ-NQ-CYQ-NQ-NQ-NQ CCAGAAUAGAUAUUUUUCG 6.05"±"0.25" CCAGAAUUGUAUAUAUUCG 89.6"±"16.5"
PUF(S8)" CQ-NQ-CQ-NQ-CYQ-NQ-SE-NQ CCAGAAUAUAUAUGUUUCG 2.79"±"0.69" CCAGAAUUGUAUAUAUUCG ND"
Table"1" Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	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modified.	   However,	   certain	   natural	   or	   engineered	   PUF	   proteins	   behave	  unpredictably.	   Thus,	   bases	   in	   the	   target	   RNA	   sequence	   can	   be	   flipped	   out	   in	   the	  protein:RNA	   complexes	   in	   vitro,	   the	   specificity	   of	   the	   engineered	   repeat	   is	  sometimes	  broadened,	  	  or	  engineered	  repeats	  can	  affect	  the	  protein’s	  recognition	  of	  bases	  adjacent	  to	  the	  target	  base22,	  30-­‐31.	   In	  addition,	  we	  have	  observed	  the	  drop	  in	  soluble	   expression	  of	   certain	  PUF	  mutants	   in	  mammalian	  or	  E.	  coli	   cells	   (data	  not	  shown),	  which	  can	  also	  be	  an	  obstacle	  for	  PUF	  engineering.	  For	  the	  development	  of	  an	   optimal	   PUF	   backbone	   for	   highly	   modular,	   predictable	   RNA	   recognition,	  systematic	  investigation	  of	  PUF	  RNA	  recognition,	  specificity,	  and	  mutant	  stability	  is	  required.	   In	   this	   section,	  we	   sought	   to	   investigate	   how	   the	   position	   of	   introduced	  mutations	   along	   PUM1	   structural	   repeats	   affects	   the	   RNA	   binding	   activity	   of	   the	  protein.	  	  To	  measure	   the	   in	   vivo	   protein-­‐RNA	   interactions	   between	   predicted	   cognate	  RNA	   and	   PUF	   domains,	   we	   implemented	   the	   yeast	   three	   hybrid	   system32.	   This	  approach	   utilizes	   the	   bacterial	   repressor	   LexA	   fusion	   with	   the	   MS2	   coat	   protein,	  which	   is	   recruited	   to	   the	   LexA	   operator	   upstream	   of	   the	   reporter	   gene.	   The	   RNA	  element	   of	   the	   system	   consists	   of	   the	   MS2-­‐binding	   site	   attached	   to	   the	   RNA	  sequence	  of	  interest,	  and	  thus	  is	  recruited	  to	  the	  reporter	  gene	  together	  with	  LexA-­‐MS2	  fusion.	  The	  protein	  of	   interest,	   in	  turn,	   is	  fused	  to	  the	  Gal4	  activation	  domain,	  which,	  upon	  the	  interaction	  with	  the	  RNA	  sequence	  of	  interest,	  is	  likewise	  recruited	  to	   the	  reporter	  gene	  and	  activates	   its	   transcription32-­‐33.	  Here,	  we	  utilized	   the	  LacZ	  gene	  as	  a	  reporter.	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Act2-­‐PUF	   Cognate	  RNA	  sequence	  (5ʹ′-­‐3ʹ′)	   PUF	  modules	  8	   7	   6	   5	   4	   3	   2	   1	  T	   UAUAUAUA	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  S1	   AAUAUAUA	   CQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  S2	   UUUAUAUA	   NQ	   NQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  S3	   UAAAUAUA	   NQ	   CQ	   CQ	   CQ	   NQ	   CQ	   NQ	   CQ	  S4	   UAUUUAUA	   NQ	   CQ	   NQ	   NQ	   NQ	   CQ	   NQ	   CQ	  S5	   UAUAAAUA	   NQ	   CQ	   NQ	   CQ	   CQ	   CQ	   NQ	   CQ	  S6	   UAUAUUUA	   NQ	   CQ	   NQ	   CQ	   NQ	   NQ	   NQ	   CQ	  S7	   UAUAUAAA	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   CQ	   CQ	  S8	   UAUAUAUU	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   NQ	  M1	   AUAUAUAU	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	  M2	   AUAUAUAA	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   CQ	  M3	   AUAUAUUA	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   NQ	   CQ	  M4	   AUAUAAUA	   CQ	   NQ	   CQ	   NQ	   CQ	   CQ	   NQ	   CQ	  M5	   AUAUUAUA	   CQ	   NQ	   CQ	   NQ	   NQ	   CQ	   NQ	   CQ	  M6	   AUAAUAUA	   CQ	   NQ	   CQ	   CQ	   NQ	   CQ	   NQ	   CQ	  M7	   AUUAUAUA	   CQ	   NQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  M8	   AAUAUAUA	   CQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  G1	   GAUAUAUA	   SE	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  WT	   UGUAUAUA	   NQ	   SE	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  G3	   UAGAUAUA	   NQ	   CQ	   SE	   CQ	   NQ	   CQ	   NQ	   CQ	  G4	   UAUGUAUA	   NQ	   CQ	   NQ	   SE	   NQ	   CQ	   NQ	   CQ	  G5	   UAUAGAUA	   NQ	   CQ	   NQ	   CQ	   SE	   CQ	   NQ	   CQ	  G6	   UAUAUGUA	   NQ	   CQ	   NQ	   CQ	   NQ	   SE	   NQ	   CQ	  G7	   UAUAUAGA	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   SE	   CQ	  G8	   UAUAUAUG	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   SE	  C1	   CAUAUAUA	   SR	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  C2	   UCUAUAUA	   NQ	   SR	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	  C3	   UACAUAUA	   NQ	   CQ	   SR	   CQ	   NQ	   CQ	   NQ	   CQ	  C4	   UAUCUAUA	   NQ	   CQ	   NQ	   SR	   NQ	   CQ	   NQ	   CQ	  C5	   UAUACAUA	   NQ	   CQ	   NQ	   CQ	   SR	   CQ	   NQ	   CQ	  C6	   UAUAUCUA	   NQ	   CQ	   NQ	   CQ	   NQ	   SR	   NQ	   CQ	  C7	   UAUAUACA	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   SR	   CQ	  C8	   UAUAUAUC	   NQ	   CQ	   NQ	   CQ	   NQ	   CQ	   NQ	   SR	  
Table	   4.3	   Mutations,	   cognate	   RNA	   oligonucleotide	   sequences,	   and	   in	   vivo	   activities	   of	   Act2-­‐PUF	  fusion	   proteins.	   Black,	   WT	   modules	   and	   corresponding	   RNA	   bases.	   Red,	   mutant	   modules	   and	  corresponding	  RNA	  bases.	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Figure	  4.4	  Relative	  luciferase	  activity	  of	  Act-­‐PUF	  proteins	  (S1-­‐S8),	  measured	  by	  yeast	  three	  hybrid	  assay.	   Predicted	   cognate	   RNA	   sequences	   are	   indicated	   (bottom-­‐top,	   5’-­‐3’).	   Data	   represented	   as	  average	  ±	  SD.	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not	  yield	  S.	  cerevisiae	  transformants	  (S5-­‐S7,	  M6-­‐M8,	  and	  G1),	  possibly	  due	  to	  chance	  mutations	  in	  plasmid	  backbones.	  Due	  to	  time	  constraints,	  these	  plasmids	  were	  not	  investigated	   further.	   The	   remaining	  Act2-­‐PUF	   fusions	  were	   investigated	   using	   the	  Beta-­‐Glo	  luciferase	  assay	  (Figure	  4.4a-­‐d).	  	  
	  
Figure	  4.5	  Relative	  luciferase	  activity	  of	  Act-­‐PUF	  proteins	  (M1-­‐M8),	  measured	  by	  yeast	  three	  hybrid	  assay.	   Predicted	   cognate	   RNA	   sequences	   are	   indicated	   (bottom-­‐top,	   5’-­‐3’).	   Data	   represented	   as	  average	  ±	  SD.	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exception	  was	  the	  mutagenesis	  of	  repeat	  8	  in	  the	  Act2-­‐PUF	  mutant	  S1	  (Figure	  4.4),	  which	  demonstrated	  a	  significant	  decrease	  in	  activity	  compared	  to	  other	  positions.	  The	   triplet	  UGU,	  which	   is	   recognized	  by	  repeats	  6-­‐8	  of	  PUF	  domains,	   is	   conserved	  among	  recognition	  sequences	  of	  many	  PUFs15.	  	  Our	  results	  suggest	  that	  PUF	  repeats	  7	  and	  8,	  and	  to	  a	  smaller	  extent,	  repeat	  6,	  may	  also	  be	  the	  most	  sensitive	  towards	  mutagenesis,	   probably	   due	   to	   a	   greater	   energetic	   contribution	   of	   these	   repeats	   to	  the	  overall	  PUF	  RNA-­‐binding	  activity.	  	  
	  
Figure	  4.6	  Relative	  luciferase	  activity	  of	  Act-­‐PUF	  proteins	  (G3-­‐G8),	  measured	  by	  yeast	  three	  hybrid	  assay.	   Predicted	   cognate	   RNA	   sequences	   are	   indicated	   (bottom-­‐top,	   5’-­‐3’).	   Data	   represented	   as	  average	  ±	  SD.	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protein,	  as	  was	  shown	  in	  Table	  4.2	  above.	  We	  suggest	  that	  this	  could	  be	  due	  to	  the	  role	   of	   the	   residues	   at	   positions	   12	   and	   16	   in	   each	   repeat	   not	   only	   in	   binding	   to	  specific	  RNA	  base,	  but	  in	  the	  structural	  stability	  of	  the	  protein	  as	  well.	  	  
	  
Figure	  4.7	  Relative	  luciferase	  activity	  of	  Act-­‐PUF	  proteins	  (C1-­‐C8),	  measured	  by	  yeast	  three	  hybrid	  assay.	   Predicted	   cognate	   RNA	   sequences	   are	   indicated	   (bottom-­‐top,	   5’-­‐3’).	   Data	   represented	   as	  average	  ±	  SD.	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of	   PUF	   proteins	   to	   contain	   S12R16	   modules	   destabilize	   the	   protein	   or	   reduce	   the	  affinity	  to	  RNA	  more	  compared	  to	  mutagenesis	  to	  other	  residues.	  
4.3	  Conclusions	  In	   this	  study,	  we	  established	  a	   toolkit	   for	  rapid	  engineering	  of	  designer	  RBPs	  that	  can	  be	  used	  for	  manipulation	  of	  endogenous	  genes.	  This	  approach	  should	  allow	  greater	  flexibility	  and	  speed	  at	  creating	  PUF	  domains	  with	  user-­‐defined	  specificities	  and	   thus	   facilitate	   the	   use	   of	   PUF-­‐based	   designer	   RBPs	   as	   a	   tool	   in	   research	   and	  therapeutics.	   We	   demonstrated	   that	   PUF	   mutants	   with	   as	   many	   as	   8/8	   mutant	  modules	   can	   be	   cloned	  with	   high	   efficiency	   and	   that	   the	   resulting	   proteins	   retain	  their	   specificity	   and	   high	   affinity	   to	   their	   cognate	   RNA	   in	   vitro.	   This	   result	   is	  consistent	  with	   the	  study	  by	  Cheong	  and	  Hall16	  and	  confirms	   the	  RNA	  recognition	  code	  and	  modularity	  of	  PUF	  domains.	  We	  envision	  the	  future	  development	  of	  PUF-­‐based	   RBPs	   with	   various	   functionalities	   that	   could	   range	   from	   endogenous	   RNA	  splicing,	   imaging,	   and	   localization	   to	  various	  base	  modifications.	  The	  development	  of	   rapid	  assembly	   tools	   for	  PUF	  specificity	  engineering,	   as	  presented	   in	   this	  work,	  could	  play	  a	  critical	  role	  in	  facilitating	  and	  enhancing	  these	  endeavors.	  	  
4.4	  Materials	  and	  Methods	  All	   the	  chemicals	  and	  solutions	  were	  purchased	   from	  Fisher	  Scientific	   (Pittsburgh,	  PA),	  unless	  noted	  otherwise.	  Oligonucleotides	  were	  purchased	  from	  Integrated	  DNA	  Technologies.	   All	   the	   enzymes	  were	   purchased	   from	  New	  England	   Biolabs	   (NEB),	  unless	  noted	  otherwise.	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4.4.1	  Cloning	  of	  the	  PUF	  Module	  Library	  The	  intermediate	  vector,	  pChlr-­‐pNEB193,	  was	  created	  by	  replacing	  the	  original	  amp	  resistance	   gene	   in	   pNEB193	   (NEB)	   plasmid	   with	   the	   cam	   resistance	   gene	   from	  pACYC	   (New	  England	  Biolabs)	  plasmid	  by	  Gibson	  Assembly	   (GA).	  Plasmid	  pTYB3-­‐PUM1-­‐HD	   [GenBank:D43951]	   was	   a	   gift	   of	   Dr.	   Traci	   M.	   Tanaka	   Hall	   (Addgene	  plasmid	  17543).	  The	  WT	  GG	  assembly	  modules	  were	  amplified	  from	  pTYB3-­‐PUM1-­‐HD	   and	   inserted	   in	   the	   SacI	   and	   HindIII	   sites	   of	   the	   intermediate	   vector.	   The	  amplification	  primers	  also	  contained	  BsaI	  sites	  for	  subsequent	  GG	  cloning.	  Some	  of	  the	  modules’	  5ʹ′	  and	  3ʹ′	  ends	  were	  modified	  with	  silent	  mutations	  for	  the	  creation	  of	  non-­‐overlapping	  BsaI	  overhangs.	  The	  mutant	  GG	  modules	  were	  created	  by	  GA	  from	  the	  corresponding	  WT	  modules.	  The	   receiving	   vector	   pET28-­‐GG-­‐PUF	   was	   GA-­‐cloned	   from	   the	   following	  fragments:	   pET28a	   (Novagen)	   digested	   with	   NdeI	   and	   SalI,	   flanking	   PUM-­‐HD	  repeats	   R1ʹ′	   and	   R8ʹ′	   amplified	   from	   pTYB3-­‐PUM1-­‐HD,	   and	   lacZα	   amplified	   from	  pNEB193.	  BsaI	  sites	  were	  introduced	  next	  to	  R1ʹ′	  and	  R8ʹ′	  for	  GG	  cloning	  of	  PUM-­‐HD.	  The	   receiving	   vector	   pCMV-­‐TTP(C147R)-­‐GG-­‐PUF	   was	   cloned	   in	   two	   steps.	   First,	  pCMV-­‐TTP-­‐GG-­‐PUF	  was	  created	  by	  replacing	  PUM-­‐HD	  with	  a	  lacZα	  gene	  flanked	  by	  BsaI	  sites	  and	  removal	  of	  3	  existing	  BsaI	  sites	  in	  the	  pCMV-­‐TTP(WT)-­‐PUM-­‐HD	  (see	  the	  effector	  plasmids	  section).	  Next,	  pCMV-­‐TTP(C147R)-­‐GG-­‐PUF	  was	  GA-­‐cloned	  by	  replacing	   Flag	  with	   3xFlag	   and	  mutating	   the	   C147R	  of	   TTP	   in	   the	   plasmid	   pCMV-­‐TTP-­‐GG-­‐PUF.	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All	  the	  plasmids	  that	  comprise	  the	  PUF	  Module	  library	  have	  been	  deposited	  to	  Addgene	   plasmid	   repository,	   and	   the	   DNA	   sequences	   of	   all	   the	   modules	   and	  receiving	  vectors	  can	  be	  found	  there.	  
4.4.2	  Golden	  Gate	  Assembly	  of	  Mutant	  PUFs	  His-­‐tagged	  PUF	  constructs	  for	  E.	  coli	  expression	  were	  assembled	  in	  pET28-­‐GG-­‐PUF.	  Receiving	  vector	  (50	  ng)	  and	  8	  modules	  of	  choice	  (75	  ng	  each)	  were	  combined	  with	  1	  μl	  T4	  DNA	  ligase	  and	  1	  μl	  BsaI	  in	  10	  μl	  1x	  T4	  DNA	  ligase	  buffer.	  The	  reactions	  were	  cycled	  10	  times	  for	  5	  min	  at	  37°C	  and	  10	  min	  at	  16°C,	  and	  a	  final	   incubation	  of	  15	  min	  at	  37°C.	  TOP10	  E.	  coli	  cells	  (Invitrogen)	  were	  then	  transformed	  with	  the	  cloning	  reactions	  and	  plated	  on	  LB	  plates	  (Cell	  Media	  Facility,	  UIUC)	  with	  kan	  selection,	  and	  supplemented	   with	   10	   μl	   0.4	   M	   IPTG	   (GoldBio)	   and	   40	   μl	   20	   mg/ml	   Bluo-­‐Gal	  (Invitrogen)	   for	   blue-­‐white	   screening.	  All	   the	  plasmids	   for	  E.	  coli	   expression	  were	  purified	  using	  Qiagen	  Qiaprep	  Spin	  Miniprep	  kit.	  
Receiving vector pACT2-GG-PUF was modified from the plasmid pACT2 (kind 
gift of Dr. Marvin P. Wickens, University of Wisconsin-Madison) to include two BsaI 
sites flanked by 1’ and 8’ regions of the PUF sequence. The Act2-PUF fusion constructs 
were cloned by the Golden Gate cloning method as previously using pACT2-GG-PUF as 
a receiving vector and 8 PUF modules of interest from the library. 	  
4.4.3	  Cloning	  of	  transcription	  vectors	  for	  Yeast	  3	  hybrid	  Assay	  For	  the	  preparation	  of	  transcription	  vectors	  for	  Act2-­‐PUF	  fusion	  proteins	  in	  groups	  S	   and	   M,	   the	   DNA	   fragments	   encoding	   target	   RNA	   sequences	   were	   designed	   to	  contain	  XmaI-­‐compatible	  overhangs	  at	  both	  ends.	  The	  fragments	  were	  synthesized	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at	  IDT	  DNA,	  the	  two	  strands	  annealed	  in	  TE	  buffer	  with	  50	  mM	  NaCl	  by	  heating	  up	  the	  mixture	  to	  90C	  for	  5	  min	  and	  slowly	  cooling	  down	  to	  4C.	  The	  ds	  oligos	  were	  then	  phosphorylated	   using	   T4	   polynucleotide	   kinase	   (NEB)	   as	   per	   manufacturer’s	  instructions.	  The	  plasmid	  p3HR2	  (kind	  gift	  of	  Dr.	  Marvin	  P.	  Wickens,	  University	  of	  Wisconsin-­‐Madison)	   was	   digested	   with	   XmaI	   and	   ligated	   with	   the	   DNA	   inserts	  containing	   the	   sequences	   encoding	   RNA	   sequences.	   For	   the	   preparation	   of	  transcription	  vectors	  for	  Act2-­‐PUF	  fusion	  proteins	  in	  groups	  S	  and	  M,	  the	  receiving	  vector	   p3HR2-­‐insert	   was	   constructed	   to	   contain	   an	   additional	   restriction	   site,	  
HindIII,	   for	   one-­‐directional	   insertion	   of	   fragments.	   To	   this	   end,	   the	   insert	   was	  designed	  to	  contain	  XmaI,	  HindIII	  and	  AgeI	  sites.	  The	  p3HR2	  plasmid	  was	  digested	  with	  XmaI,	  while	   the	   insert	  was	  digested	  with	  XmaI	  and	  AgeI.	  The	  AgeI	   restriction	  site	   was	   destroyed	   by	   ligation.	   Next,	   the	   PUF-­‐binding	   sites	   were	   cloned	   into	   the	  p3HR2-­‐insert	  plasmid	  using	  XmaI	  and	  HindIII	  restriction	  sites.	  	  
4.4.4	  Protein	  Expression	  and	  Purification	  His-­‐tagged	   recombinant	   PUF	   proteins	  were	   expressed	   in	  E.	   coli	   strain	   BL21(DE3)	  (Novagen).	   The	   transformed	   BL21	   cultures	   were	   grown	   in	   100	   ml	   LB	   until	   they	  reached	  an	  OD600	  of	  0.8,	  induced	  with	  0.4	  mM	  IPTG	  and	  expressed	  at	  18°C,	  250	  RPM	  overnight.	  Bacterial	  pellets	  were	  resuspended	  in	  lysis	  buffer	  (25mM	  Tris-­‐HCl	  pH	  7.5,	  0.3	  M	  NaCl,	  0.5%	  Triton	  (Bio-­‐Rad),	  5%	  glycerol	  (Sigma),	  1	  mg/ml	  lysozyme	  (Sigma),	  and	  0.002	  U/μl	  DNase	  I)	  and	  lysed	  by	  sonication.	  The	  proteins	  were	  purified	  using	  Talon	   Spin	   Columns	   (Clontech),	   according	   to	   manufacturer’s	   instructions.	   The	  eluted	  protein	  was	  flash-­‐frozen	  in	  25%	  glycerol	  in	  dry	  ice	  and	  stored	  in	  aliquots	  at	  -­‐80°C.	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4.4.5	  Bradford	  Assay	  The	  protein	  concentrations	  were	  measured	  by	  mixing	  20	  μl	  of	  appropriately	  diluted	  protein	   solution	   with	   980	   μl	   of	   Coomassie	   Plus	   Protein	   Assay	   Reagent	   (Thermo	  Scientific)	   in	  1	  ml	   cuvette.	  Quick	  Start	  Bovine	  Serum	  Albumine	  Standard	  Set	   (Bio-­‐Rad)	  was	   used	   to	   build	   a	   protein	   standard	   curve.	   A595	  was	  measured	   5	  min	   later	  using	  Nanodrop.	  	  
4.4.6	  Fluorescence	  Polarization	  RNA	   oligomers	   were	   modified	   with	   6-­‐carboxyfluorescein	   (IDT)	   at	   the	   5ʹ′-­‐end.	   To	  determine	  active	  protein	  fractions,	  we	  performed	  saturation	  assays	  for	  PUF	  proteins	  against	  their	  cognate	  RNA	  (a	  representative	  saturation	  curve	  is	  shown	  in	  Fig.	  S2a).	  High	  concentrations	   (100	  nM)	  of	  RNA	  oligomers	   in	   fluorescence	  anisotropy	  buffer	  (20	  mM	  Tris-­‐HCl	   pH	  7.5,	   0.5	  mM	  EDTA,	   50	  mM	  KCl,	   0.1	  mg/ml	  BSA)	  were	  mixed	  with	   various	   protein	   concentrations	   (determined	   by	   Bradford	   assay),	   and	   200	   μl	  protein-­‐RNA	  mixtures	  were	   assayed	   (for	   fluorescence	  polarization	  measurements,	  see	  below)	  in	  black	  96-­‐well	  plates	  (Corning).	  The	  stoichiometric	  points	  were	  used	  to	  estimate	   the	   active	   protein	   fractions,	   which	   were	   determined	   to	   be	   31%	   for	  PUF(WT),	   30%	   for	   PUF(S2),	   30%	   for	   PUF(S4),	   33%	   for	   PUF(S6),	   and	   29%	   for	  PUF(S6).	   Corrected	   active	   protein	   concentrations	   were	   used	   in	   the	   subsequent	  binding	   curves	   for	   the	  determination	  of	   the	  dissociation	   constants	  KD,	  where	  RNA	  oligomers	   (250	  pM	  RNA	   for	  PUF(WT)	  and	  1	  nM	  RNA	   for	  PUF(S2)-­‐PUF(S8))	   in	   the	  fluorescence	  anisotropy	  buffer	  were	  mixed	  with	  various	  protein	  concentrations,	  and	  duplicates	  of	  200	  μl	  protein-­‐RNA	  mixtures	  were	  assayed.	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Fluorescence	  polarization	  measurements	  were	  taken	  on	  Tecan	  Infinite	  200Pro	  using	  excitation	  and	  emission	  wavelengths	  of	  485	  nm	  and	  535	  nm,	  respectively.	  The	  fluorescence	  polarization	  values	  were	  converted	  to	   fluorescence	  anisotropy	  values	  using	  Equation	  1,	  where	  A	  is	  anisotropy	  and	  P	  is	  polarization.	  The	  KD	  was	  calculated	  by	   curve	   fitting	   on	   Origin	   8.5	   using	   Equation	   2,	   where	   A	   is	   observed	   anisotropy	  value,	  Af	  is	  anisotropy	  of	  free	  RNA,	  Ab	  is	  anisotropy	  of	  bound	  RNA,	  LT	  is	  total	  ligand	  (RNA)	  concentration,	  and	  RT	  is	  total	  receptor	  (protein)	  concentration.	  
	  	  	  	  	  	  	  	  	  (1)	   	  
	  	  	  	  	  	  (2)	  
	  
4.4.7	  Yeast	  Heat	  Shock	  Transformation	  The	   YBZ-­‐1	   Saccharomyces	   cerevisiae	   strain	   (kind	   gift	   of	   Dr.	   Marvin	   P.	   Wickens,	  University	  of	  Wisconsin-­‐Madison)	  was	  transformed	  with	  plasmids	  pACT2-­‐PUF	  and	  p3HR2-­‐target	  plasmids	   containing	   cognate	  PUF-­‐binding	   sites	  using	   the	  heat	   shock	  protocol.	  To	  this	  end,	  50	  ml	  YPAD	  medium	  was	  inoculated	  with	  a	  0.5	  ml	  overnight	  yeast	  culture	  and	  shaken	  at	  30	  °C	  and	  250	  rpm	  for	  4–5	  h	  until	  OD600	  reached	  0.8–1.0.	  Yeast	   cells	  were	   harvested	   by	   centrifugation	   at	   4°C	   and	  4000	   rpm	   for	   5	  min.	   The	  supernatant	  was	  discarded	  and	  the	  cell	  pellet	  was	  washed	  with	  25	  ml	  ice-­‐cold	  Milli-­‐Q	   double-­‐deionized	   water,	   followed	   by	   another	   wash	   with	   cold	   1	   ml	   water,	   and	  finally	  resuspended	  in	  500	  μl	  water,	  aliquoted	  to	  50	  μl	  samples,	  after	  which	  the	  cells	  were	  centrifuged	  again	  and	  the	  supernatant	  removed.	  The	  transformation	  mixture	  was	  prepared	  by	  adding	  240	  μl	  PEG	  (50%	  w/v),	  50	  μl	  single	  stranded	  salmon	  sperm	  
A = 2P3−P
A = Af + (Ab − Af )*
(LT +KD + RT )− (LT +KD + RT )2 − 4LTRT
2LT
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DNA	   (prepared	   by	   boiling	   and	   immediately	   chilling	   on	   ice),	   1	   μg	   of	   each	   plasmid	  DNA	  in	  a	  total	  of	  34	  μl	  aqueous	  solution,	  and	  36	  μl	  1.0	  M	  LiAc	  in	  the	  order	  listed	  on	  top	  of	  the	  cell	  pellets.	  The	  mixtures	  were	  vortexed	  and	  heat-­‐shocked	  at	  42	  °C	  for	  20	  minutes.	  The	  cells	  were	  centrifuged	  at	  8,000	  rpm	  for	  15	  seconds,	  the	  transformation	  mix	  was	   removed	  and	  replaced	  with	  100	  μl	  double-­‐distilled	  water.	  The	  cells	  were	  spread	  on	  SC-­‐Ura	  plates	  for	  the	  selection	  of	  the	  transformants,	  and	  the	  plates	  were	  incubated	  at	  30	  °C	  for	  2–4	  days	  until	  colonies	  appeared.	  	  
4.4.8	  Yeast	  3-­‐Hybrid	  Assay	  (with	  Stella	  Xinzi	  Wu	  at	  Zhao	  Lab)	  Three	   colonies	  were	   randomly	  picked	   into	  2	  ml	  SC-­‐Ura	   liquid	  medium	  and	  grown	  for	   1	   day	   at	   30	   °C	   and	   250	   rpm,	   after	   which	   the	   β-­‐galactosidase	   activity	   was	  measured	   using	   the	   Beta-­‐Glo	   Assay	   System	   (Promega)	   as	   per	   manufacturer’s	  instructions.	  Briefly,	  cells	  were	  diluted	  1/40	  in	  the	  medium	  and	  grown	  for	  4	  hours	  at	  30C	  until	  they	  reached	  an	  A600	  of	  0.1.	  The	  cell	  samples	  (50	  ul)	  were	  mixed	  with	  an	  equal	  volume	  of	  Beta-­‐Glo	  Reagent	  in	  white	  96-­‐well	  plates	  (Greiner	  Bio	  One),	  and	  the	  mixtures	   were	   incubated	   at	   room	   temperature	   in	   the	   dark	   for	   60	   minutes.	   The	  samples	  were	   then	  read	   in	  a	   luminometer	  (Tecan	   Infinite	  200Pro)	   for	  one	  second.	  The	  luminescent	  signal	  values	  were	  normalized	  with	  optical	  density	  (OD600)	  values	  (Nanodrop	  2000).	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Chapter	  5.	  Engineering	  of	  TPUF,	  or	  PUF-­‐Repressor	  
5.1	  Introduction	  The	  ability	   to	  specifically	  and	  potently	  knock	  down	  the	  expression	  of	  specific	  genes	   could	   be	   a	   powerful	   tool	   both	   in	   basic	   research	   and	   therapeutics.	   RNA	  interference	   (RNAi)	   technology	   has	   been	   a	   remarkable	   advancement	   of	   the	   past	  decade	   that	   has	   enabled	   such	   selective	   gene	   silencing.	   The	   technology	   has	   been	  successfully	   used	   to	   silence	   numerous	   disease-­‐causing	   genes	   for	   the	   treatment	   of	  viral	   diseases,	   neurodegenerative	   disorders,	   and	   cancers2-­‐3.	   However,	   for	   the	   safe	  and	   effective	   application	   in	   the	   clinic,	   the	   technology	   still	   has	   a	   few	   hurdles	   to	  overcome,	  which	  include	  off-­‐target	  effects,	  toxicity	  due	  to	  saturation	  of	  endogenous	  RNAi	   pathways,	   rapid	   degradation	   by	   nucleases,	   and	   induction	   of	   interferon	   1	  responses.	   Although	   novel	   strategies	   are	   being	   developed	   to	   overcome	   these	  limitations2-­‐3,	   developing	   alternative	   tools	   that	   could	   be	   used	   in	   lieu	   of	   or	   in	  combination	  with	  the	  RNAi	  technology	  would	  allow	  greater	  flexibility	  in	  the	  field.	  	  RNA-­‐binding	   proteins	  with	   programmable	   specificity	   for	   post-­‐transcriptional	  regulation	   of	   gene	   expression	   could	   become	   a	   powerful	   alternative	   or	  complementation	  to	  the	  RNAi	  technology.	  Targeted	  translation	  regulation	  using	  the	  PUF	  domain	  as	  a	  scaffold	  was	  originally	  reported	  by	  Cooke	  et	  al.,	  who	  showed	  that	  
Xenopus	   translational	   repressor	   CAF1	   linked	   to	   a	   PUF	   domain	   could	   sequence-­‐specifically	   promote	   mRNA	   deadenylation	   and	   corresponding	   reporter	   gene	  repression	  in	  Xenopus	  oocytes4;	  however,	  repression	  of	  an	  endogenous	  gene	  was	  not	  reported.	   During	   the	   engineering	   work	   of	   our	   PUF-­‐repressor,	   Choudhury	   et	   al.	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reported	   a	   synthetic	   endoribonuclease	   by	   fusing	   the	   PUF	   domain	   to	   non-­‐specific	  endonuclease	   PIN5,	   and	   showed	   that	   they	   were	   able	   to	   sequence-­‐specifically	   cut	  target	   mRNA	   and	   silence	   the	   corresponding	   endogenous	   gene	   in	   E.	   coli	   and	   a	  mitochondrially-­‐encoded	   gene	   in	   human	   cells.	   While	   comparable	   in	   its	   ability	   to	  sequence-­‐specifically	   knock	   down	   a	   gene,	   the	   PUF-­‐based	   repressor	   engineered	   in	  our	   lab	   functions	  via	  a	  different	  mechanism	  (see	   later).	  Thus,	  ours	  and	  previously	  reported	   engineering	   examples	   cross-­‐corroborate	   the	   feasibility	   and	   efficacy	   of	  using	   PUF	   as	   a	   scaffold	   for	   modular	   construction	   of	   post-­‐transcriptional	   gene	  regulation	  devices.	  	  As	   a	   proof-­‐of-­‐concept	   engineering	   of	   PUF-­‐based	   chimeric	   proteins,	   we	   fused	  the	   RNA-­‐binding	   PUM-­‐HD	   of	   PUM1	   to	   known	   post-­‐transcriptional	   repressor	  domains.	  For	  the	  candidates	  of	  repression	  domains	  to	  be	  fused	  to	  the	  PUF	  domain,	  we	   considered	   human	   tristetraprolin	   (TTP)	   and	   human	   up-­‐frameshift	   protein	   1	  (UPF1).	  TTP	  is	  known	  to	  bind	  to	  the	  AU-­‐rich	  elements	  (AREs)	  in	  the	  3ʹ′-­‐untranslated	  region	   (UTR)	   of	   the	   target	   genes	   and	   promote	   mRNA	   degradation	   by	   recruiting	  enzymes	   involved	   in	   deadenylation6-­‐8	   and	   decapping8-­‐9.	   TTP	   is	   also	   known	   to	  promote	  ARE-­‐dependent	  translation	  repression	  through	  cooperation	  with	  a	  general	  translation	   inhibitor	   RCK/P5410,	   although	   the	   details	   of	   this	   mechanism	   remain	  unknown.	  It	  was	  reported	  that	  the	  C-­‐terminal	  domain	  (CTD)	  of	  TTP	  (residues	  176-­‐326	  of	  full-­‐length	  TTP),	  which	  lacks	  the	  RNA-­‐binding	  CCCH-­‐type	  zinc-­‐finger	  domain	  of	  the	  full-­‐length	  TTP,	  alone	  could	  activate	  mRNA	  decay8.	  UPF1,	  on	  the	  other	  hand,	  targets	   mRNA	   for	   nonsense-­‐mediated	   decay	   when	   bound	   downstream	   of	   a	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termination	  codon11.	  In	  addition,	  it	  is	  involved	  in	  staufen1-­‐mediated	  mRNA	  decay12-­‐
13	  and	  replication-­‐dependent	  histone	  mRNA	  decay14.	  	  In	   this	   chapter,	  we	  developed	  a	  PUF-­‐based	   repressor	   for	  post-­‐transcriptional	  regulation	   of	   gene	   expression.	   To	   this	   end,	   we	   fused	   the	   PUM-­‐HD	   domain	   to	   a	  translational	  repressor,	  optimized	  the	  construct	  as	  well	  as	  the	  reporter	  gene	  assay	  to	  measure	  the	  effectiveness	  of	  the	  chimeric	  protein,	  and	  tested	  the	  effectiveness	  of	  the	  engineered	  protein	  for	  the	  repression	  of	  an	  endogenously	  expressed	  gene.	  	  
5.2	  Results	  
5.2.1	  Choice	  of	  a	  Repression	  Domain	  As	  an	  example	  of	  engineering	  a	  PUF-­‐based	  post-­‐transcriptional	  repressor,	  we	  fused	  human	  TTP	  and	  UPF1	  to	  the	  N-­‐terminus	  of	  the	  WT	  RNA-­‐binding	  PUM-­‐HD	  through	  a	  flexible	   (G4S)3G4	   linker.	   We	   reasoned	   that	   utilization	   of	   the	   minimal	   repression	  domain	  of	  TTP	  could	  be	  advantageous	  due	  to	  the	  smaller	  size	  of	  the	  construct	  and	  minimization	   of	   the	   interference	   of	   the	   RNA-­‐binding	   region	   of	   TTP.	  We	   therefore	  also	   tested	   a	   fusion	   construct	   containing	   the	   CTD	   truncation	   of	   TTP.	   These	   DNA	  constructs	  were	  co-­‐transfected	  with	  firefly	  luciferase	  (FL)	  containing	  either	  5	  PUF-­‐binding	  sites	  (PBSs)	   in	   the	  3ʹ′	  UTR	  or	  no	  PBSs,	  as	  well	  as	  Renilla	   luciferase	  (RL)	  as	  transfection	   control.	   Repression	   activities	   of	   fusion	   proteins	  were	   estimated	   from	  the	   dual	   luciferase	   assay,	   where	   FLPBS5x/RL	   activity	   was	   normalized	   to	   FL/RL.	   As	  shown	  in	  Figure	  5.1,	  only	  the	  TTP-­‐PUF	  fusion	  construct	  exhibited	  some	  repression	  activity	  and	  was	  chosen	  for	  further	  optimization.	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5.2.2	  Optimization	  of	  the	  Luciferase	  Assay	  To	  optimize	  the	  dual	   luciferase	  assay	  conditions,	  1-­‐10	  (PBSs)	  separated	  by	  6-­‐18	   nt	  were	   cloned	   (Figure	   5.2a)	   to	   the	   3ʹ′	   UTR	   of	   FL.	   As	   described	   previously,	   RL	  lacking	  any	  PBSs	  was	  co-­‐transfected	  with	  FL	  as	  a	   transfection	  control.	   In	  addition,	  FLRandom,	  was	  constructed,	  where	  10	  PBSs	  were	  replaced	  with	  a	  random	  sequence	  of	  identical	  length,	  since	  it	  was	  found	  that	  the	  length	  of	  the	  3ʹ′	  UTR	  also	  affects	  apparent	  FL	   activity	   (data	   not	   shown).	   Values	   of	   FLPBS/RL	   normalized	   to	   FLRandom/RL	  were	  reported	   as	   “relative	   FL/RL	   activity.”	   For	   reproducibility,	   we	   chose	   to	   assess	   the	  reporter	  activity	  in	  the	  linear	  correlation	  range	  between	  transfected	  FL	  DNA	  amount	  and	  measured	  FL	  activity.	  We	  determined	  that	  the	  correlation	  is	  linear	  in	  the	  range	  of	   50-­‐400	  ng	   FL	  DNA	   in	   a	   24-­‐well	   plate	   format	   (Figure	   5.2b).	  However,	  when	   co-­‐transfected	  with	  75	  ng	  of	  TTP-­‐PUM-­‐HD	  DNA	  construct,	  the	  upper	  limit	  of	  the	  linear	  correlation	  range	  was	  reduced	  to	  200	  ng	  FL	  DNA	  (Figure	  5.2c).	  Thus,	  we	  used	  150	  ng	  of	  FL	  and	  75	  ng	  of	  TTP-­‐PUF	  fusion	  in	  our	  subsequent	  assays.	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b 	   c	  
Figure	   5.2	   Double	   luciferase	   assay	   optimization.	   (a)	   Schematic	   of	   luciferase	   reporters.	   Orange	  boxes,	   PUF	   binding	   sites.	   (b	   and	   c)	   Linearity	   ranges	   between	   FL	   DNA	   and	   FL/RL	   activity.	   (b)	  Linearity	  range	  when	  HeLa	  cells	  were	  transfected	  with	  indicated	  amounts	  of	  FL	  DNA,	  2	  ng	  RL	  DNA,	  and	  pCMV5	  to	  500	  ng.	  R2=	  0.995	  (c)	  Linearity	  range	  when	  transfected	  with	  indicated	  amounts	  of	  FL	  DNA,	  2ng	  RL	  DNA,	  75	  ng	  TTP(WT)-­‐PUM-­‐HD,	  and	  pCMV5	  to	  500	  ng.	  R2=	  0.997	  Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	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using	   5-­‐6	   binding	   sites	   in	   tethering	   assays	   of	   TTP	   and	   other	  ARE-­‐mediated	   decay	  activation	  domains8,	  10.	  	  
	  




















Figure	   5.3	   Dual	   luciferase	   assay	   showing	   TTP-­‐PUFWT	   repression	   of	   FLPBS(WT)	  with	   increasing	  number	   of	  PBSs	   in	   the	  3ʹ′UTR	  of	   the	   reporter	  gene.	   Data	   are	   represented	   as	  mean	   fold	   change	  relative	  to	  cells	  transfected	  with	  FL	  with	  no	  PBS	  ±	  SD	   Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	  
	   121	  









1                                853                   1146   1188  
  1                                                326     828                   1176  
CCCH PUM-HD CRCH 
GSL TTP(C147R)-
PUM-HD 













Renilla Luciferase 3' UTR 
transfection control 
pA 













































































































1                               853                   1 46   1188  
1                                              326     828                   1176  
CCCH PUM-HD CRCH 
GSL TTP(C147R)-
PUM-HD 













Renilla Luciferase 3' UTR 
transfection control 
pA 







































































a	   c	  
b	  
Figure	   5.4	  Analysis	   and	  optimization	  of	  TPUF.	  (a)	  Dual	   luciferase	  assay	   shows	  that	  TTP-­‐PUM-­‐HDWT	   down-­‐regulates	   FLPBS(WT)	   expression	   the	   most	   compared	   with	   TTP	   or	   PUM-­‐HDWT	   alone.	  Relative	  FLRandom/RL	  activity	   is	   indicated	  with	  a	  dashed	   line.	  (b)	  Schematic	  of	  full-­‐length	  PUM1,	  TTP(WT),	   and	   TPUF	   constructs.	   CCCH,	   zinc	   finger	   domain;	   GSL,	   glycine-­‐serine	   linker.	   (c)	  TPUF(WT)	  binding	  to	  ARE	  is	  reduced.	   Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	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which	   one	   of	   the	   two	   zinc	   fingers	   was	   disrupted,	   and	   compared	   its	   activity	   with	  TTP(WT)-­‐PUM-­‐HDWT	  at	  repressing	  FLPBS(WT)	  and	  FLARE	  (10x	  ARE	  in	  the	  3ʹ′	  UTR).	  As	  expected,	   PUM-­‐HD	   fused	   to	   TTP(WT)	   repressed	   both	   FLPBS(WT)	   and	   FLARE	   (Figure	  5.4c).	  In	  contrast,	  fusion	  to	  TTP(C147R)	  decreased	  repression	  of	  FLARE	  from	  80%	  to	  40%.	   Thus,	   TTP(C147R)-­‐PUM-­‐HDWT	   fusion	   scaffold,	   which	   showed	   lower	  interference	   towards	   PBS	   binding,	   was	   used	   in	   further	   experiments	   and	   was	  referred	  to	  as	  TPUF.	  	  














































Figure	   5.5	  Relative	   levels	   of	   FL/RL	  mRNA,	  normalized	   to	   FLRandom/RL	  mRNA	   in	   the	   presence	   of	  effectors.	   	   Fluorescence	   RT-­‐PCR	   data	   were	   analyzed	   by	   ΔΔCT	   method.	   Data	   are	   represented	   as	  mean	  fold	  change	  relative	  to	  cells	  transfected	  with	  FLRandom	  (dashed	  line,	  unrepressed	  level)	  ±	  SD:	  n.s.,	  not	  significant	  (n=3,	  t	  test).	   Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	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tethering	   assay10,	   where	   luciferase	   activity	   was	   knocked	   down	   despite	   little	   RNA	  destabilization.	   We	   suggest	   that	   the	   TPUF	   constructs	   function	   similarly,	   by	  promoting	  translational	  repression	  rather	  than	  RNA	  degradation10.	  	  
5.2.4	  Validation	  of	  the	  TPUF	  and	  Luciferase	  Assay	  	  
	   To	   further	   test	   the	   design	   concept,	   we	   used	   our	   GG	   toolkit	   to	   assemble	   two	  previously	  reported	  PUF	  mutants1.	  TPUF(1SE)	  has	  repeat	  1	  replaced	  for	  recognition	  of	   G8	   [PBS(A8G)],	   and	   TPUF(6SE,7NQ)	   has	   repeats	   6	   and	   7	   replaced	   for	   the	  recognition	  of	  G	  and	  U	  at	  positions	  2	  and	  3,	  respectively.	  TPUF(WT)	  and	  the	  two	  PUF	  mutants	   exhibited	   highest	   repression	   activities	   towards	   their	   cognate	   PBSs,	   with	  repression	  levels	  of	  76%,	  79%,	  and	  88%,	  respectively.	  Compared	  with	  cognate	  PBSs,	  





Ct"" 8  7  6  5  4  3  2  1  Nt" 5' 12345678 3'"
TPUF(A)" NQ-SE-NQ-SE-NQ-SE-SE-SQ UGUGUGGA 
TPUF(B)" CQ-SE-NQ-CQ-NQ-CQ-CQ-NQ AGUAUAAU 
TPUF(C)"" NQ-SYR-NQ-NQ-NQ-CQ-CQ-SQ UCUUUAAA 
TPUF(D)" NQ-SE-NQ-CQ-CQ-NQ-CQ-NQ UGUAAUAU 














































































































































































































































Protein Protein modules PBS 
Ct   8  7  6  5  4  3  2  1  Nt 5' 12345678 3' 
TPUF(A) NQ-SE-NQ-SE-NQ-SE-SE-SQ UGUGUGGA 
TPUF(B) CQ-SE-NQ-CQ-NQ-CQ-CQ-NQ AGUAUAAU 
TPUF(C)  NQ-SYR-NQ-NQ-NQ-CQ-CQ-SQ UCUUUAAA 
TPUF(D) NQ-SE-NQ-CQ-CQ-NQ-CQ-NQ UGUAAUAU 
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we	   observe	   a	   diminished	   activity	   towards	   PBSs	   with	   1	   or	   2	   mismatches,	   though	  some	   cross-­‐reactivity	  was	   evident	   (Figure	   5.6).	   These	   observations	   are	   consistent	  with	   cross-­‐reactivity	   between	   WT	   and	   PUF(1SE)	   in	   in	   vitro	   assays1	   and	   similar	  cross-­‐reactivity	  between	  WT	  and	  other	  mutant	  PUF	  proteins1,	  17	   that	  differ	  by	  1-­‐2	  repeats.	   Western	   Blotting	   showed	   that	   TPUF(WT)	   and	   mutants	   TPUF(1SE)	   and	  TPUF(6SE,7NQ)	   are	   expressed	   at	   similar	   levels,	   thus	   excluding	   the	   possibility	   of	  protein	  abundance	  variability	  distorting	  the	  observed	  repression	  activities.	  Overall,	  luciferase	  repression	  by	   the	  TPUF	  constructs	  was	  sequence-­‐specific,	   corroborating	  the	  validity	  of	  the	  TPUF-­‐reporter	  system.	  	  	  
5.2.5	  Analysis	  of	  Mutant	  TPUF	  Activities	  
	   To	  further	  analyze	  our	  repressor	  construct,	  we	  used	  PUF	  modifications	  S2-­‐S8	  (Table	   4.2).	   TPUF(S2)	   and	   TPUF(S4)	   demonstrated	   repression	   levels	   of	   82%	   and	  
Protein Protein modules PBS 
Ct   8  7  6  5  4  3  2  1  Nt 5' 12345678 3' 
TPUF(A) NQ-SE-NQ-SE-NQ-SE-SE-SQ UGUGUGGA 
TPUF(B) CQ-SE-NQ-CQ-NQ-CQ-CQ-NQ AGUAUAAU 
TPUF(C)  NQ-SYR-NQ-NQ-NQ-CQ-CQ-SQ UCUUUAAA 
TPUF(D) NQ-SE-NQ-CQ-CQ-NQ-CQ-NQ UGUAAUAU 
TPUF(E)  CQ-SYR-CQ-NQ-NQ-CQ-NQ-SQ ACAUUAUA 






















TPUF(A) 0.25 1.03 1.02 0.96 1.12 
TPUF(B) 0.97 0.83 1 1.02 0.93 
TPUF(C)  0.91 1.07 0.26 0.93 0.98 
TPUF(D) 0.92 0.88 0.91 0.42 0.93 
TPUF(E)  1.01 0.64 0.98 0.79 0.57 






















































































































































a	   b	  
Figure	  5.7	  Analysis	  of	  TPUFs	  S2-­‐S8.	  (a)	  Repression	  by	  TPUFs	  S2-­‐S8	  in	  HeLa	  cells	  decreases	  with	  increased	  number	  of	  mutant	  modules	  used.	  (b)	  Western	  blotting	  of	  3xFlag-­‐tagged	  TPUF	  constructs.	  α-­‐tubulin	  was	  imaged	  as	  a	  loading	  control.	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67%	   respectively	   (Figure	   5.7a).	   However,	   TPUF(S6)	   and	   TPUF(S8)	   showed	   a	  significantly	   lower	   repression	   activity	   (25%	   and	   20%,	   respectively),	   despite	   their	  high	  binding	   affinities	   in	  vitro.	   These	  data	   could	   indicate	   a	   correlation	  between	   in	  
vitro	  binding	  affinity	  and	  protein	  activity	  in	  cell	  cultures	  since	  PUF(S6)	  and	  PUF(S8)	  showed	   lower	   in	  vitro	  RNA	  binding	  affinities	  compared	  with	  PUF(S2)	  and	  PUF(S4)	  (Table	  4.2).	  In	  addition,	  lower	  repression	  activities	  of	  TPUFs	  S6	  and	  S8	  could	  in	  part	  be	  due	  to	  decreased	  solubility.	  To	  test	   this,	  we	  analyzed	  the	  soluble	  expression	  by	  immunoblotting	   of	   the	   transfected	   HeLa	   cell	   lysates,	   but	   did	   not	   observe	   a	  significant	   TPUF	   expression	   difference	   (Figure	   5.7b).	   Thus,	   we	   observed	   a	  correlation	   between	   PUF	   mutation	   number,	   in	   vitro	   binding	   affinity,	   and	   specific	  TPUF	   activity,	   as	  well	   as	   over-­‐sensitivity	   of	   TPUF	   constructs	   to	  more	   than	   4	   PUF	  repeat	  replacements	  in	  our	  luciferase	  assay.	  	  In	  order	  to	  further	  verify	  the	  functionality	  of	  the	  cloning	  method	  and	  the	  TPUF	  platform,	   we	   assembled	   more	   TPUF	   constructs	   with	   mutant	   repeats	   randomly	  introduced	  throughout	  the	  PUF	  domain	  (Figure	  5.8a),	  denoted	  as	  TPUFs	  A-­‐E.	  Out	  of	  5	   TPUF	  mutants,	   only	   TPUF(B)	   showed	   low	   (17%)	   repression	   activity	   towards	   a	  cognate	  PBS,	  whereas	  TPUFs	  A,	  C-­‐E	  showed	  repression	  activities	  ranging	  from	  43%	  to	   75%	   (Figure	   5.8b).	   TPUFs	   with	   all	   8	   replaced	   modules	   demonstrated	   poor	  repression	  activities	  (data	  not	  shown),	  indicating	  that	  accumulation	  of	  mutations	  in	  the	  PUF	  domain	  does	  not	  always	  result	  in	  active	  TPUF	  proteins	  in	  vivo.	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We	  next	   analyzed	   the	   orthogonality	   of	   these	  TPUF	   variants	   to	   each	   other	   by	  analyzing	  cross-­‐repression	  of	  PBSs	  among	  all	   five	  protein	  constructs.	  We	  observed	  that	  TPUFs	  A-­‐D	  had	  highest	   repression	   activities	   towards	   their	   cognate	  PBSs,	   and	  insignificant	   repression	   activity	   towards	   noncognate	   PBSs	   (Figure	   5.8c).	   Only	  TPUF(E)	   showed	   significant	   repression	   activity	   towards	   noncognate	   PBS(B).	   By	  comparing	   and	   contrasting	   the	   architecture	   of	   TPUFs(A-­‐E),	   as	  well	   as	   TPUFs	   (S2-­‐S8),	  we	  noticed	  that	  TPUFs	  with	  the	  worst	  performance	   in	  vivo,	  such	  as	  repression	  activity	  or	  specificity,	  all	  had	  the	  first	  module	  mutated	  to	  8C12Q16.	  This	  finding	  is	  not	  unexpected,	   since	  most,	   if	   not	   all,	   natural	   PUF	   proteins	   recognize	   RNA	   containing	  UGU	   at	   the	   5	   end	   of	   the	   target	   sequence,	   corresponding	   to	   modules	   6,	   7,	   and	   8,	  implying	  that	  these	  modules	  could	  be	  the	  most	  important	  in	  the	  recognition	  of	  the	  
Figure	   5.8	   Analysis	   of	   TPUFs	  A-­‐E	  with	  mutant	   repeats	   randomly	   introduced	   throughout	   the	   PUF	  domain.	  (a)	  Mutations	  and	  PBSs	  of	  TPUFs	  A-­‐E.	  Black,	  WT	  modules.	  Red,	  mutant	  modules.	  (b)	  TPUFs	  A-­‐E	  repress	  FL	  with	  cognate	  PBSs.	  (c)	  Cross-­‐activity	  of	  TPUFs	  A-­‐E.	  (d)	  Western	  Blot	  of	  TPUFs	  A-­‐E.	  Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	  
Protein Protein modules PBS 
Ct   8  7  6  5  4  3  2  1  Nt 5' 12345678 3' 
TPUF(A) NQ-SE-NQ-SE-NQ-SE-SE-SQ UGUGUGGA 
TPUF(B) CQ-SE-NQ-CQ-NQ-CQ-CQ-NQ AGUAUAAU 
TPUF(C)  NQ-SYR-NQ-NQ-NQ-CQ-CQ-SQ UCUUUAAA 
TPUF(D) NQ-SE-NQ-CQ-CQ-NQ-CQ-NQ UGUAAUAU 
TPUF(E)  CQ-SYR-CQ-NQ-NQ-CQ-NQ-SQ ACAUUAUA 






















TPUF(A) 0.25 1.03 1.02 0.96 1.12 
TPUF(B) 0.97 0.83 1 1.02 0.93 
TPUF(C)  0.91 1.07 0.26 0.93 0.98 
TPUF(D) 0.92 0.88 0.91 0.42 0.93 
TPUF(E)  1.01 0.64 0.98 0.79 0.57 
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consensus	   and	   least	   amenable	   to	   mutagenesis.	   Our	   data	   indeed	   suggest	   that	   the	  modification	   of	   the	   8th	   module	   can	   often	   result	   in	   the	   drop	   of	   the	   PUF	   binding	  activity.	  The	  difference	  between	  TPUF	  activities	   in	  a	  cell	   line	  could	  also	  be	  dependent	  on	   the	   expression	   and	   solubility	   levels	   of	   the	   fusion	   proteins.	   We	   therefore	  investigated	   soluble	   expression	   levels	   of	   the	   effector	   proteins	   mentioned	   above	  using	  Western	   blotting	   (Figure	   5.8d).	  We	   noticed	   some	   variability	   among	   soluble	  expression	   levels	   of	   TPUFs(A-­‐E);	   however,	   this	   variability	   does	   not	   seem	   to	   be	  consistent	  with	   the	  observed	  TPUF	  activities.	   In	  particular,	   it	  does	  not	  explain	   the	  apparent	  lower	  activities	  of	  TPUF(B)	  and	  TPUF(E).	  	  	  
5.2.6	  Analysis	  of	  Module	  4	  of	  TPUF	  Most	  stacking	  amino	  acids	  in	  the	  PUM-­‐HD	  are	  either	  tyrosine	  or	  arginine,	  with	  two	  exceptions	   being	   asparagine	   in	   repeat	   7	   and	   histidine	   in	   repeat	   4	   (Table	   4.1).	  Although	  Dong	  et	  al.	  reported	  that	  module	  3S12R16	  requires	  a	  tyrosine	  as	  a	  stacking	  residue	  in	  the	  adjacent	  module	  4	  for	  in	  vivo	  activity18,	  the	  effect	  of	  this	  mutation	  on	  the	   recognition	   of	   the	   5th	   base	   recognized	   by	   module	   4	   was	   not	   investigated.	   In	  order	   to	   test	   if	   all	   four	   variants	   of	  module	   4Y13	   possess	   similar	   activity	   and	   base	  preference	  as	  the	  WT	  4H13	  modules,	  we	  compared	  TPUF	  constructs	  containing	  4Y13	  with	  TPUF	  constructs	  containing	  4H13	  against	  all	  possible	  5th	  base	  variations	  in	  the	  target	  sequence.	  All	  other	  modules	  were	  unchanged.	  	  The	  dual	  luciferase	  assay	  was	  used	  as	  described	  previously	  to	  test	  the	  activities	  of	  TPUF	  variants.	  We	  observed	  that	  all	  TPUFs	  containing	  the	  WT	  4H13	  preferred	  the	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5G	   base.	   Thus,	   the	   4N12Q16	   and	   4C12Q16	  modules	   wrongly	   preferred	   the	   5G	   base,	  instead	  of	  the	  predicted	  5U	  and	  5A,	  respectively	  (Figure	  5.9a).	  The	  4S12E16	  module	  correctly	  recognized	  5G,	  whereas	  the	  4S12R16	  module	  preferred	  5G	  and	  5C	  equally.	  In	   contrast,	   the	   4N12Y13Q16	   module	   preferred	   the	   5U	   as	   predicted	   by	   the	   general	  code,	   and	   module	   4C12Y13Q16	   did	   not	   prefer	   any	   specific	   base	   in	   the	   position	   5	  (Figure	   5.9b).	   The	   bases	   preferences	   of	   modules	   4S12Y13E16	   and	   4S12Y13R16	  resembled	   the	   counterparts	   with	   the	   WT	   stacking	   amino	   acids.	   We	   therefore	  conclude	  that	  module	  4	  with	   the	  4Y13	  mutation	  has	  a	  comparable,	   if	  not	  better	  (at	  least	   for	   the	   module	   4N12Y13Q16),	   specificity	   compared	   to	   the	   WT	   histidine	   at	  position	  13.	  	  
	   	  
Figure	  5.9	  Comparison	  of	  TPUFs	  containing	  modules	  WT	  and	  4H13Y	  as	  the	  “stacking”	  amino	  acid.	  (a)	  Base	  preferences	  of	  the	  4H13	  modules.	  (b)	  Base	  preferences	  of	  the	  4H13Y	  modules.	  










































a	   b	  
	  	  	  4N12Q16	  	  	  	  	  	  	  	  	  	  	  4C12Q16	  	  	  	  	  	  	  	  	  	  	  4S12E16	  	  	  	  	  	  	  	  	  	  	  	  4S12R16	  	   	   	  	  4N12Y13Q16	  	  	  	  	  4C12Y13Q16	  	  	  	  	  	  	  	  4S12Y13E16	  	  	  	  	  4S12Y13R16	  	  
	  	  	  	  	  	  (5U)	   	  	  	  	  	  	  	  	  	  	  	  (5A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5G)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5(C)	   	   	  	  	  	  	  	  	  	  (5U)	   	  	  	  	  	  	  	  	  	  	  	  	  (5A)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5G)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5(C)	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5.2.7	  Endogenous	  Gene	  Repression	  by	  Designer	  TPUFs	  As	   a	   proof	   of	   concept	   for	   implementing	   designer	   RBP	   for	   endogenous	   gene	  regulation,	   we	   designed	   TPUFs	   that	   bind	   to	   the	   3ʹ′	   UTR	   of	   human	   vascular	  endothelial	  growth	  factor-­‐A	  (VEGFA)	  mRNA.	  VEGFA	  is	  one	  of	  the	  central	  mediators	  of	  angiogenesis,	  and	  was	  shown	  to	  be	  overexpressed	  in	  many	  human	  tumors.	  VEGFA	  is	   up-­‐regulated	   in	   these	   tumors	   by	   hypoxic	   growth	   conditions	   that	   many	   tumors	  create19.	  As	  such,	  VEGFA	  is	  an	  attractive	  target	  for	  the	  development	  of	  therapeutics	  to	   inhibit	   pathological	   angiogenesis.	   We	   reasoned	   that	   for	   our	   TPUF	   repression	  assay,	   elevated	  VEGFA	   levels	   are	  more	   therapeutically	   relevant	   than	  physiological	  lower	   levels,	   and	   therefore	   employed	   two	   different	   strategies	   to	   up-­‐regulate	  endogenous	   VEGFA	   expression.	   In	   the	   first	   strategy,	   we	   incubated	   HEK293	   cells	  with	   500	   μM	   CoCl2,	   an	   agent	   that	   causes	   conditions	   mimicking	   hypoxia20,	   and	  achieved	  an	  8-­‐fold	  VEGFA	  induction	  compared	  to	  cells	  grown	  in	  the	  absence	  of	  the	  agent	  (Figure	  5.10b).	  In	  the	  second	  strategy,	  we	  used	  a	  HEK293	  cell	  line	  in	  which	  a	  small	  molecule-­‐responsive	  gene	  switch	  for	  VEGFA	  expression	  was	  stably	  integrated	  
21.	   Upon	   induction	  with	   4,4ʹ′-­‐dihydroxybenzyl	   (DHB),	   endogenous	   VEGFA	  was	   up-­‐regulated	  19-­‐fold	  (Figure	  5.10c)	  21.	  For	   the	  post-­‐transcriptional	  down-­‐regulation	  of	  VEGFA,	  we	  assembled	  TPUFs	  VEGF1,	  VEGF3,	  and	  VEGF7	  (Figure	  5.10a),	  which	  have,	  respectively,	  1,	  3,	  and	  7	  PBSs	  in	   the	  3ʹ′	  UTR	  of	  all	  known	   transcript	  variants	  of	  VEGFA	   gene.	  PUF	  domains	   in	   the	  TPUF	   VEGF3	   and	   VEGF7	   constructs	   each	   carry	   one	   mutant	   repeat	   and	   were	  previously	   reported	   to	   be	   active	   in	   vitro1.	   TPUF(VEGF1)	   has	   repeats	   6	   and	   7	  replaced	  for	  the	  recognition	  of	  2A	  and	  3C	  in	  the	  PBS.	  WT	  repeat	  4N12Q16	  was	  left	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Protein Protein modules PBS 
Ct   8  7  6  5  4  3  2  1  Nt 5' 12345678 3' 
TPUF(VEGF1) NQ-CQ-SR-CQ-NQ-CQ-NQ-SQ UACAGAUA 
TPUF(VEGF3) NQ-NQ-NQ-CQ-NQ-CQ-NQ-SQ UUUAUAUA 














































































































































Figure	  5.10	  TPUF	  represses	  endogenously	  expressed	  VEGFA	  gene	  in	  HEK293	  cell	  line.	  (a)	  Mutations	  and	   binding	   sequences	   of	   TPUFs	   designed	   for	   VEGFA	   3ʹ′UTR	   recognition.	   Black,	  WT	   modules	   and	  corresponding	  RNA	  bases.	  Red,	  mutant	  modules	  and	  corresponding	  RNA	  bases.	  Blue,	  a	  mismatch	  in	  the	   recognition	   sequence.	   Ct,	   C-­‐terminus,	   Nt,	   N-­‐terminus	   of	   the	   protein.	   (b)	   Inhibition	   of	   hypoxia-­‐induced	  VEGFA	  expression	  by	  TPUF.	   Secreted	  VEGFA	   levels	  measure	  by	  ELISA	  were	  normalized	   to	  total	  protein	  amounts	  from	  lysed	  cells	  measured	  by	  Bradford	  Assay.	  Data	  represented	  as	  mean	  ±	  SD:	  n.s.,	   not	   significant,	   *P	   ≤	   0.05,	   **P	   ≤	   0.01,	   (n=3,	   t	   test).	   (c)	   Inhibition	   of	   DHB-­‐induced	   VEGFA	  expression	   by	   TPUF.	   	   Secreted	   VEGFA	   levels	   measure	   by	   ELISA	  were	   normalized	   to	   total	   protein	  amounts	   from	   lysed	   cells	   measured	   by	   Bradford	   Assay.	   Data	   represented	   as	  mean	   ±	   SD:	   n.s.,	   not	  significant,	  *P	  ≤	  0.05.	  (d)	  Western	  blot	  of	  effector	  proteins	  using	  anti-­‐Flag	  antibody.	  Anti-­‐α–tubulin	  antibody	  was	  used	  as	  a	  loading	  control.	  
Abil	  et	  al.	  J	  Biol	  Eng	  	  2014,	  8:7	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unchanged	  for	  the	  recognition	  of	  5G	  (Figure	  5.10a,	  blue),	  since	  this	  repeat	  is	  known	  to	  be	  promiscuous22.	  TPUF(S4)	  was	  shown	  to	  be	  active	  for	  its	  cognate	  RNA	  using	  the	  luciferase	  assay	  (Figure	  5.7a);	  however,	  it	  does	  not	  have	  binding	  sites	  in	  the	  3ʹ′	  UTR	  of	  VEGFA	  mRNA,	  and	  therefore	  was	  not	  expected	  to	  repress	  the	  gene.	  Fortuitously,	  PBS(WT)	  is	  present	  3	  times	  in	  the	  3ʹ′	  UTR	  of	  VEGFA	  mRNA,	  which	  allowed	  us	  to	  use	  TPUF(WT)	  as	  a	  reference	  for	  assaying	  activities	  of	  mutant	  TPUFs.	  To	   assay	   the	   repression	   activity,	   we	   transiently	   transfected	   recombinant	  HEK293	   cells	   with	   equimolar	   amounts	   of	   GFP	   or	   one	   of	   the	   TPUF	   constructs,	  induced	  the	  expression	  of	  VEGFA	  24	  hours	  after	  transfection,	  and	  assayed	  secreted	  levels	  of	  VEGFA	  by	  ELISA	  24	  hours	  after	  induction.	  VEGFA	  levels	  were	  normalized	  to	  total	   protein	   concentration,	   which	   we	   assumed	   to	   correlate	   with	   cell	   number.	  Bradford	   Assay	   was	   used	   to	   measure	   the	   total	   protein	   concentrations	   from	   cell	  lysates.	   We	   found	   that	   VEGFA	   amounted	   to	   less	   than	   1%	   of	   total	   protein	  concentration	   by	   mass	   (Figure	   5.10b	   and	   c),	   hence	   the	   variations	   of	   VEGFA	  concentrations	   in	   the	   cell	   would	   have	   no	   significant	   effect	   on	   total	   protein	  concentration.	  In	  both	  induction	  strategies,	  the	  VEGFA	  levels	  were	  not	  significantly	  affected	   by	   TPUF(S4)	   compared	   to	   samples	   transfected	   with	   GFP,	   as	   expected	  (Figure	   5.10	   b	   and	   c).	   For	   the	   cells	   treated	   with	   CoCl2,	   only	   TPUF(VEGF3)	   and	  TPUF(VEGF7)	  significantly	  repressed	  VEGFA	  expression,	  which	  was	  down-­‐regulated	  by	  38%	  and	  57%,	  respectively	  (Figure	  5.10b).	  On	  the	  other	  hand,	  for	  cells	  induced	  with	   DHB,	   TPUF(WT)	   caused	   considerable	   (44%)	   repression	   of	   VEGFA,	   whereas	  TPUFs	  VEGF1,	  VEGF3,	   and	  VEGF7	  knocked	  down	  VEGFA	   levels	  by	  55%,	  77%,	  and	  74%,	  respectively	  (Figure	  5.10c).	  We	  are	  currently	  unaware	  of	  the	  reason	  why	  cells	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exposed	   to	   hypoxia	   were	   more	   resistant	   to	   VEGFA	   repression	   by	   our	   TPUF	  constructs	  compared	  with	  cells	  that	  expressed	  the	  gene	  switch,	  but	  speculate	  that	  it	  could	   be	   due	   to	   yet	   undiscovered	   transcriptional	   and/or	   translational	   gene	  regulatory	  response	  of	  cells	  to	  hypoxia.	  The	  lower	  TPUF	  activity	  at	  hypoxia	  might	  be	  due	   to	   either	   lower	   expression	   of	   constructs	   at	   hypoxic	   conditions	   or	   due	   to	   an	  unknown	   interference	   of	   hypoxia	  with	   TTP	   function.	  Whatever	   the	   reason	   of	   this	  difference	  might	  be,	  we	  observed	  a	  considerable	  sequence-­‐specific	  down-­‐regulation	  of	  VEGFA	  in	  both	  conditions,	  and	  confirmed	  the	  efficacy	  of	  the	  TPUF	  platform	  in	  the	  down-­‐regulation	   of	   an	   endogenous	   gene	   in	   human	   cells	   as	   yet	   another	  demonstration	  of	   the	  applicability	  of	  PUF-­‐based	  RBPs	  at	  post-­‐transcriptional	   gene	  regulation4-­‐5.	  To	   compare	   the	   expression	   levels	   of	   TPUF	   constructs	   among	   each	   other,	  we	  performed	  a	  Western	  blot	  analysis	  of	  the	  effector	  proteins	  under	  normoxia	  (Figure	  5.10d).	   	   We	   observed	   a	   substantially	   greater	   soluble	   expression	   of	   TPUF(VEGF3)	  and	  TPUF(VEGF7),	  compared	  to	  the	  other	  constructs,	  which	  might	  be	  the	  reason	  of	  these	  constructs’	  higher	  overall	  activity.	  
5.3	  Discussion	  In	   this	   work,	   we	   demonstrated	   the	   implementation	   of	   the	   protein-­‐based	   post-­‐transcriptional	  repressor	  for	  down-­‐regulation	  of	  an	  endogenous	  gene	  using	  the	  PUF	  domain	  as	  a	  scaffold.	  Due	  to	  the	  development	  of	  the	  GG	  assembly	  library,	  which	  was	  described	   in	   Chapter	   4,	   the	   RNA-­‐sequence	   specificity	   of	   the	   TPUF	   can	   be	   easily	  engineered	   for	   the	   amino	   acids	   of	   choice	   at	   positions	   12	   and	   16	   in	   each	   of	   the	   8	  modules	   and	   cloned	   directly	   into	   the	   TPUF	   receiving	   vector,	   thus	   enabling	   easy	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modification	  of	   the	  TPUF	  for	  down-­‐regulation	  of	  mRNA	  of	  choice.	  We	  showed	  that	  the	  TPUF	  platform	  introduced	  in	  this	  work	  exhibits	  modular	  and	  sequence-­‐specific	  down-­‐regulation	   of	   genes.	   Analysis	   of	   a	   number	   of	   mutant	   TPUFs	   showed	   that	  modification	   of	   the	   8th	   module	   often	   results	   in	   decreased	   RNA	   affinity,	   poor	  repression	   activities,	   or	   promiscuity	   in	   RNA	   recognition.	   We	   therefore	   suggest	  selecting	  RNA	  target	  sequences	  that	  would	  start	  with	  a	  5ʹ′-­‐U	  (base	  1U),	  which	  is	  part	  of	   the	   5ʹ′-­‐UGU	   consensus	   that	   is	   recognized	   by	   most	   of	   the	   known	   natural	   PUF	  domains.	  In	  addition,	  we	  showed	  that	  the	  H	  to	  Y	  mutation	  in	  the	  13th	  position	  (the	  “stacking”	   residue)	   of	   the	   notoriously	   promiscuous	   repeat	   4	   improves	   the	  recognition	  of	  the	  U	  base	  in	  the	  5th	  position	  of	  the	  target	  sequence	  when	  the	  4N12Q16	  module	  is	  used.	  Similarly,	  the	  “wrong”	  recognition	  of	  the	  G	  base	  in	  the	  5th	  position	  is	  diminished	  by	  the	  4C12Q16	  when	  the	  “stacking”	  residue	  is	  tyrosine.	  Overall,	  our	  TPUF	  platform	   has	   been	   shown	   to	   be	   promising	   in	   further	   engineering	   of	   PUF-­‐based	  translational	  regulators.	  There	   is	   still	   some	   room	   for	   improvement	   of	   some	  TPUF	   characteristics.	   For	  example,	  TPUF	  requires	  10	  PBS	  in	  the	  3ʹ′	  UTR	  of	  a	  reporter	  gene	  to	  achieve	  a	  robust	  60-­‐80	   %	   repression.	   As	   a	   trans-­‐acting	   repressor,	   TTP	   can	   be	   more	   sensitive	   to	  interactions	   with	   the	   PUF	   domain	   compared	   with	   cys-­‐acting	   repressors,	   due	   to	  blockage	  of	  one	  or	  more	  surface	  areas	  responsible	  for	  the	  recruitment	  of	  cys-­‐acting	  repressors.	   Thus,	   further	   engineering	   of	   TPUF	   for	   better	   architecture	   can	   be	  beneficial	  for	  the	  increase	  of	  overall	  functional	  activity.	  	  
In	  vivo	   TPUF	   activities	   could	   also	   be	   dependent	   on	   various	   factors,	   including	  soluble	   protein	   expression;	   unequal	   contributions	   of	   different	   repeat-­‐base	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interactions	   to	   the	   binding	   energy	   of	   the	   RNA-­‐protein	   complexes1,	  23,	   resulting	   in	  different	   overall	   binding	   affinities	   to	   cognate	   RNA;	   binding	   to	   noncognate	   RNA24	  that	  would	  allow	  sequestration	  of	  the	  protein	  to	  non-­‐target	  RNA	   in	  vivo;	  as	  well	  as	  sporadic	   domain	   interactions	   in	   fusion	   proteins	   that	   would	   interfere	   with	   RNA	  binding.	   	  We	   cannot	   yet	   predict	   the	   contribution	   of	   each	   of	   these	   factors	   on	   PUF	  activity	   in	  vivo,	   and	   therefore	   suggest	   that	   the	  effect	  of	   these	  and	  other	   factors	  on	  engineered	  PUF	  activity	  has	  to	  be	  systematically	  investigated.	  Based	   on	   our	   findings	   on	   the	   repression	   of	   VEGFA,	   we	   conclude	   that	   the	  implementation	   of	   TPUFs	   for	   down-­‐regulation	   of	   endogenous	   genes	   with	   high	  efficacy	  is	  possible.	  The	  VEGFA	  repression	  levels	  that	  we	  observed	  are	  comparable	  to	   those	   in	  similar	  assays	  conducted	  with	  zinc	   finger	   transcriptional	   repressors	  or	  small	  interfering	  RNA	  (siRNA).	  For	  example,	  hypoxia-­‐induced	  VEGFA	  protein	  levels	  in	   HEK293	   cells	   were	   knocked	   down	   by	   74%	   using	   an	   engineered	   zinc	   finger	  transcriptional	   repressor25	   and	   VEGFA	   mRNA	   was	   knocked	   down	   by	   50%	   by	  another	  zinc	  finger	  repressor	  in	  HEK293	  cells	  grown	  in	  normoxia26.	  Similarly,	  siRNA	  knocked-­‐down	   endogenous	  VEGFA	  by	   up	   to	   43%	   in	   ID8	   cells27	   and	   up	   to	   71%	   in	  hypoxic	   HEK293	   cells25.	   	   Thus,	   the	   TPUF	   system	   that	   we	   have	   engineered	   is	   as	  effective	   as	   some	   other	   existing	   technologies	   that	   are	   often	   used	   to	   knock	   down	  gene	  expression	  levels,	  and	  can	  serve	  as	  a	  powerful	  alternative.	  	  However,	  factors	  determining	  tight	  binding	  of	  Pumilio	  domains	  to	  RNA	  in	  vitro,	  as	  well	  as	  factors	  determining	  high	  in	  vivo	  activities	  are	  still	  largely	  unknown,	  and	  a	  systematic	   investigation	   is	   needed.	   In	   vitro	   RNA	   binding	   affinities	   and	   in	   vivo	  activities	   show	   only	   a	   rough	   correlation4,	  17,	   and	   soluble	   expression	   levels	   do	   not	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always	   predict	   activity	   differences	   (Figures	   5.8d	   and	   5.10d).	   Therefore,	   for	  engineering	  of	  TPUFs	  with	  novel	  specificities	  or	  PUM-­‐HD-­‐based	  proteins	  with	  novel	  functionalities,	   we	   recommend	   building	   a	   reporter	   system	   suitable	   for	   the	   given	  protein	  activity,	  and	  directly	  screening	  the	  functional	  efficacy	  of	  the	  assembled	  PUF	  variants.	  	  Finally,	  for	  certain	  applications,	  specific	  recognition	  of	  8	  nt	  sequences	  may	  not	  be	   enough	   for	   unique	   recognition	   in	   a	   transcriptome.	   The	   specificity	   can	   be	  increased	  by	  using	  a	  split-­‐protein	  method,	  where	  two	  PUF	  domains,	  each	  fused	  to	  a	  fragment	  of	  a	  functional	  domain,	  can	  reassemble	  the	  functional	  domain	  on	  an	  RNA	  scaffold,	   as	   was	   shown	   for	   PUF-­‐based	   fluorescent	   probe	   engineering28-­‐30.	   This	  approach	   would	   increase	   the	   total	   number	   of	   PUF	   repeats	   to	   16,	   thus	   likely	  increasing	   the	   overall	   specificity	   of	   the	   system.	   Alternatively,	   a	   GG	   platform	   for	  assembly	  of	  single	  polypeptide	  PUF	  domains	  with	  more	  RNA-­‐binding	  repeats	  can	  be	  developed,	   as	  was	   proposed	  by	   Filipovska	   and	   coworkers	  who	   constructed	   a	   PUF	  domain	  comprising	  16	  repeats31.	  	  
5.4	  Materials	  and	  Methods	  
5.4.1	  Materials	  
	  All	  the	  chemicals	  and	  solutions	  were	  purchased	  from	  Fisher	  Scientific	  (Pittsburgh,	  PA),	  unless	  noted	  otherwise.	  Oligonucleotides	  were	  purchased	  from	  Integrated	  DNA	  Technologies	   (Coralville,	   IA).	   All	   the	   enzymes	  were	   purchased	   from	  New	  England	  Biolabs	  (Ipswich,	  MA),	  unless	  noted	  otherwise.	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5.4.2	  Construction	  of	  Reporter	  Plasmids	  pCMV-­‐Fluc	  plasmid	  was	  created	  by	  amplification	  of	  the	  firefly	  luciferase	  gene	  from	  pGL3	  plasmid	  (Promega)	  and	  insertion	  into	  SacI	  and	  KpnI	  sites	  of	  pCMV5	  vector	  (a	  gift	  of	  Dr.	  David	  Russell).	  All	   the	  pCMV-­‐Fluc-­‐10xPBS	  plasmids,	  pCMV-­‐Fluc-­‐10xARE,	  as	  well	  as	  pCMV-­‐Fluc-­‐Random	  were	  cloned	  by	  primer-­‐extension	  of	  6	  primers	  (Table	  S3)	   carrying	   10	   PBSs	   and	   subsequent	   GA-­‐cloning	   into	   PstI	   and	   XmaI	   sites	   of	   the	  pCMV-­‐Fluc	  plasmid.	  The	  6-­‐18	  nt	  spacers	  between	  the	  10	  PBS	  in	  the	  3ʹ′	  UTR	  of	  the	  FL	  were	  the	  same	  in	  different	  FL-­‐PBS	  sequences,	  and	  were	  designed	  in	  such	  a	  way	  to	  minimize	   secondary	   structure	   formation	   that	   would	   involve	   these	   spacers.	   The	  pCMV-­‐Fluc-­‐Random	  was	  created	  by	  replacing	  all	  the	  PBSs	  in	  the	  pCMV-­‐Fluc-­‐10xPBS	  with	  10	  different	  scrambled	  sequences	  of	  8	  nt	  with	  approximately	  50%	  GC	  content.	  Plasmid	  pRL-­‐SV40	  was	  a	  gift	  of	  Dr.	  David	  J.	  Shapiro.	  
	  
5.4.3	  Construction	  of	  Effector	  Plasmids	  The	   effector	   plasmid	   pCMV-­‐TTP(WT)-­‐PUM-­‐HD	  was	   GA-­‐cloned	   from	   the	   following	  fragments:	  2.2	  kb	  and	  2.4	  kb	  pCMV5	  fragments,	  GS-­‐PUM-­‐HD	  amplified	  from	  pTYB3-­‐PUM1-­‐HD,	   and	   TTP-­‐GS	   amplified	   from	   cDNA	   (Open	   Biosystems	   catalog	   number	  MHS4768-­‐99609440	  [GenBank:	  BC009693.1]).	  pCMV-­‐TTP(WT)	  and	  pCMV-­‐PUM-­‐HD	  have	  been	  assembled	  from	  the	  same	  vector	  backbone	  fragments,	  as	  well	  as	  TTP-­‐stop	  or	  Flag-­‐PUM-­‐HD	  fragments,	  respectively	  (for	  primers,	  see	  Table	  S4).	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5.4.4	  Golden	  Gate	  Assembly	  of	  Mutant	  Effector	  Plasmids	  
	  3xFlag-­‐tagged	  TPUF	  constructs	   for	  mammalian	  cell	  expression	  were	  assembled	   in	  the	  pCMV-­‐TTP(C147R)-­‐GG-­‐PUF	  destination	  vector.	  Receiving	  vector	   (50	  ng)	  and	  8	  modules	  of	  choice	  (75	  ng	  each)	  were	  combined	  with	  1	  μl	  T4	  DNA	  ligase	  and	  1	  μl	  BsaI	  in	  10	  μl	  1x	  T4	  DNA	   ligase	  buffer.	  The	  reactions	  were	  cycled	  10	   times	   for	  5	  min	  at	  37°C	  and	  10	  min	  at	  16°C,	  and	  a	  final	  incubation	  of	  15	  min	  at	  37°C.	  TOP10	  E.	  coli	  cells	  (Invitrogen)	   were	   then	   transformed	   with	   the	   cloning	   reactions	   and	   plated	   on	   LB	  plates	  (Cell	  Media	  Facility,	  UIUC)	  with	  amp	  selection,	  and	  supplemented	  with	  10	  μl	  0.4	   M	   IPTG	   (GoldBio)	   and	   40	   μl	   20	   mg/ml	   Bluo-­‐Gal	   (Invitrogen)	   for	   blue-­‐white	  screening.	   All	   the	   plasmids	   for	   mammalian	   cell	   expression	   were	   purified	   using	  Qiagen	  Plasmid	  Mini	  kit.	  	  
5.4.5	  Cell	  Line	  Transfection	  and	  Dual	  Luciferase	  Assay	  Transfection	   of	  HeLa	   cells	   (ATCC)	  was	   performed	   in	   triplicates	   in	   a	   24-­‐well	   plate	  format	   with	   Fugene-­‐HD	   transfection	   reagent	   (Promega).	   Transfection	   mixtures	  contained	  150	  ng	  FL,	  2	  ng	  pRL-­‐SV40,	  and	  75	  ng	  TPUF	  or	  equimolar	  amounts	  of	  other	  effector	  DNA	  constructs,	  and	  empty	  vector	  pCMV5	  to	  500	  ng	  total.	  Cells	  were	  lysed	  in	   Passive	   Lysis	   Buffer	   (Promega)	   48h	   after	   transfection	   and	   FL	   and	  RL	   activities	  were	  measured	  in	  white	  96-­‐well	  plates	  (Greiner	  Bio	  One)	  using	  Dual-­‐Glo	  Luciferase	  Assay	   System	   (Promega)	   with	   measurements	   taken	   on	   Analyst	   HT	   microplate	  reader	  at	  the	  High-­‐Throughput	  Screening	  Facility	  at	  UIUC.	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5.4.6	  Reverse	  Transcription	  Real-­‐Time	  PCR	  Total	  RNA	  was	  isolated	  from	  HeLa	  cells	  48	  hours	  after	  transfection	  using	  the	  RNeasy	  Mini	   Kit	   (Qiagen)	   following	   manufacturer’s	   instructions,	   and	   DNA	   was	   removed	  from	  samples	  with	  Turbo	  DNase	  (Life	  Technologies).	  RNA	  was	  reverse	  transcribed	  into	   cDNA	   with	   ProtoScript	   First	   Strand	   cDNA	   Synthesis	   kit	   (NEB)	   using	   the	  d(T)23VN	   primer.	   Reverse	   transcriptase	   was	   omitted	   in	   control	   samples.	   RT-­‐PCR	  was	  performed	  using	  Power	   SYBR	  Green	  Master	  Mix	   (Life	  Technologies)	  with	   the	  7900HT	  Fast	  Real-­‐Time	  PCR	  System	  (Applied	  Biosystems).	  Reactions	  were	  carried	  out	   in	   triplicates	   in	   20	   μl	   reactions	   with	   500	   nM	   of	   each	   primer.	   	   The	   primer	  sequences	   for	   FL	   were	   5ʹ′-­‐GCGCGGAGGAGTTGTGTTTG	   and	   5ʹ′-­‐ATCTTTCCGCCCTTCTTGGC;	   and	   for	   RL	   5ʹ′-­‐GCAGCATATCTTG	   AACCATTC	   and	   5ʹ′-­‐TTGTACAACGTCAGGTTTACC.	  	  ΔΔCT	  method	  was	  used	  for	  RNA	  level	  analysis,	  where	  FL	   mRNA	   levels	   were	   normalized	   to	   RL	   mRNA,	   and	   FLPBS(WT)	   mRNA	   levels	   were	  normalized	  to	  FLRandom.	  	  
5.4.7	  VEGFA	  Induction	  and	  ELISA	  For	   hypoxia-­‐induced	   VEGFA,	   HEK293	   cells	   were	   transfected	   in	   a	   24-­‐well	   plate	  format	  in	  triplicates	  with	  Fugene-­‐HD.	  Transfection	  mixtures	  contained	  500	  ng	  TPUF	  DNA	   constructs	   or	   350	   ng	   pmaxGFP	   (Lonza)	   and	   150	   ng	   pCMV5.	   The	   cells	   were	  induced	   with	   500	   μM	   CoCl2	   24h	   after	   transfection,	   and	   the	   supernatant	   was	  collected	   for	   assay	   24	   hours	   after	   the	   induction.	   For	   gene-­‐switch-­‐induced	   VEGFA,	  HEK293	   cell	   line	   with	   retrovirally	   integrated	   DHB-­‐inducible	   V24P-­‐GS60	  transcription	   activator	   was	   used21.	   The	   cells	   were	   transfected	   in	   a	   24-­‐well	   plate	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format	   in	   triplicates	   as	   above.	   The	   cells	  were	   induced	   24h	   after	   transfection	  with	  100	  nM	  DHB,	   in	   the	  presence	  of	  pen/strep	   (Gibco).	  The	   supernatant	  was	  collected	  24h	  after	  induction	  and	  subjected	  to	  ELISA.	  The	  assay	  was	  performed	  by	  pre-­‐coating	  the	  96-­‐well	  clear	  plate	  with	  a	  goat	  anti-­‐mouse	  antibody	  (Thermo	  Scientific)	  at	  4°C	  overnight,	   and	   then	   following	   the	   instructions	   of	   human	   VEGF	   DuoSet	   kit	   (R&D	  Systems).	  The	  absorption	  readings	  were	   taken	  on	  a	  SpectraMax	  340PC	  microplate	  reader.	  The	  cell	  monolayer	  was	  saved	  for	  Bradford	  assay.	  
	  
5.4.8	  Bradford	  Assay	  The	  cell	  monolayers	  were	  lysed	  using	  RIPA	  lysis	  buffer.	  The	  protein	  concentrations	  were	  measured	   in	   technical	  duplicates	  by	  mixing	  4	  μl	  of	   cell	   lysate	  with	  295	  μl	  of	  Coomassie	  Plus	  Protein	  Assay	  Reagent	  (Thermo	  Scientific)	   in	  a	  96-­‐well	  clear	  plate.	  Quick	   Start	   Bovine	   Serum	   Albumine	   Standard	   Set	   (Bio-­‐Rad)	   was	   used	   to	   build	   a	  protein	  standard	  curve.	  A595	  was	  measured	  5	  min	   later	  using	  a	  SpectraMax	  340PC	  microplate	   reader.	   The	   total	   protein	   concentrations	   measured	   by	   Bradford	   assay	  were	  used	  to	  normalize	  the	  VEGF	  concentrations.	  	  
5.4.9	  Western	  Blotting	  V24P-­‐GS60-­‐integrated	  HEK293	  cells	  as	  well	  as	  HeLa	  cells	  were	   transfected	   in	  a	  6-­‐well	   plate	   format	   with	   Fugene-­‐HD	   and	   3	   μg	   of	   effector	   plasmid.	   Cells	   were	   lysed	  using	   RIPA	   lysis	   buffer	   (Santa	   Cruz	   Biotech).	   The	   proteins	   were	   detected	   using	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mouse	   anti-­‐Flag	   and	   anti-­‐α-­‐tubulin	   antibodies	   (GeneScript)	   and	   imaged	   using	  SuperSignal	  West	  Dura	  chemilluminescent	  substrate	  (Thermo	  Scientific).	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Chapter	  6.	  Engineering	  of	  a	  PUF-­‐Motor4	  
6.1	  Introduction	  Subcellular	  mRNA	  localization	  is	   increasingly	  believed	  to	  play	  an	  important	  role	  in	  posttranscriptional	   regulation.	   Indeed,	   a	   broad	   role	   for	   RNA	   localization	   was	  suggested	  by	   the	   revelation	   that	  up	   to	  70%	  of	   endogenous	  RNA	  was	  differentially	  localized	   in	  Drosophila	   embryos1.	   Differential	   mRNA	   localization	   and	   local	   mRNA	  translation	   were	   found	   to	   be	   implicated	   in	   diverse	   cellular	   processes	   including	  asymmetric	   cell	   division,	   embryogenesis,	   and	   cell	   migration2-­‐3.	   In	   addition,	   local	  mRNA	   translation	   is	   likewise	   important	   in	   highly	   polarized	   cells	   like	   neurons.	   In	  particular,	   the	   importance	   of	   differential	   mRNA	   localization	   and	   local	   protein	  synthesis	  was	  reported	   in	  a	  number	  neurological	  processes	   including	  growth	  cone	  chemotropic	   response4-­‐6,	   synapse	   formation	   and	   plasticity7-­‐8,	   transmitter	  biogenesis9-­‐10,	   cell	   survival	   and	   axon	  maintenance11-­‐13,	   and	   axon	   regeneration14-­‐15.	  Notably,	   mislocalization	   of	   mRNA	   in	   neurites	   has	   been	   linked	   with	  neurodegenerative	  disorders	  such	  as	   fragile	  X	  syndrome,	  spinal	  muscular	  atrophy,	  and	  amyotrophic	  lateral	  sclerosis16-­‐17.	  Although	   subcellular	   mRNA	   localization	   was	   in	   some	   cases	   reported	   to	   be	  established	   through	   localized	   protection	   from	   degradation18-­‐19	   and	   localized	  anchorage20,	   active	   transport	   on	   the	   cytoskeleton	   using	   molecular	   motors	   is	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4	  This	  work	  was	  done	  in	  collaboration	  with	  Dr.	  Casper	  C.	  Hoogenraad	  and	  Dr.	  Laura	  F.	  Gumy	  at	  Utrecht	  University,	  the	  Netherlands. 	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regarded	  as	  the	  major	  pathway	  of	  mRNA	  transport2.	  In	  the	  case	  of	  active	  transport	  of	  mRNA,	  ribonucleoprotein	  complexes	  are	   loaded	  on	  motor	  proteins	  belonging	  to	  all	   three	   motor	   families:	   myosins,	   kinesins,	   and	   dyneins21-­‐22.	   Kinesins	   usually	  transport	   cellular	   cargos,	   such	   as	   RNAs,	   vesicles,	   and	   organells,	   to	   the	   (+)	   end	   of	  microtubules23,	   whereas	   dyneins	   transport	   cargos	   to	   the	   (-­‐)	   end	   of	   the	  microtubules24.	   Meanwhile,	   myosins	   transport	   cargos,	   including	   RNAs,	   along	   the	  actin	  filaments	  of	  the	  cytoskeleton25.	  It	  is	  generally	  believed	  that	  linking	  RNA	  cargo	  to	   cellular	   motors	   occurs	   through	   an	   interaction	   between	   RNA-­‐binding	   proteins	  (RBPs),	  and	  additional	  adapter	  proteins	  that	  recruit	  motors	  to	  the	  RBPs21.	  Although	  in	  most	  cases	  the	  identities	  of	  these	  RBPs	  and	  adapters	  remain	  unknown,	  some	  well	  studied	  RBPs-­‐adapter	  complexes	  include	  She2p	  and	  She3p	  in	  budding	  yeast26-­‐27,	  as	  well	  as	  egalitarian	  and	  bicaudal-­‐D	  (BicD)	  in	  Drosophila28.	  	  The	   development	   of	   synthetic	   devices	   capable	   of	   controlling	   endogenous	  mRNA	  transport	  would	  contribute	  to	  the	  investigation	  of	  significance	  of	  subcellular	  mRNA	  localization.	  Furthermore,	   it	  would	  expand	  our	  capability	   in	  regulating	  RNA	  metabolism,	   with	   potential	   future	   applications	   in	   synthetic	   biology	   and	  neurobiology.	  Our	  current	  ability	  to	  manipulate	  mRNA	  transport	  and/or	  local	  mRNA	  requires	   prior	   tagging	   of	   the	   RNA	   of	   interest27,	   29-­‐31.	   In	   order	   to	   target	   unaltered	  endogenous	   RNA	   targets,	   devices	   would	   require	   RBPs	   with	   reprogrammable	  specificity,	   such	   that	   the	   RBP	   could	   be	   predictably	   engineered	   for	   specificity	   for	  every	  new	  RNA	   target.	  This	   criterion	   is	   satisfied	  by	   the	  Pumilio	  and	   fem3-­‐binding	  factor	   (PUF)	   homology	   proteins,	   which	   are	   repeat	   proteins	   that	   bind	   RNA	   in	   a	  modular	  1:1	  repeat	  :	  base	  fashion32-­‐33.	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The	   crystal	   structure	   of	   the	   PUF	   domain	   from	   the	   human	   Pumilio1	   protein	  (PUM1)	   bound	   to	   Nanos-­‐response	   element	   (NRE)	   RNA	   revealed	   that	   amino	   acid	  residues	  at	  positions	  12	  and	  16	  in	  each	  PUF	  repeat	  interact	  with	  a	  single	  RNA	  base,	  and	  suggested	  a	  code	  for	  recognition	  of	  RNA	  bases	  adenine,	  uracil,	  and	  guanine	  by	  PUF	   proteins32.	   Amino	   acid	   residue	   at	   position	   13	   of	   each	   repeat	   is	   sandwiched	  between	   two	  adjacent	  RNA	  bases	   in	  a	   stacking	   interaction32.	  Mutagenesis	  of	   these	  key	   amino	   acids	   according	   to	   the	   code	   was	   shown	   to	   predictably	   alter	   the	   RNA-­‐binding	   specificity	   of	   PUF33.	   The	   development	   of	   artificial	   PUF	   repeats	   for	   the	  recognition	  of	   cytosine	   expanded	  our	   ability	   to	   engineer	  PUF	   specificity	   to	   almost	  any	  sequence	  of	  8	  RNA	  bases34-­‐35.	  In	  this	  work,	  we	  created	  a	  device	  that	  allows	  directional	  transport	  of	  mRNA	  in	  eukaryotes.	  The	  device	  consists	  of	  two	  components:	  a	  transporter,	  which	  provides	  a	  directional	   movement,	   and	   a	   component	   containing	   an	   RBP.	   The	   transporter	   is	  tagged	  with	  an	  FRB	  domain,	  whereas	  the	  RBP	  engineered	  from	  the	  PUF	  scaffold	   is	  tagged	  with	  FKBP.	  These	  two	  domains	  heterodimerize	  upon	  addition	  of	  rapamycin	  analog	  (AP21967,	  henceforth	  called	  rapalog)36	  (Figure	  6.1b).	  Our	  transporters	  come	  in	  two	  flavors:	  Kif5b,	  which	  is	  a	  cellular	  motor	  that	  transports	  the	  cargo	  molecules	  to	  the	  (+)	  end	  of	  the	  microtubules	  located	  in	  the	  cell	  periphery,	  and	  BicD,	  which	  is	  an	  adaptor	  protein	  that	  interacts	  with	  cellular	  motor	  dynein	  and	  transports	  the	  cargos	  to	   the	   (-­‐)	   end	   of	  microtubules	   located	   in	   the	   centrosome.	  We	   show	  here	   that	   our	  PUF-­‐motor	   system	   is	   capable	   of	   sequence-­‐specific	   recognition	   and	   transport	   of	  mRNA	  in	  cancerous	  mammalian	  cell	  cultures	  as	  well	  as	  in	  hippocampal	  neurons. 
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6.2	  Results	  and	  Discussion	  
6.2.1	  Engineering	  of	  the	  PUF-­‐Motor	  System	  In	   order	   to	   ensure	   motility	   function	   to	   our	   device,	   we	   implemented	   the	  proteins	   previously	   shown	   to	   exhibit	   directional	   transport	   on	   microtubules	   in	  cultured	  mammalian	  cells.	  Thus,	   for	   the	  minus	  end-­‐directed	   transport,	  we	  utilized	  the	  N-­‐terminal	  domain	  of	  mouse	  BicD2	  protein	  (amino	  acid	  residues	  1-­‐594),	  which	  was	   shown	   to	   be	   sufficient	   for	   the	   interaction	   with	   cytoplasmic	   dynein	   and	  induction	   of	   transport37-­‐38.	   For	   the	   plus	   end-­‐directed	   transport,	   we	   utilized	   a	  truncated	   human	   kinesin	   (amino	   acid	   residues	   1-­‐807)	   without	   the	   tail	   domain,	  which	  was	  shown	  to	  be	  sufficient	  for	  cargo	  transport39.	  Both	  of	  the	  constructs	  were	  fused	  to	  a	  single	  FRB	  domain	  via	  a	  GGGS	  linker.	  The	   RNA-­‐binding	   component	   of	   our	   system	   consists	   of	   two	   PUF	   domains,	  enhanced	   green	   fluorescent	   protein	   (eGFP)	   for	   tracking	   the	   localization	   of	   the	  constructs,	  and	  1	  or	  2	  consecutive	  FKBP	  domains,	  all	   fused	  to	  a	  single	  polypeptide	  chain	  with	  GGGS	  linkers.	  In	  order	  to	  minimize	  the	  unintended	  interaction	  of	  the	  PUF	  with	  the	  endogenous	  sites	  in	  the	  human	  transcriptome,	  we	  used	  a	  mutant	  version	  of	  the	  PUF	  domain	  from	  human	  PUM1	  protein,	  where	  repeats	  6	  and	  7	  were	  mutated	  so	  that	   the	   PUF	   recognizes	   the	   RNA	   sequence	   5ʹ′-­‐UUGAUAUA-­‐3ʹ′	   (see	   Chapter	   5).	  We	  used	  two	  PUF	  domains	  and	  in	  some	  cases	  two	  FKBP	  domains	  with	  the	  intention	  of	  maximizing	  the	  avidity	  between	  PUF	  and	  RNA,	  as	  well	  as	  PUF	  and	  the	   transporter	  proteins	  (Figure	  6.1a).	  Since	  a	  polypeptide	  chain	  consisting	  of	  4-­‐5	  domains	  linked	  by	  flexible	  linkers	  might	  assume	  insoluble	  conformations	  or	  conformations	  prohibitive	  to	  interaction	  with	  RNA	  or	  FRB,	  we	  constructed	  4	  configurations	  of	  this	  component	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that	  had	  various	  order	  of	  these	  domains	  in	  the	  polypeptide	  chain	  (Figure	  6.1a),	  and	  tested	  them	  all	  for	  the	  ability	  to	  be	  transported	  by	  our	  transporter	  constructs.	  The	  denomination	   of	   these	   four	   RBP	   constructs	   was	   an	   abbreviation	   of	   the	   domain	  names	  in	  the	  order	  of	  these	  domains	  appearing	  in	  the	  polypeptide	  chain	  from	  the	  N-­‐terminus	  to	  the	  C-­‐terminus	  of	  the	  fusion	  protein.	  Thus,	  the	  construct	  FFGPP	  consists	  of	  two	  domains	  of	  FKBP,	  eGFP,	  and	  two	  PUF	  domains	  in	  the	  aforementioned	  order	  from	   the	  N-­‐terminus	   to	   the	  C-­‐terminus	  of	   the	   fusion	  protein.	  All	   of	   the	   constructs	  belonging	   to	   both	   transporter	   and	   RBP	   parts	   of	   the	   system	   were	   cloned	   under	  cytomegalovirus	  (CMV)	  promoter.	  
	  





PUF PUF FKBP eGFP 
PUF PUF FKBP eGFP 
PUF PUF FKBP eGFP FKBP 
PUF PUF FKBP eGFP FKBP 
Figure . Schematic of the PUF-motor system. (a) Schematic of f ur PUF-GFP-FKBP fusion 
constructs with different order of domains (Left to right: N-terminus to C-terminus of the 
polypeptides). (b) Schematic of PUF/Kinesin and PUF/BicD-N systems for the transport of 
reporter mRNA to the (+) and (-) end of microtubules, respectfully. The  two PUF domains in 
the FFGPP or GPPF fusions interact with the PUF-binding sites in the 3’UTR of of firefly 
luciferas  mRNA. Upon addition of the rapalog, the FKB  domai   FFGPP or GPPF 
constructs dimerize with the FRB domain, which is in turn fused to either kinesin or BicD-N. 
BicD-N interacts with the cellular motor dynein. Heterodimerization allows the assembly of 
the PUF-motor system and the transport of RNA. 
Microtubule (-) end (+) end 
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   In	  order	  to	  test	  which	  of	  the	  PUF-­‐containing	  polypeptides	  were	  functional,	  we	  co-­‐transfected	   each	   of	   these	   constructs	   with	   either	   Kif5b-­‐FRB	   or	   BicD-­‐N-­‐FRB	   in	  HeLa	   cells.	   Since	  HeLa	   cells	   contain	   radial	  microtubule	   arrays	   stretching	   from	   the	  centrosome	  at	  their	  minus	  end	  to	  the	  cell	  periphery	  in	  their	  plus	  ends,	  we	  expected	  BicD-­‐N	   and	   Kif5b	   constructs	   to	   transport	   the	   PUF	   constructs	   towards	   the	  centrosomes	  or	  cell	  periphery,	   respectively	   (Figure	  6.1b).	  Twenty-­‐four	  hours	  after	  transfection,	  rapalog	  was	  added	  at	  the	  final	  concentration	  of	  1	  μM	  to	  the	  cells	  in	  the	  conditioned	  medium	   for	   1	   hour	   before	   imaging.	   Live-­‐cell	   imaging	   using	  widefield	  fluorescence	   microscopy	   revealed	   that	   when	   co-­‐transfected	   with	   Kif5b-­‐FRB	   and	  treated	  with	  rapalog,	  construct	  FFGPP	  localized	  to	  the	  cell	  periphery	  (Figure	  6.2a),	  whereas	   it	  was	  spread	  throughout	   the	  cell	  cytoplasm	  when	  co-­‐transfected	  with	  an	  empty	   vector	   and	   treated	   with	   rapalog	   (Figure	   6.2b).	   BicD-­‐N-­‐FRB,	   on	   the	   other	  hand,	   interacted	   best	  with	   the	   construct	   GPPF,	   and	   allowed	   its	   localization	   in	   the	  perinuclear	   space	   (Figure	   6.2c).	   When	   co-­‐transfected	   with	   an	   empty	   vector	   and	  treated	  with	  rapalog,	  GPPF	  did	  not	  show	  the	  same	  perinuclear	  localization,	  but	  was	  spread	  evenly	   throughout	   the	   cellular	   cytoplasm	   (Figure	  6.2d),	   indicating	   that	   the	  transport	  is	  indeed	  dependent	  on	  the	  introduced	  transporter	  constructs.	  Constructs	  PGPF	  and	  FFPGP	  were	  both	  solubly	  expressed,	  as	  judged	  from	  similar	  fluorescence	  intensities	  under	  widefield	  microscopy	  (data	  not	  shown).	  However,	  these	  constructs	  showed	   minimal	   localization	   to	   either	   cell	   periphery	   or	   perunuclear	   space	   upon	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treatment	   with	   rapalog	   and	   in	   the	   presence	   of	   respective	   transporter	   constructs	  (data	  not	  shown).	  	  
	  
Figure	  6.2	  Transport	  of	  the	  PUF	  fusion	  constructs	  FFGPP	  and	  GPPF	  to	  the	  cell	  poles	  corresponding	  to	  the	   (+)	   and	   (-­‐)	   ends	   of	  microtubules.	   (a)	   HeLa	   cells	   were	   transfected	  with	   Kif5b-­‐FRB	   and	   FFGPP,	  grown	   for	   24	   hours	   and	   treated	   with	   1 μM	   rapalog	   for	   1	   hour	   before	   imaging	   by	   widefield	  microscopy.	  GFP-­‐tagged	  PUF	  is	  observed	  at	  the	  cell	  periphery.	  (b)	  HeLa	  cells	  were	  transfected	  with	  empty	   vector	   and	   FFGPP,	   grown	   for	   24	   hours	   and	   treated	   with	   1	   μM	   rapalog	   for	   1	   hour	   before	  imaging	  by	  widefield	  microscopy.	  (c)	  HeLa	  cells	  were	  transfected	  with	  BicD-­‐N-­‐FRB	  and	  GPPF,	  grown	  for	  24	  hours	  and	  treated	  with	  1	  μM	  rapalog	  for	  1	  hour	  before	  imaging	  by	  widefield	  microscopy.	  GFP-­‐tagged	  PUF	  is	  aggregated	  at	  the	  perinuclear	  space.	  (d)	  HeLa	  cells	  were	  transfected	  with	  empty	  vector	  and	  GPPF,	  grown	  for	  24	  hours	  and	  treated	  with	  1	  μM	  rapalog	  for	  1	  hour	  before	  imaging	  by	  widefield	  microscopy.	  	  
6.2.2	  Intracellular	  Transport	  of	  Reporter	  mRNA	  by	  the	  PUF-­‐Motor	  To	   assay	   the	   effectiveness	   of	   the	   device	   for	   the	   transport	   of	  mRNA,	  we	   utilized	   a	  reporter	  firefly	  luciferase	  (FL)	  mRNA,	  in	  the	  3ʹ′	  untranslated	  region	  (UTR)	  of	  which	  we	  placed	  2	  or	  10	  cognate	  PUF-­‐binding	  sites	   (PBS)	  or	  a	   random	  250	  bp-­‐sequence	  (Figure	  6.1b).	  In	  the	  construct	  with	  10	  PBS,	  each	  PBS	  was	  separated	  from	  another	  by	  a	  spacer	  with	  a	  random	  sequence	  and	  alternating	  lengths	  of	  6	  or	  18	  nucleotides	  (nt),	  resulting	   in	  a	  3ʹ′	  UTR	  of	  approximately	  250	  bases.	   In	   the	  construct	  with	  2	  PBS,	   the	  
BicD-N-FRB GPPF pCMV5 GPPF Kif5b-FRB FFGPP pCMV5 FFGPP 
a b c d 
Figure 2. Tra sport of the PUF fusion constructs FFGPP and GPPF to the cell poles 
corresponding to the (+) and (-) ends of microtubules. (a) HeLa cells were transfected with 
Kif5b-FRB and FFGPP, grown for 24 hours and exposed to 1uM rapalog for 1 hour before 
imaging by widefield microscopy. GFP-tagged PUF is observed at the cell periphery. (b) HeLa 
cells were transfected with empty vector and FFGPP, grown for 24 hours and exposed to 
1uM rapalog for 1 hour before imaging by widefield microscopy. (c) HeLa cells were 
transfected with BicD-N-FRB and GPPF, grown for 24 hours and exposed to 1uM rapalog for 
1 hour before imaging by widefield microscopy. GFP-tagged PUF is aggregated in the 
centrosome. (d) HeLa cells were transfected with empty vector and GPPF, grown for 24 
hours and expos d to 1uM rapalog for 1 hour before imaging by widefiel  microscopy. 
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PBS	   were	   separated	   by	   6	   nt.	   The	   three	   components	   of	   the	   reporter	   assay	   (the	  transporter,	  corresponding	  RBP,	  and	  reporter	  mRNA)	  were	  co-­‐transfected	   in	  HeLa	  cells.	  After	  48	  hours	  of	  cell	  growth,	   rapalog	  was	  added	   for	  1	  hour,	  after	  which	   the	  cells	  were	   fixed	   and	   the	   localization	   of	   all	   three	   constructs	  was	   analyzed	   by	   RNA	  fluorescence	  in	  situ	  hybridization	  (FISH)	  and	  immunofluorescence.	  	  
	  
Figure	   6.3	   Transport	   of	   FL	  mRNA	  by	   the	   PUF-­‐motor	   system	   consisting	   of	  Kif5b-­‐FRB	   and	   the	   PUF	  construct	   FFGPP.	  HeLa	   cells	  were	   transfected	  with	  Kif5b-­‐FRB,	   FFGPP,	   and	  FL	  with	   0,	   2,	   or	   10	  PBS	  after	  the	  stop	  codon,	  grown	  for	  48	  hours	  and	  treated	  with	  1	  μM	  rapalog	  for	  1	  hour	  before	  fixing.	  The	  samples	  were	   subjected	   to	   combined	   immunofluorescence	   and	  FISH	   for	   the	   assessment	   of	   protein	  and	  mRNA	  localization	  in	  the	  cells.	  After	  treatment	  with	  rapalog	  and	  in	  the	  presence	  of	  PBS	  in	  the	  3’	  UTR	  of	  FL	  mRNA,	  Kif5b-­‐FRB,	  FFGPP	  and	  mRNA	  are	  co-­‐localized	  in	  the	  periphery	  of	  the	  cells.	  	  


































+      2 
Figure 3. Transport of FL mRNA by the PUF-motor system consisting of Kif5b-FRB and the 
PUF construct FFGPP. HeLa cells were transfected with Kif5b-FRB, FFGPP, and FL with 0, 2, 
or 10 PBS after the stop codon, grown for 48 hours and treated with 1uM rapalog for 1 hour 
before fixing. The samples were subjected to combined immunofluorescence and FISH for 
the assessment of protein and mRNA localization in the cells. After treatment with rapalog 
and in the presence of PBS in the 3’ UTR of FL mRNA, Kif5b-FRB, FFGPP and mRNA are co-
localized in the periphery of the cells. The transport is rapalog-dependent and sequence-
specific. 
	   151	  
	  
	  
Figure	  6.4	  Transport	  of	  FL	  mRNA	  by	  the	  PUF-­‐motor	  system	  consisting	  of	  BicD-­‐N-­‐FRB	  and	  the	  PUF	  construct	  GPPF.	  HeLa	  cells	  were	  transfected	  with	  BicD-­‐N-­‐FRB,	  GPPF,	  and	  FL	  with	  0,	  2,	  or	  10	  PBS	  after	  the	   stop	   codon,	   grown	   for	   48	   hours	   and	   treated	  with	   1	   μM	   rapalog	   for	   1	   hour	   before	   fixing.	   The	  samples	  were	   subjected	   to	   combined	   immunofluorescence	   and	  FISH	   for	   the	   assessment	   of	   protein	  and	  mRNA	  localization	  in	  the	  cells.	  After	  treatment	  with	  rapalog	  and	  in	  the	  presence	  of	  PBS	  in	  the	  3’	  UTR	  of	  FL	  mRNA,	  BicD-­‐N-­‐FRB,	  GPPF,	  and	  mRNA	  are	  co-­‐localized	  at	  the	  centrosome.	  	  
	   Widefield	   fluorescence	   microscopy	   revealed	   that	   when	   FFGPP	   was	   co-­‐transfected	  with	  Kif5b-­‐FRB,	  FFGPP	  co-­‐localized	  with	  Kif5b-­‐FRB	   in	   the	  presence	  of	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Figure 4. Transport of FLmRNA by the PUF-motor system consisting of BicD-N-FRB and the 
PUF construct GPPF. HeLa cells were transfected with BicD-N-FRB, GPPF, and FL with 0, 2, 
or 10 PBS after the stop codon, grown for 48 hours treated with 1uM rapalog for 1 hour 
before fixing. The samples were subjected to combined immunofluorescence and FISH for 
the assessment of protein and mRNA localization in the cells. After treatment with rapalog 
and in the presence of PBS in the 3’ UTR of FLmRNA, BicD-N-FRB, GPPF, and mRNA are co-
localized at the centrosome. The transport is rapalog-dependent and sequence-specific. 
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rapalog,	  but	  not	  in	  the	  absence	  of	  rapalog	  (Figure	  6.3).	  Moreover,	  FL	  mRNA	  was	  co-­‐localized	  with	  FFGPP	  when	  the	  3ʹ′	  UTR	  of	  its	  mRNA	  contained	  10	  PBS,	  but	  not	  when	  the	  mRNA	  contained	  only	  2	  or	  no	  PBS	   (Figure	  6.3).	  These	  results	   suggest	   that	   the	  transport	  of	  mRNA	  to	  the	  minus	  end	  of	  the	  microtubules	  by	  the	  PUF-­‐motor	  system	  is	  motor-­‐dependent	   and	   RNA	   sequence-­‐dependent.	   However,	   the	   avidity	   between	  the	   FFGPP	   and	   the	   target	   RNA	   needs	   to	   be	   strong	   enough	   to	   have	   an	   observable	  transport	  of	  mRNA	  in	  HeLa	  cells.	  	  Likewise,	  when	  GPPF	  was	  co-­‐transfected	  with	  BicD-­‐N-­‐FRB,	  GPPF	  co-­‐localized	  with	   BicD-­‐N-­‐FRB	   in	   the	   presence	   of	   rapalog,	   but	   not	   in	   the	   absence	   of	   rapalog	  (Figure	  6.4).	  In	  addition,	  FL	  mRNA	  was	  co-­‐localized	  with	  GPPF	  when	  the	  3ʹ′	  UTR	  of	  its	  mRNA	  contained	  10	  PBS,	   but	   less	   efficiently	  when	   the	  mRNA	  contained	  only	  2	  PBS.	  GPPF	  and	  FL	  mRNA	  did	  not	  co-­‐localize	  when	  the	  3ʹ′	  UTR	  of	  mRNA	  contained	  a	  random	   sequence	   (Figure	   6.4).	   These	   results	   likewise	   imply	   that	   the	   transport	   of	  mRNA	   in	   the	   plus-­‐end	   direction	   of	   the	   microtubules	   is	   BicD-­‐N	   as	   well	   as	   RNA	  sequence-­‐dependent.	  	  In	   order	   to	   quantify	   the	   effectiveness	   of	  mRNA	   transport	   by	   our	   PUF-­‐motor	  system,	  we	  calculated	  the	   localization	   index	  of	  FL	  mRNA	  using	  the	   intensity	  of	   the	  fluorescence	   signal	   from	   the	   probe	   generated	   against	   the	   FL	   open	   reading	   frame.	  The	  localization	  index	  was	  calculated	  as	  !!!!	  ,	  where	  Vl	  is	  background-­‐subtracted	  mean	  gray	   value	   of	   the	   RNA	   FISH	   signal	   in	   a	   region	   where	   most	   immunofluorescence	  signal	   from	  Kif5b	  or	  BicD-­‐N	  was	  observed	   in	   the	  cell.	  Vc	   is	  background-­‐subtracted	  mean	   gray	   value	   of	   the	   RNA	   FISH	   signal	   in	   a	   region	   of	   the	   same	   size,	   but	   in	   an	  adjacent	  area	  in	  the	  cytoplasm.	  	  
	   153	  
	  
Figure	  6.5	  Quantification	  of	  FL	  mRNA	  localization	  from	  samples	  exemplified	  in	  Figure	  3	  and	  Figure	  4.	   (a)	   Localization	   index	   of	   FL	  mRNA	   in	   samples	   co-­‐transfected	  with	  Kif5b-­‐FRB	   and	   FFGPP.	   *,	   P	   <	  0.05.	  ***,	  P	  <	  0.001.	  (b)	  Localization	   index	  of	  FL	  mRNA	  in	  samples	  co-­‐transfected	  with	  BicD-­‐N-­‐FRB	  and	  GPPF.	  NS,	  not	  significant.	  Error	  bars	  represent	  standard	  error.	  	  
We	   thus	   calculated	   and	   averaged	   the	   localization	   index	   of	   RNA	   in	   20-­‐30	  randomly	  picked	  HeLa	   cells	   that	   exhibited	   immunofluorescence	   signals	   from	  GFP-­‐tagged	  PUF,	  HA-­‐tagged	  transporter	  proteins,	  as	  well	  as	  FISH	  signal	   from	  luciferase	  mRNA.	   With	   the	   Kif5b/FFGPP	   combination,	   the	   localization	   index	   of	   luciferase	  mRNA	  was	  ~2	  times	  greater	  in	  mRNA	  3ʹ′	  UTR	  of	  which	  contained	  10	  PBS	  compared	  to	   random	   sequence	   (Figure	   6.5a).	   The	   localization	   index	   was	   not	   significantly	  greater	   for	   mRNA	   3ʹ′	   UTR	   of	   which	   contained	   only	   2	   PBS	   compared	   to	   random	  sequence	   (P	   <	   0.05).	   On	   the	   other	   hand,	   with	   the	   BicD-­‐N/GPPF	   combination,	   the	  localization	   index	   of	   luciferase	  mRNA	  was	  ~11	   times	   greater	   in	  mRNA	   3ʹ′	   UTR	   of	  which	   contained	   10	   PBS	   compared	   to	   random	   sequence	   (Figure	   6.5b).	   The	  localization	   index	   was	   50%	   greater	   in	   mRNA	   3ʹ′	   UTR	   of	   which	   contained	   2	   PBS	  compared	   to	  random	  sequence	   (P	  <	  0.05).	  These	  results	  corroborate	  our	  previous	  conclusion	  that	  the	  PUF-­‐motor	  system	  is	  RNA	  sequence-­‐dependent,	  but	  the	  avidity	  
Figure 5. Quantification of luciferase mRNA localization from samples exemplified in 
Figure 3 and Figure 4. (a) Localization index of luciferase mRNA in samples co-transfected 
with Kif5b-FRB and FFGPP. *, P < 0.05.  ***, P < 0.001. (b) Localization index of luciferase 
mRNA in samples co-transfected with BicD-N-FRB and GPPF. NS, not significant. Error bars 
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between	   the	   PUF	   constructs	   and	   the	   target	   RNA	   plays	   an	   important	   role	   in	   the	  effectiveness	   of	   mRNA	   transport.	   These	   results	   are	   the	   first	   demonstration	   of	   an	  engineered	   device	   that	   is	   capable	   of	   re-­‐distributing	   mRNA	   localization	   in	   higher	  eukaryotes.	  
6.2.3	  Directional	  Transport	  of	  PUF	  and	  mRNA	  in	  Hippocampal	  Neurons	  	  To	   apply	   our	   PUF-­‐motor	   system	   for	   the	   transport	   of	   endogenous	   mRNA,	   we	   re-­‐engineered	  both	  of	  the	  PUF	  domains	  for	  binding	  to	  β-­‐actin	  mRNA	  and	  re-­‐assembled	  them	   in	   the	   GPPF	   configuration.	   We	   chose	   β-­‐actin	   mRNA,	   since	   its	   intercellular	  localization	   in	   neurons	   and	   local	   translation	   are	   studied	   better	   than	   most	   other	  mRNAs.	   Local	   translation	   of	   β-­‐actin	  mRNA	  was	   implicated	   in	   axonal	   growth	   cone	  chemotropic	  response4,	  axonal	  branching40,	  and	  growth	  of	  dendritic	  filopodia41.	  	  Target	  name	   Target	  sequence	   Target	  length	  actb1	   TGTTTTTTGTTTTTGTTTTTT	   21	  actb2	   TGTTTTTTTGTTTTTTGTTTTTG	   23	  actb3	   TGTGGCTGAGGACTTTGATTGTACATT	   27	  actb4	   TGTGGCTGAGGACTTTGATTGTA	   23	  actb5	   TGACAGCATTGCTTCTGTGTAAATT	   25	  actb6	   TGTGTAAATTATGTACTTG	   19	  actb7	   TGTATGAAGGCTTTGGTCTCCCTGGGAGTGGTTTGAGGTGTTGAGG	   46	  actb8	   TGGTTTGAGGTGTTGAGG	   18	  
	  
Table	   6.1	   Target	   sites	   in	   rat	   β-­‐actin	  mRNA	   that	  were	   chosen	   for	  PUF	  engineering.	  Red,	   8-­‐nt	  PUF	  binding	  sites.	  
The	  natural	  PUF	  proteins	  have	  a	   strong	   consensus	   in	   the	   first	   three	  bases	  of	  their	  target	  sequence	  (5ʹ′-­‐UGU)32,	  which	  are	  bound	  by	  the	  last	  three	  PUF	  repeats.	  For	  this	  reason,	  the	  two	  adjacent	  PUF	  target	  sites	  were	  chosen	  from	  the	  3ʹ′	  UTR	  sequence	  of	  rat	  β-­‐actin	  mRNA	  so	  that	  minimal	  mutagenesis	  would	  be	  required	  in	  PUF	  repeats	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6,	  7,	  and	  8.	  We	  chose	  8	  potential	  double	   target	  sites,	  with	  3-­‐30	  nt	  spacer	  between	  the	   two	   putative	   PBS	   (Table	   6.1).	   We	   next	   constructed	   8	   GPPF	   (GPPFact1-­‐8)	  variants	  with	   the	   two	  PUF	  domains	  engineered	   to	  bind	   to	   the	   two	  adjacent	   target	  sites,	   in	   accordance	  with	   the	  RNA-­‐binding	   code	  of	   PUF32,	  34-­‐35.	   The	   construction	  of	  these	   individual	  PUF	  variants	  was	   facilitated	  by	   the	  PUF	  Golden	  Gate	  assembly	  kit	  previously	   developed	   in	   our	   laboratory42.	   In	   order	   to	   screen	   the	  most	   effective	   of	  these	   engineered	   GPPF	   constructs,	   we	   tested	   them	   using	   the	   FL	   assay	   described	  above.	  To	   this	   end,	  we	   individually	   cloned	  each	  of	   the	  8	  putative	  RNA	   target	   sites	  into	  the	  3ʹ′	  UTR	  of	  the	  FL	  gene.	  	  The	   effectiveness	   of	   FL	   mRNA	   transport	   by	   these	   reprogrammed	   GPPF	   was	  next	   assayed	   using	   the	   BicDN-­‐FRB/eGPF	   system.	   Of	   all	   the	   GPPF	   constructs,	  GPPFact1	  and	  GPPFact6	  showed	  significant	  mRNA	  transport	  (Figure	  6.6).	  Since	  the	  GPPFact6	   yielded	   higher	   fluorescence	   signal	   compared	   to	   other	   constructs	   under	  similar	  conditions	  (data	  not	  shown),	  we	  assumed	  that	  GPPFact6	  is	  more	  soluble	  and	  proceeded	   with	   this	   construct	   for	   the	   transport	   of	   endogenous	   β-­‐actin	   mRNA	   in	  hippocampal	  neurons.	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Figure	   6.6	   Assessment	   of	   activity	   of	   GPPF	   designed	   for	   binding	   to	   β-­‐actin	   3’	   UTR	   using	   the	   FL	  reporter	  assay.	  *,	  P	  ≤	  0.05.	  **,	  P	  <	  0.01.	  Error	  bars	  represent	  standard	  error.	  	  
To	  use	  this	  reprogrammed	  RBP	  for	  the	  transport	  of	  endogenous	  β-­‐actin	  mRNA,	  the	   GPPFact6	   construct	   was	   sub-­‐cloned	   under	   GW1	   promoter	   and	   used	   with	   the	  BicD-­‐N-­‐FRB	   construct	   under	   β-­‐actin	   promoter.	   The	   two	   PUF	   mutants	   in	   the	  GPPFact6	  construct	  were	  also	  sub-­‐cloned	  into	  the	  FFGPP	  configuration	  under	  GW1	  promoter	   for	   the	   interaction	   with	   the	   Kif5b-­‐FRB.	   In	   accordance	   with	   previous	  reports43,	  we	   expected	  Kif5b	   and	  BicD-­‐N	   constructs	   to	   target	   cargos	   to	   axons	   and	  dendrites,	   respectively.	   FFGPPact6	   was	   co-­‐transfected	   with	   Kif5b-­‐FRB	   and	   blue	  fluorescent	  protein	  (BFP)	  into	  rat	  hippocampal	  neurons	  that	  were	  cultured	  8	  days	  in	  vitro	  (DIV8).	  On	  the	  second	  day	  after	  transfection,	  rapalog	  was	  added	  to	  the	  medium	  at	   0.1	   uM	   concentration,	   and	   the	   neurons	  were	   grown	   for	   24	  more	   hours	   before	  fixation	  and	  analysis	  with	  widefield	  fluorescence	  microscopy.	  	  
Figure 6. Assessment of activity of of GPPF designed for binding to β-actin 3’ UTR using 
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Figure 8. Quantification of the PUF-motor system efficacy in targeting endogenous β-actin 
mRNA. (a) FFGPP localization in axonal growth cones in DIV11 rat hippocampal neurons when co-
transfected with Kif5b-FRB. The background-subtracted mean gray value of PUF-fused GFP 
fluorescence intensity wa  normalized to background-subtracted mean gray value of BFP 
fluorescence intensity. Fifty axonal growth cones from 10 randomly picked neurons were analyzed 
and averaged. Data repre ented as average ± st ndard err r. ***, P < 0.001. (b) F-actin 
localization in growth cones in DIV11 rat hippocampal neurons transfected with Kif5b-FRB and β-
actin-specific FFGPP. F-actin was phalloidin-stained and its localization in axonal growth cones 
quantified. The background-subtracted mean gray value of Alexa Fluor 568 fluorescence intensity 
was normalized to background-subtracted mean gray value of BFP fluorescence intensity. Fifty 
axonal growth cones from 10 randomly picked neurons were analyzed and averaged. Data 
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phalloidin-­‐staining	   of	   neurons	   for	   F-­‐actin	   revealed	   5-­‐fold	   increase	   in	   F-­‐actin	  localization	   in	   axonal	   growth	   cones	   (Figure	   6.8b),	   which	   could	   be	   due	   to	   local	   β-­‐actin	   mRNA	   translation	   in	   axonal	   growth	   cones	   enriched	   with	   FFGPPact6-­‐transported	   mRNA.	   To	   confirm	   PUF-­‐motor	   mediated	   re-­‐distribution	   of	   β-­‐actin	  mRNA	  in	  the	  neurons,	  we	  estimated	  mRNA	  amounts	   in	  axonal	  growth	  cones	  using	  RNA	  FISH	  in	  the	  presence	  and	  absence	  of	  rapalog	  (Figure	  6.9	  a	  and	  b).	  Although	  no	  obvious	   difference	   is	   observed	   from	   representative	   images,	   estimation	   of	   β-­‐actin	  mRNA	   amounts	   averaged	   from	   20	   randomly	   picked	   growth	   cones	   revealed	   an	  almost	   two-­‐fold	   increase	   of	   β-­‐actin	   mRNA	   in	   axonal	   growth	   cones	   of	   neurons	  treated	   with	   rapalog	   (Figure	   6.10).	   Although	   more	   investigation	   is	   required	   to	  definitively	  confirm	  this	  change	  being	  due	  to	  local	  protein	  synthesis,	  it	  is	  tempting	  to	  suggest	   that	   the	   increase	   in	   F-­‐actin	   amount	   in	   axonal	   growth	   cones	   is	   due	   to	   the	  increased	  amount	  of	  transported	  β-­‐actin	  mRNA.	  The	  effect	  of	  BicD-­‐N-­‐FRB	  and	  rapalog	  to	  the	  localization	  of	  GPPFact6	  as	  well	  as	  F-­‐actin	   is	   currently	   being	   analyzed.	   We	   predict	   that	   the	   transfection	   of	   these	  constructs	  would	   sequester	   β-­‐actin	  mRNA	   from	   axonal	   growth	   cones	   to	   neuronal	  cell	  bodies	  and	  dendrites,	  thus	  reducing	  the	  amount	  of	  β-­‐actin	  mRNA	  in	  the	  growth	  cones.	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Figure 9. Application of the PUF-
motor system for targeting 
endogenous β-actin mRNA. FFGPP 
localization in axonal growth cones in 
DIV11 rat hippocampal neurons 
when co-transfected with Kif5b-FRB 
and either not treated (a) or treated 
(b) with rapalog for 24 hours. After 
fixation, β-actin mRNA was visualized 
using FISH. Representative axonal 
growth cones are shown. 
a b 
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Figure	   6.10	   Quantification	   of	   β-­‐actin	   mRNA	   in	   axonal	   growth	   cones	   estimated	   by	   measuring	   the	  mean	  gray	  value	  from	  the	  RNA-­‐FISH	  signal.	  Twenty	  axonal	  growth	  cones	  from	  10	  randomly	  picked	  neurons	  were	  analyzed	  and	  averaged.	  Data	  represented	  as	  average	  ±	  standard	  error.	  **,	  P	  <	  0.01.	  
6.3	  Conclusions	  In	  this	  work,	  we	  developed	  a	  synthetic	  device	  for	  sequence-­‐specific	  transport	  of	  mRNA	   in	   eukaryotic	   cells.	   To	   the	   best	   of	   our	   knowledge,	   this	  work	   is	   the	   first	  demonstration	   of	   the	   efficacy	   of	   an	   engineered	   device	   capable	   of	   redistributing	  endogenous	  mRNA.	   The	   transport	   can	   be	   achieved	   in	   (+)	   or	   (-­‐)	   directions	   of	   the	  microtubules	   in	  cultured	  cancerous	  mammalian	  cells	  or	  mammalian	  neurons.	  This	  prototypical	   synthetic	   device	   can	  potentially	   control	   intracellular	   transport	   of	   any	  endogenous	  mRNA	  of	   interest	   in	   eukaryotes,	   as	  well	   as	   local	  mRNA	   translation	   in	  polarized	  eukaryotic	  cells.	  Eventually,	  we	  believe	  that	  this	  device	  will	  broaden	  our	  capability	   in	   regulating	   mRNA	   metabolism	   and	   gene	   expression,	   which	   will	   be	  helpful	  in	  basic	  science	  and	  therapeutics.	  
6.4	  Materials	  and	  Methods	  

















Figure 10. Quantification of β-actin mRNA in axonal growth cones 
estimated by measuring the mean gray value from the RNA-FISH 
signal. Twenty axonal growth cones from 10 randomly picked 
neurons were analyzed and averaged. Data represented as average ± 
standard error. **, P < 0.01.  
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promoter.	   To	   this	   end,	   the	  backbone,	   including	   the	   start	   codon	   and	   the	  3xflag	   tag	  were	   amplified	   from	   the	   pCMV-­‐TTP	   (C147R)-­‐GG-­‐PUF	   plasmid	   (Chapter	   5).	   Kif5b-­‐FRB	   was	   PCR-­‐amplified	   from	   HA-­‐Kif5b(1-­‐807)-­‐FRB43,	   and	   BicDN-­‐FRB	   was	   PCR-­‐amplified	  from	  the	  HA-­‐BICD2-­‐N(1-­‐594)-­‐FRB	  plasmid43,	  which	  were	  then	  assembled	  into	   the	   amplified	   vector	   backbone	   using	   the	  Gibson	  Assembly	  method.	   PUF-­‐GFP-­‐FKBP	   constructs	  were	   similarly	   assembled	   into	   the	   amplified	   vector	   using	  Gibson	  Assembly	  method.	  For	   this	  purpose,	   the	  modified	  PUF	  domain	  was	  amplified	   from	  TPUF	   (6SE,7NQ)	   	   plasmid	   (Chapter	   5).	   The	   eGFP	   gene	   was	   amplified	   from	   the	  pCMV5-­‐eGFP	  plasmid,	  and	  double	  or	  single	  FKBP	  domains	  were	  amplified	  from	  the	  PEX-­‐RFP-­‐FKBP43	  plasmid.	  For	  the	  construction	  of	  GPPFact(1-­‐8)	  plasmids,	  individual	  PUF	  domains	  were	  first	  assembled	  in	  pET28	  vector	  using	  the	  Golden	  Gate	  assembly	  method	   and	   the	   parts	   library	   developed	   previously42.	   The	   complete	   GPPFact(1-­‐8)	  constructs	   were	   then	   assembled	   into	   the	   pCMV5	   backbone	   from	   mutant	   PUF	  domains,	  eGFP,	  and	  FKBP	   fragments	  using	   the	  Gibson	  Assembly	  method	  as	  above.	  Plasmid	  maps	  are	  available	  upon	  request.	  
The	   construction	   of	   plasmids	   for	   transcription	   of	   firefly	   luciferase	   mRNA	  containing	  a	  3ʹ′	  UTR	  with	  10	  PBS,	  or	  a	  random	  sequence	  were	  described	  previously	  (Chapter	  5).	  The	  plasmid	  for	  the	  transcription	  of	  firefly	  luciferase	  mRNA	  containing	  a	  3ʹ′	  UTR	  with	  2	  PBS	  was	  constructed	  by	  Gibson	  Assembly.	  For	  this	  purpose,	  double	  stranded	   (ds)	  oligomer	  was	  prepared	  by	   annealing	   single	   stranded	   (ss)	   oligomers	  5ʹ′-­‐TATCGATAAGCTTGCATGCCTGCAGTTGATATAAAGTGTTTGATATAGGTGG	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  and	   5ʹ′-­‐GGGGTCACAGGGATGCCACCTATATCAAACACTTTATATCAACTGCAG	   and	  assembled	   with	   the	   PstI	   and	   XmaI-­‐digested	   pCMV5-­‐Fluc	   (construction	   of	   this	  plasmid	   was	   described	   in	   Chapter	   5).	   The	   plasmids	   for	   transcription	   of	   firefly	  luciferase	  mRNA	  with	  3ʹ′	  UTRs	  containing	  short	  inserts	  from	  the	  3ʹ′	  UTR	  of	  rat	  β-­‐actin	  mRNA	  were	   prepared	   by	   ligation	   of	   ds	   oligomers	   into	   the	  PstI	   and	  XmaI-­‐digested	  pCMV5-­‐Fluc	   plasmid.	   The	   ds	   oligomers	   were	   prepared	   by	   annealing	   two	   ss	  oligomers	   and	   subsequent	   5ʹ′-­‐phosphorylation	   using	   the	   T4	   polynucleotide	   kinase	  (NEB),	  as	  per	  manufacturer’s	  protocol.	  For	  expression	  in	  hippocampal	  cells,	  the	  BicD-­‐N-­‐FRB	  construct	  was	  subcloned	  under	   the	   β-­‐actin	   promoter.	   To	   this	   end,	   the	   BicD-­‐N-­‐FRB	   fragment	  was	   amplified	  from	  pCMV5-­‐BicD-­‐N-­‐FRB	  and	  ligated	  into	  HindIII	  and	  SalI	  sites	  in	  the	  β-­‐actin	  vector.	  Similarly,	  the	  Kif5b-­‐FRB	  fragment	  was	  amplified	  from	  pCMV5-­‐Kif5b-­‐FRB	  and	  ligated	  into	  AscI	  and	  SalI	  sites	  of	   the	  β-­‐actin2b-­‐MCS-­‐ATG	  vector.	  FFGPPact6	  and	  GPPFact6	  constructs	   were	   cloned	   under	   GW1	   promoter.	   For	   this	   purpose,	   GPPFact6	   was	  amplified	   from	  pCMV5-­‐GPPFact6	   and	   ligated	   into	   the	  HindIII	   and	   SalI	   sites	   of	   the	  GW1-­‐HA-­‐2b	   vector.	   FFGPPact6	   was	   cloned	   by	   amplification	   of	   the	   GW1	   vector,	  2xFKBP	   fragment	   from	   the	   PEX-­‐RFP-­‐FKBP	   plasmid,	   and	   the	   eGFP-­‐PUF-­‐PUF	  fragment	   (with	   a	   primer-­‐added	   stop	   codon)	   from	   the	   GPPFact6	   construct,	   and	  subsequent	  splicing	  using	  the	  Gibson	  Assembly	  method.	  
6.4.2	  Cell	  Culture	  and	  Transfection	  HeLa	  cells	  were	  maintained	  in	  modified	  Eagle’s	  Medium	  (MEM)	  supplemented	  with	  10	  %	  Fetal	  Bovine	  Serum	  (FBS).	  HeLa	  cells	  were	  plated	  a	  day	  before	  transfection	  at	  a	  density	  of	  1x104	  cells/well	  in	  8-­‐well	  poly-­‐L-­‐lysine-­‐coated	  μ-­‐slide	  (Ibidi)	  in	  300	  μl	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of	   MEM	   with	   10%	   FBS.	   The	   next	   day,	   transfection	   mixtures	   were	   prepared	   by	  mixing	   15	   μl	   OptiMEM	   (Life	   Technologies),	   300	   ng	   DNA,	   and	   0.9	   μl	   Fugene	   HD	  reagent	  (Promega).	  The	  DNA	  mixture	  contained	  100	  ng	  transporter	  plasmid,	  100	  ng	  PGF	  plasmid,	  and	  100	  ng	  firefly	  luciferase	  plasmid.	  The	  transfection	  mixtures	  were	  incubated	   for	   15	  minutes	   at	   room	   temperature	   and	   added	   to	   the	  wells	  with	   cells.	  The	  cells	  were	  allowed	  to	  recover	  and	  grow	  for	  48	  hours	  before	  heterodimerization	  of	   motor	   and	   PGF	   constructs	   in	   200	   μl	   media	   supplemented	   with	   1	   μM	   A/C	  heterodimerizer	  (Clontech	  Laboratories)	  for	  1	  hour	  at	  37C.	  Primary	   hippocampal	   cultures	  were	   prepared	   from	   embryonic	   day	   18	   (E18)	  rat	  brains	  as	  described	  previously43.	  Briefly,	  cells	  were	  plated	  on	  coverslips	  coated	  with	   poly-­‐L-­‐lysine	   (30	   μg/ml)	   and	   laminin	   (2	   μg/ml)	   at	   a	   density	   of	   75,000/well.	  Hippocampal	  cultures	  were	  grown	  in	  Neurobasal	  medium	  (NB)	  supplemented	  with	  B27,	   0.5	   mM	   glutamine,	   12.5	   μM	   glutamate,	   and	   penicillin-­‐streptomycin.	  Hippocampal	   neurons	   were	   transfected	   at	   DIV8	   with	   Lipofectamine	   2000	  (Invitrogen).	  DNA	  (1.8	  g	  μg/well)	  was	  mixed	  with	  3.3	  ml	  Lipofectamine	  2000	  in	  200	  μl	  NB,	  incubated	  for	  30	  min,	  and	  then	  added	  to	  the	  neurons	  in	  NB	  at	  37°C	  in	  5	  %	  CO2	  for	  45	  min.	  Next,	  neurons	  were	  washed	  with	  NB	  and	  transferred	  to	  the	  conditioned	  medium	  at	  37	  °C	   in	  5	  %	  CO2	   .	  Rapalog	  was	  added	  to	  the	  media	  at	  DIV10	  to	  a	   final	  concentration	  of	  0.1	  μM	  and	  the	  neurons	  were	  grown	  for	  additional	  24	  hours	  at	  37	  °C	  in	  5	  %	  CO2.	  
6.4.3	  RNA-­‐FISH,	  Immunofluorescence,	  and	  Phalloidin	  Staining	  For	   combined	   RNA-­‐FISH	   and	   immunofluorescence,	   HeLa	   cells	  were	  washed	   twice	  with	  phosphate	  buffer	  saline	  (PBS)	  and	  fixed	  with	  4%	  formaldehyde	  (Polysciences)	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in	  2x	  saline-­‐sodium-­‐citrate	  (SSC)	  buffer	   for	  10	  minutes	  at	  room	  temperature	  (RT).	  The	   cells	   were	   washed	   twice	   in	   PBS	   and	   permeabilized	   with	   70%	   ethanol	   at	   4C	  overnight,	   after	   which	   they	   were	   washed	   in	   a	   washing	   buffer	   (2xSSC,	   10	   %	  formamide	  -­‐Sigma)	  for	  5	  minutes	  at	  RT.	  RNA-­‐FISH	  co-­‐immunofluorescence	  staining	  was	   performed	   by	   incubation	   with	   170	   nM	   Stellaris	   Quasar	   670-­‐tagged	   firefly	  luciferase	  48	  probe	  mix	  (Biosearch	  Technologies),	  1	  μg/ml	  mouse	  monoclonal	  anti-­‐HA	  tag	  IgG	  antibody	  (Abcam),	  and	  5	  μg/ml	  rabbit	  monoclonal	  anti-­‐GFP	  IgG	  Abfinity	  antibody	  (Invitrogen)	  in	  the	  FISH-­‐IF	  buffer	  (10	  %	  dextran	  sulfate,	  10	  %	  formamide,	  	  2x	   SSC,	   2mM	   vanadyl	   rybonucleoside	   complex,	   0.02	   %	   RNase-­‐free	   bovine	   serum	  albumin	  (BSA))	  overnight	  at	  37	  °C	  in	  the	  dark.	  The	  cells	  were	  washed	  three	  times	  in	  the	  washing	  buffer	  and	  incubated	  with	  4	  μg/ml	  Alexa-­‐Fluor568-­‐tagged	  anti-­‐mouse	  IgG	   antibodies	   and	   10	   μg/ml	   Alexa-­‐Fluor488-­‐tagged	   anti-­‐rabbit	   antibody	  (Invitrogen)	  in	  the	  FISH-­‐IF	  buffer	  for	  1	  hour	  at	  RT	  in	  the	  dark,	  after	  which	  they	  were	  subsequently	   washed	   three	   times	   in	   the	   washing	   buffer.	   The	   cells	   were	  subsequently	  conterstained	  in	  130	  ng/ml	  Hoechst	  33342	  (Pierce)	   for	  5	  minutes	  at	  RT,	  and	  washed	  three	  times	  in	  2xSSC	  buffer.	  After	  washing	  in	  the	  oxygen	  scavenger	  (GLOX)	  buffer	  (2xSSC,	  0.4	  %	  glucose,	  10	  mM	  Tris-­‐HCl	  pH	  8)	  for	  5	  minutes	  at	  RT,	  the	  cells	   were	   imaged	   in	   GLOX	   solution	   (37	   μg/ml	   glucose	   oxidase	   (Sigma)	   and	   100	  μg/ml	  catalase	  (Sigma)	  in	  GLOX	  buffer).	  For	  RNA-­‐FISH	  of	  embryonic	  rat	  hippocampal	  cells,	  transfected	  DIV11	  neurons	  were	  fixed	  in	  4%	  paraformaldehyde	  supplemented	  with	  4	  %	  sucrose	  for	  10	  min	  at	  RT,	  washed	  3x	  with	  PBS,	  and	  permeabilized	  in	  70%	  ethanol	  overnight	  at	  4	  °C.	  The	  coverslips	  were	  next	  washed	  in	  the	  washing	  buffer	   for	  5	  minutes	  at	  RT.	  RNA-­‐FISH	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was	   performed	   by	   incubation	  with	   170	   nM	   Stellaris	   Quasar	   670-­‐tagged	   48	   probe	  mix	  specific	  for	  rat	  actb	  (Biosearch	  Technologies)	  in	  the	  FISH-­‐IF	  buffer	  overnight	  at	  37	   °C	   in	   the	   dark.	   The	   cells	   were	   washed	   three	   times	   in	   the	   washing	   buffer	   and	  imaged	  in	  the	  GLOX	  buffer	  as	  above.	  	  
For	  visualization	  of	  F-­‐actin	  in	  neurons,	  fixed	  cells	  were	  permeabilized	  in	  0.1	  %	  Triton	  X-­‐100	  in	  PBS	  for	  15	  minutes	  at	  RT,	  and	  washed	  in	  PBS.	  The	  coverslips	  were	  next	  treated	  with	  0.4	  units/ml	  Alexa	  Fluor	  568	  Phalloidin	  (Life	  Technologies)	  in	  1	  %	  goat	  serum	  and	  1x	  PBS	  for	  20	  minutes	  at	  RT,	  after	  which	  they	  were	  washed	  in	  PBS	  and	  mounted	  using	  Vectashield	  mounting	  medium	  (Vector	  laboratories).	  	  
6.4.4	  Image	  Acquisition	  and	  Quantification	  Images	   were	   acquired	   using	   the	   Zeiss	   Axiovert	   200M	   widefield	   fluorescence	  microscope	   equipped	   with	   the	   40x	   NA	   1.4	   oil	   objective,	   Zeiss	   Axiocam	   506	   high	  resolution	   camera,	   and	  DAPI,	   FITC/GFP,	   Rhodamine,	   and	   Cy5	   excitation/emission	  filter	  set	  (Sutter).	  Localization	  index	  was	  determined	  by	  calculating	  the	  ratio	  of	  Cy5	  (RNA)	   intensity	   co-­‐localized	   with	   either	   Kif5b-­‐FRB	   or	   BicDN-­‐FRB	   versus	  cytoplasmic	  intensity	  by	  measuring	  the	  mean	  gray	  value	  of	  the	  localized	  spot	  and	  in	  an	   area	   of	   equal	   size	   in	   the	   adjacent	   cytoplasm	   using	   ImageJ	  (http://rsb.info.nih.gov/ij/index.html).	  Localization	  indexes	  were	  averaged	  over	  20-­‐30	   cells	   and	   a	   statistical	   analysis	  was	   performed	  with	   student’s	   t	   test	   assuming	   a	  two-­‐tailed	   and	   unequal	   variation.	   Origin	   8.5	   software	   was	   used	   to	   plot	   the	  localization	  indexes	  on	  box-­‐plot	  charts.	  Neurons	  were	   imaged	  using	  a	  Nikon	  Eclipse	  80i	  microscope	  equipped	  with	  a	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Plan	   Fluor	   60x	  N.A.	   1.40	   oil	   objective,	   Chroma	   ET-­‐DAPI	   (49000),	   Chroma	   ET-­‐GFP	  (49002),	   and	   Chroma	   ET-­‐mCherry	   (49008)	   filters,	   and	   a	   Photometrics	   CoolSNAP	  HQ2	  CCD	  camera.	  Mean	  gray	  values	  of	  GFP,	  BFP,	  and	  Alexa	  Fluor	  568	  fluorescence	  signals	  ere	  measured	  using	  ImageJ.	  The	  background-­‐subtracted	  mean	  gray	  value	  of	  PUF-­‐fused	  GFP	  fluorescence	  intensity	  or	  Alexa	  Fluor	  568	  fluorescence	  intensity	  was	  normalized	   to	   background-­‐subtracted	   mean	   gray	   value	   of	   BFP	   fluorescence	  intensity.	   Fifty	   axonal	   growth	   cones	   from	   10	   randomly	   picked	   neurons	   were	  analyzed	  and	  averaged.	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Appendix	  A	  DNA	   sequences	   of	   target	   and	   random	   double	   stranded	   oligonucleotides	   used	   in	  fluorescence	   polarization	   experiments.	   Note	   that	   the	   abbreviation	   /56-­‐FAM/	  corresponds	  to	  5’	  6-­‐FAM,	  which	  is	  a	  single	  isomer	  derivative	  of	  fluorescein.	  	  






















Cognate	  DNA	  sequence 
56FAM-5’-ATCTAGCAACCTCAAACAGACACCATACG-3’ 
      3’-TAGATCGTTGGAGTTTGTCTGTGGTATGC-5’ 
Random	  DNA	  sequence 
56FAM-5’-ATCAGACCGACATCTAATCCGCAACACAA-3’ 
      3’-TAGTCTGGCTGTAGATTAGGCGTTGTGTT-5’ 
   1  2  3  4  5  6  7  8  9  10 11 12 13 14 15 16 17 18 19 20 21 21.5 
T  A  G  C  A  A  C  C  T  C  A  A  A  C  A  G  A  C  A  C  C  A  T   
   NI NN HD NI NI HD HD HG HD NI NI NI HD NI NN NI HD NI HD HD NI NG 
target	  nucleotide	  position: target	  nucleotide: RVD: 
	   172	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